U.S. patent application number 10/103098 was filed with the patent office on 2003-10-23 for kinase inhibitors.
Invention is credited to Arnold, Lee D., Burchat, Andrew, Hirst, Gavin C., Ji, Zhiqin, Michaelides, Michael R., Muckey, Melanie, Wada, Carol K., Wishart, Neil.
Application Number | 20030199525 10/103098 |
Document ID | / |
Family ID | 28452362 |
Filed Date | 2003-10-23 |
United States Patent
Application |
20030199525 |
Kind Code |
A1 |
Hirst, Gavin C. ; et
al. |
October 23, 2003 |
Kinase inhibitors
Abstract
The present application is directed to pyrazolopyrimidine and
furopyrimnidine analogs of the formula (I) 1 wherein the
substituents are as defined herein, which are useful as kinase
inhibitors.
Inventors: |
Hirst, Gavin C.;
(Marlborough, MA) ; Arnold, Lee D.; (Westborough,
MA) ; Burchat, Andrew; (Shrewsbury, MA) ;
Wishart, Neil; (Holden, MA) ; Wada, Carol K.;
(Gurnee, IL) ; Michaelides, Michael R.;
(Libertyville, IL) ; Ji, Zhiqin; (Libertyville,
IL) ; Muckey, Melanie; (Trevor, WI) |
Correspondence
Address: |
John D. Conway, Esq.
Abbott Bioresearch Center, Inc.
100 Research Drive
Worcester
MA
01605-4314
US
|
Family ID: |
28452362 |
Appl. No.: |
10/103098 |
Filed: |
March 21, 2002 |
Current U.S.
Class: |
514/260.1 ;
514/262.1; 514/263.2; 514/263.22; 514/263.23; 514/265.1; 544/255;
544/256; 544/277; 544/280 |
Current CPC
Class: |
A61P 29/00 20180101;
C07D 491/04 20130101; A61P 9/00 20180101; A61P 11/00 20180101; A61P
27/02 20180101; A61P 9/10 20180101; A61P 11/06 20180101; A61P 33/02
20180101; A61P 37/02 20180101; C07D 487/04 20130101; A61P 5/14
20180101; A61P 17/06 20180101; A61P 1/04 20180101; A61P 31/18
20180101; A61P 31/04 20180101; A61P 1/16 20180101; A61P 35/02
20180101; A61P 17/02 20180101; A61P 31/22 20180101; A61P 15/08
20180101; A61P 19/02 20180101; A61P 3/10 20180101; A61P 13/12
20180101; A61P 27/06 20180101; A61P 35/00 20180101; A61P 37/06
20180101; A61P 31/12 20180101; A61P 7/06 20180101; A61P 43/00
20180101; A61P 9/12 20180101; A61P 7/00 20180101 |
Class at
Publication: |
514/260.1 ;
514/262.1; 514/263.2; 514/263.22; 514/263.23; 544/277; 544/255;
544/256; 514/265.1; 544/280 |
International
Class: |
A61K 031/52; A61K
031/519; C07D 491/02; C07D 487/02; C07D 473/34 |
Claims
What is claimed is:
1. A compound of the formula I, 41the racemic-diastereomeric
mixtures, optical isomers, pharmaceutically-acceptable salts,
prodrugs or biologically active metabolites thereof, wherein the
dotted line in the structure of formula (I) represents an optional
double bond; X is CR.sup.1 or NR.sup.1;Y is O, CR.sub.q or N; Q is
N, NR.sup.2or O; R.sup.3 for each occurrence is independently
hydrogen, hydroxy, substituted or unsubstituted alkyl or
substituted or unsubstituted alkoxy; when X is CR.sup.1, Y is
CR.sub.q, Q is O and there is a double bond between X and Y; or
when X is CR.sup.1, Y is N, Q is O and there is a double bond
between X and Y; or when X is CR.sup.1, Y is O, Q is N and there is
a double bond between Q and the pyrimidinyl ring, then 42where
Z.sup.100 is nitro, optionally substituted amino, 43or a group
optionally substituted with R.sub.b selected from the group
consisting of cycloalkyl, naphthyl, tetrahydronaphthyl,
benzothienyl, furanyl, thienyl, benzoxazolyl, benzothiazolyl,
44thiazolyl, benzofuranyl, 2,3-dihydrobenzofuranyl, indolyl,
isoxazolyl, tetrahydropyranyl, tetrahydrofuranyl, piperidinyl,
pyrazolyl, pyrrolyl, oxazolyl, isothiazolyl, oxadiazolyl,
thiadiazolyl, indolinyl, indazolyl, benzoisothiazolyl,
pyrido-oxazolyl, pyrido-thiazolyl, pyrimido-oxazolyl,
pyrimido-thiazolyl and benzimidazolyl; when a is 1 and D.sub.1,
G.sub.1, J.sub.1, L.sub.1 and M.sub.1 are each independently
selected from the group consisting of CR.sub.a and N, provided that
at least two of D.sub.1, G.sub.1, J.sub.1, L.sub.1 and M.sub.1 are
CR.sub.a; or when a is 0, and one of D.sub.1, G.sub.1, L.sub.1 and
M.sub.1 is NR.sub.a, one of D.sub.1, G.sub.1, L.sub.1 and M.sub.1
is CR.sub.a and the remainder are independently selected from the
group consisting of CR.sub.a and N; when b is 1 and D.sub.2,
G.sub.2, J.sub.2, L.sub.2 and M.sub.2 are each independently
selected from the group consisting of CR.sub.a and N, provided that
at least two of D.sub.2, G.sub.2, J.sub.2, L2 and M.sub.2 are
CR.sub.a; or when b is 0, and one of D.sub.2, G.sub.2, L.sub.2 and
M.sub.2 is NR.sub.a, one of D.sub.2, G.sub.2, L.sub.2 and M.sub.2
is CR.sub.a and the remainder are independently selected from the
group consisting of CR.sub.a and N; R.sub.a and R.sub.b each
represent one or more substituents and are for each occurrence
independently selected from the group consisting of hydrogen,
halogen, --CN, --NO.sub.2, --C(O)OH, --C(O)H, --OH, --C(O)O-alkyl,
-Z.sup.105-C(O)N(R).sub.2, -Z.sup.105-N(R)--C(O)-Z.sup.200,
-Z.sup.105-N(R)--S(O).sub.2-Z.sup.200,
-Z.sup.105-N(R)--C(O)--N(R)-Z.sup.200, R.sub.c, CH.sub.2OR.sub.c,
tetrazolyl, trifluoromethylcarbonylamino,
trifluoromethylsulfonamido, and an optionally substituted group
selected from the group consisting of carboxamido, alkyl, alkoxy,
aryl, alkenyl, aryloxy, heteroaryloxy, arylalkyl, alkynyl, amino,
aminoalkyl, amido groups, heteroarylthio and arylthio; Z.sup.105
for each occurrence is independently a covalent bond or
(C.sub.1-C.sub.6); Z.sup.200 for each occurrence is independently
an optionally substituted (C.sub.1-C.sub.6), optionally substituted
phenyl, or optionally substituted --(C.sub.1-C.sub.6)-phenyl;
R.sub.c for each occurrence is independently hydrogen, optionally
substituted alkyl, optionally substituted aryl,
--CH.sub.2--NR.sub.dR.sub.e,
--W--(CH.sub.2).sub.t--NR.sub.dR.sub.e,
--W--(CH.sub.2).sub.t-Oalkyl, --W--(CH.sub.2).sub.t--S-alkyl or
--W--(CH.sub.2).sub.t--OH; R.sub.d and R.sub.e for each occurrence
are independently H, alkyl, alkanoyl or SO.sub.2--alkyl; or
R.sub.d, R.sub.e and the nitrogen atom to which they are attached
together form a five- or six-membered heterocyclic ring; t for each
occurrence is independently an integer from 2 to 6; W for each
occurrence is independently a direct bond or O, S, S(O),
S(O).sub.2, or NR.sub.f; R.sub.f for each occurrence is
independently H or alkyl; Z.sup.110 is a covalent bond, or an
optionally substituted (C.sub.1-C.sub.6) which is optionally
substituted with one or more substituents selected from the group
consisting of alkyl, CN, OH, halogen, NO.sub.2, COOH, optionally
substituted amino and optionally substituted phenyl; Z.sup.111 is a
covalent bond, an optionally substituted (C.sub.1-C.sub.6) or an
optionally substituted
--(CH.sub.2).sub.n-cycloalkyl-(CH.sub.2).sub.n--; where the
optionally substituted groups are optionally substituted with one
or more substituents selected from the group consisting of alkyl,
CN, OH, halogen, NO.sub.2, COOH, optionally substituted amino and
optionally substituted phenyl; or R.sup.1 is a substituted or
unsubstituted carbocyclic or heterocyclic ring fused with ring 2; A
is a covalent bond, --O--; --S--; --S(O).sub.p--; --N(R)--;
--N(C(O)OR)--; --N(C(O)R)--; --N(SO.sub.2R)--; --CH.sub.2O--;
--CH.sub.2S--; --CH.sub.2N(R)--; --CH(NR)--; --CH.sub.2N(C(O)R))--;
--CH.sub.2N(C(O)OR)--; --CH.sub.2N(SO.sub.2R)--; --CH(NHR)--;
--CH(NHC(O)R)--; --CH(NHSO.sub.2R)--; --CH(NHC(O)OR)--;
--CH(OC(O)R)--; --CH(OC(O)NHR); --CH.dbd.CH--; --C(.dbd.NOR)--;
--C(O)--; --CH(OR)--; --C(O)N(R)--; --N(R)C(O)--;
--N(R)S(O).sub.p--; --OC(O)N(R)--; ;
--N(R)--C(O)--(CH.sub.2).sub.n--N(R)--, --N(R)C(O)O--;
--N(R)--(CH.sub.2).sub.n+1--C(O)--, --S(O).sub.pN(R)--;
--O--(CR.sub.2).sub.n+1--C(O)--, --O--(CR.sub.2).sub.n+1--O--,
--N(C(O)R)S(O).sub.p--; --N(R)S(O).sub.pN(R)--;
--N(R)--C(O)--(CH.sub.2).- sub.n--O--, --C(O)N(R)C(O)--;
--S(O).sub.pN(R)C(O)--; --OS(O).sub.pN(R)--; --N(R)S(O).sub.pO--;
--N(R)S(O).sub.pC(O)--; --SO.sub.pN(C(O)R)--; --N(R)SO.sub.pN(R)--;
--C(O)O--; --N(R)P(OR.sub.g)O--; --N(R)P(OR.sub.g)--;
--N(R)P(O)(OR.sub.g)O--; --N(R)P(O)(OR.sub.g)--;
--N(C(O)R)P(OR.sub.g)O--; --N(C(O)R)P(OR.sub.g)--;
--N(C(O)R)P(O)(OR.sub.g)--, or --N(C(O)R)P(OR.sub.g)--; p is 1 or
2; R for each occurrence is independently H, optionally substituted
alkyl, optionally substituted arylalkyl or optionally substituted
aryl; R.sub.g for each occurrence is independently H, or an
optionally substituted group selected from the group consisting of
alkyl, arylalkyl, cycloalkyl and aryl; or R, R.sub.g, the nitrogen
atom and the phosphorus atom, together form a five- or six-membered
heterocyclic ring when R and R.sub.g are in a phosphorus containing
group; or A is NRSO.sub.2 and R, R.sub.a and the nitrogen atom
together form an optionally substituted five or-six-membered
heterocyclic ring fused to ring 1; n for each occurrence is
independently an integer from 0 to 6; R.sub.q is selected from the
group consisting of hydrogen, alkoxyalkyl, alkyl, optionally
substituted arylalkyl, optionally substituted cycloalkyl,
optionally substituted cycloalkylalkyl, optionally substituted
heteroaralkyl, optionally substituted (heterocycloalkyl)alkyl, and
halo; wherein the arylalkyl, the cycloalkyl, the cycloalkylalkyl,
the heteroaralkyl, and the (heterocycloalkyl)alkyl are each
optionally substituted with one, two, three, four, or five
substituents independently selected from the group consisting of
alkoxy, alkoxyalkyl, alkyl, cyano, halo, haloalkyl, hydroxy,
hydroxyalkyl and nitro; or when X is NR.sup.1 and R.sup.3 are each
H, then Y is N, Q is CR.sup.2, there is a double bond between Y and
Q, and R.sup.1 is 45wherein R.sub.a is H or --OMe; A is --NH--CO--,
--NH--SO.sub.2--, --NH--C(O)O--or --NH--C(O)--NH--; B is
N-methyl-indol-2-yl, (fluoro)(trifluoromethyl)phenyl, phenyl or
benzyl; R.sup.2 is H, 4-piperidinyl, 46N-ethylpiperidin-4-yl or
47when X is CR.sup.1 and one of R.sup.3 is not H, then Y is N, Q is
NR.sup.2, there is a double bond between X and Y, and 48where
Z.sup.100 is nitro, optionally substituted amino, 49or a group
optionally substituted with R.sub.b selected from the group
consisting of cycloalkyl, naphthyl, tetrahydronaphthyl,
benzothienyl, furanyl, thienyl, benzoxazolyl, benzothiazolyl,
50thiazolyl, benzofuranyl, 2,3-dihydrobenzofuranyl, indolyl,
isoxazolyl, tetrahydropyranyl, tetrahydrofuranyl, piperidinyl,
pyrazolyl, pyrrolyl, oxazolyl, isothiazolyl, oxadiazolyl,
thiadiazolyl, indolinyl, indazolyl, benzoisothiazolyl,
pyrido-oxazolyl, pyrido-thiazolyl, pyrimido-oxazolyl,
pyrimido-thiazolyl and benzimidazolyl; when a is 1 and D.sub.1,
G.sub.1, J.sub.1, L.sub.1 and M.sub.1 are each independently
selected from the group consisting of CR.sub.a and N, provided that
at least two of D.sub.1, G.sub.1, J.sub.1, L.sub.1and M.sub.1 are
CR.sub.a; or when a is 0, and one of D.sub.1, G.sub.1, L.sub.1 and
M.sub.1 is NR.sub.a, one of D.sub.1, G.sub.1, L.sub.1 and M.sub.1
is CR.sub.a and the remainder are independently selected from the
group consisting of CR.sub.a and N; when b is 1 and D.sub.2,
G.sub.2, J.sub.2, L.sub.2 and M.sub.2 are each independently
selected from the group consisting of CR.sub.a and N, provided that
at least two of D.sub.2, G.sub.2, J.sub.2, L.sub.2 and M.sub.2 are
CR.sub.a; or when b is 0, and one of D.sub.2, G.sub.2, L.sub.2 and
M.sub.2 is NR.sub.a, one of D.sub.2, G.sub.2, L.sub.2 and M.sub.2
is CR.sub.a and the remainder are independently selected from the
group consisting of CR.sub.a and N; R.sub.a and R.sub.b each
represent one or more substituents and are for each occurrence
independently selected from the group consisting of hydrogen,
halogen, --CN, --NO.sub.2, --C(O)OH, --C(O)H, --OH, --C(O)O-alkyl,
-Z.sup.105-C(O)N(R).sub.2, -Z.sup.105-N(R)--C(O)--Z.sup.200,
-Z.sup.105-N(R)--S(O).sub.2Z.sup.200, -Z.sup.105
-N(R)--C(O)--N(R)-Z.sup.200, R.sub.c, CH.sub.2OR.sub.c, tetrazolyl,
trifluoromethylcarbonylamino, trifluoromethylsulfonamido, and an
optionally substituted group selected from the group consisting of
carboxamido, alkyl, alkoxy, aryl, alkenyl, aryloxy, heteroaryloxy,
arylalkyl, alkynyl, amino, aminoalkyl, amido groups, heteroarylthio
and arylthio; Z.sup.105 for each occurrence is independently a
covalent bond or (C.sub.1-C.sub.6); Z.sup.200 for each occurrence
is independently an optionally substituted (C.sub.1-C.sub.6),
optionally substituted phenyl, or optionally substituted
--(C.sub.1-C.sub.6)-phenyl; R.sub.c for each occurrence is
independently hydrogen, optionally substituted alkyl, optionally
substituted aryl, --CH.sub.2--NR.sub.dR.sub.e,
--W--(CH.sub.2).sub.t--NR.sub.dR.sub.e,
--W--(CH.sub.2).sub.t-Oalkyl, --W--(CH.sub.2).sub.t--S-alkyl or
--W--(CH.sub.2).sub.t--OH; R.sub.d and R.sub.e for each occurrence
are independently H, alkyl, alkanoyl or SO.sub.2-alkyl; or R.sub.d,
R.sub.e and the nitrogen atom to which they are attached together
form a five- or six-membered heterocyclic ring; t for each
occurrence is independently an integer from 2 to 6; W for each
occurrence is independently a direct bond or O, S, S(O),
S(O).sub.2, or NR.sub.f; R.sub.f for each occurrence is
independently H or alkyl; Z.sup.110 is a covalent bond, or an
optionally substituted (C.sub.1-C.sub.6) which is optionally
substituted with one or more substituents selected from the group
consisting of alkyl, CN, OH, halogen, NO.sub.2, COOH, optionally
substituted amino and optionally substituted phenyl; Z.sup.111 is a
covalent bond, an optionally substituted (C.sub.1-C.sub.6) or an
optionally substituted
--(CH.sub.2).sub.n-cycloalkyl-(CH.sub.2).sub.n--; where the
optionally substituted groups are optionally substituted with one
or more substituents selected from the group consisting of alkyl,
CN, OH, halogen, NO.sub.2, COOH, optionally substituted amino and
optionally substituted phenyl; or R.sup.1 is a substituted or
unsubstituted carbocyclic or heterocyclic ring fused with ring 2; A
is a covalent bond, --O--; --S--; --S(O).sub.p--; --N(R)--;
--N(C(O)OR)--; --N(C(O)R)--; --N(SO.sub.2R)--, --CH.sub.2O--;
--CH.sub.2S--; --CH.sub.2N(R)--; --CH.sub.2N(C(O)R))--;
--CH.sub.2N(CO)OR)--; --CH.sub.2N(SO.sub.2R)--; --CH(NHR)--;
--CH(NHC(O)R)--; --CH(NHSO.sub.2R)--; --CH(NHC(O)OR)--;
--CH(OC(O)R)--; --CH(OC(O)NHR); --CH.dbd.CH--; --C(.dbd.NOR)--;
--C(O)--; --CH(OR)--; --C(O)N(R)--; --N(R)C(O)--;
--N(R)S(O).sub.p--; --OC(O)N(R)--;
;--N(R)--C(O)--(CH.sub.2).sub.n--N(R)--, --N(R)C(O)O--;
--N(R)--(CH.sub.2).sub.n+1--C(O)--, --S(O).sub.pN(R)--;
--O--(CR.sub.2).sub.n+1--C(O)--, --O--(CR.sub.2).sub.n+1--O--,
--N(C(O)R)S(O).sub.p--; --N(R)S(O).sub.pN(R)--;
--N(R)--C(O)--(CH.sub.2).- sub.n--O--, --C(O)N(R)C(O)--;
--S(O).sub.pN(R)C(O)--; --OS(O).sub.pN(R)--; --N(R)S(O).sub.pO--;
--N(R)S(O).sub.pC(O)--; --SO.sub.pN(C(O)R)--; --N(R)SO.sub.pN(R)--;
--C(O)O--; --N(R)P(OR.sub.g)O--; --N(R)P(OR.sub.g)--;
--N(R)P(O)(OR.sub.g)O--; --N(R)P(O)(OR.sub.g)--;
--N(C(O)R)P(OR.sub.g)O--; --N(C(O)R)P(OR.sub.g)--;
--N(C(O)R)P(O)(OR.sub.g)O--, or --N(C(O)R)P(OR.sub.g)--; p is 1 or
2; R for each occurrence is independently H, optionally substituted
alkyl, optionally substituted arylalkyl or optionally substituted
aryl; R.sub.g for each occurrence is independently H, or an
optionally substituted group selected from the group consisting of
alkyl, arylalkyl, cycloalkyl and aryl; or R, R.sub.g, the nitrogen
atom and the phosphorus atom, together form a five- or six-membered
heterocyclic ring when R and R.sub.g are in a phosphorus containing
group; or A is NRSO2 and R, R.sub.a and the nitrogen atom together
form an optionally substituted five or-six-membered heterocyclic
ring fused to ring 1; R.sup.2 is -Z.sup.101-Z.sup.102; Z.sup.101 is
a covalent bond, --(C.sub.1-C.sub.6)--, --(C.sub.1-C.sub.6)--O--,
--(C.sub.1-C.sub.6)--C(O- )--, --(C.sub.1-C.sub.6)--C(O)O--,
--(C.sub.1-C.sub.6)--C(O)--NH--,
--(C.sub.1-C.sub.6)--C(O)--N((C.sub.1-C.sub.6))--or an optionally
substituted phenyl group; Z.sup.102 is hydrogen, an optionally
substituted alkyl group, an optionally substituted cycloalkyl
group, an optionally substituted saturated or unsaturated
heterocyclic group, or an optionally substituted saturated or
unsaturated heterobicyclic group; said substituted heterocyclic or
substituted heterobicyclic group having one or more substituents
each independently selected from the group consisting of hydroxyl,
cyano, optionally substituted alkoxy, optionally substituted
sulfonamido, optionally substituted ureido, optionally substituted
carboxamido; optionally substituted amino, oxo, a saturated or
unsaturated or aromatic optionally substituted heterocyclic group;
wherein the heterocyclic group comprises one or more nitrogen
atoms, one or more oxygen atoms or a combination thereof and where
said nitrogen atoms are independently optionally substituted by a
substituted or unsubstituted alkyl, substituted or unsubstituted
aryl, or substituted or unsubstituted arylalkyl; or R.sup.2 is of
the formula B-E; B is hydroxy or an optionally substituted group
selected from the group consisting of cycloalkyl, azacycloalkyl,
amino, aminoalkylsulfonyl, alkoxyalkyl, alkoxy,
aminoalklylcarbonyl, alkylenyl, aminoalkyl, alkylenylcarbonyl and
aminoalkylcarbonyl; E is an optionally substituted group selected
from the group consisting of azacycloalkyl, azacycloalkylcarbonyl,
azacycloalkylsulfonyl, azacycloalkylalkyl, heteroaryl,
heteroarylcarbonyl, heteroarylsulfonyl, heteroarylalkyl,
azacycloalkylcarbonylamino, heteroarylcarbonylamino and aryl; and n
for each occurrence is independently an integer from 0 to 6.
2. A compound according to claim 1, wherein X is CR.sup.1, Y is
CR.sub.q, Q is O and there is a double bond between X and Y; or X
is CR.sup.1, Y is N, Q is O and there is a double bond between X
and Y; or X is CR.sup.1, Y is O, Q is N and there is a double bond
between Q and the pyrimidinyl ring.
3. A compound according to claim 2 of formula (II), 51wherein
R.sub.q is selected from the group consisting of hydrogen,
alkoxyalkyl, alkyl, optionally substituted arylalkyl, optionally
substituted cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted heteroaralkyl, optionally substituted
(heterocycloalkyl)alkyl, and halo, wherein the arylalkyl, the
cycloalkyl, the cycloalkylalkyl, the heteroaralkyl, and the
(heterocycloalkyl)alkyl are each optionally substituted with one,
two, three, four, or five substituents independently selected from
the group consisting of alkoxy, alkoxyalkyl, alkyl, cyano, halo,
haloalkyl, hydroxy, hydroxyalkyl, and nitro; A is selected from the
group consisting of --N(R)--C(O)--(CH.sub.2).sub.n--N(R- )--,
--N(R)--, --N(R)C(O)--, and --N(R)S(O).sub.p--; Z.sup.100 is
selected from the group consisting of optionally substituted aryl
and optionally substituted heteroaryl; n is 0; p is 2; and R is
hydrogen.
4. The compound of claim 3 wherein R.sub.q is hydrogen.
5. The compound of claim 4 selected from the group consisting of
N-[4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-methylphenyl)urea;
N-[4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methylphenyl)urea;
N-[4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2-methylphenyl)urea;
N-[4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-chlorophenyl)urea;
5-[4-(1,3-benzoxazol-2-ylamino)phenyl]furo[2,3-d]pyrimidin-4-amine;
N-[4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl]benzamide; and
N-[4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl]benzenesulfonamide.
6. The compound of claim 3 wherein R.sub.q is selected from the
group consisting of alkyl and halo.
7. The compound of claim 6 selected from the group consisting of
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2-methylpheny-
l)urea;
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-meth-
ylphenyl)urea;
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]benz- amide;
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]benzenesulfo-
namide;
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-meth-
ylphenyl)urea;
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N'--
(3-chlorophenyl)urea;
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phen-
yl]-N'-(3-methoxyphenyl)urea;
N-[4-(4-amino-6-bromofuro[2,3-d]pyrimidin-5--
yl)phenyl]-N'-(3-methylphenyl)urea;
N-[4-(4-amino-6-methylfuro[2,3-d]pyrim-
idin-5-yl)phenyl]-N'-(3-bromophenyl)urea;
N-[4-(4-amino-6-methylfuro[2,3-d-
]pyrimidin-5-yl)phenyl]-N'-(3-ethylphenyl)urea;
N-[4-(4-amino-6-methylfuro-
[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3,5-dimethylphenyl)urea;
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3,5-dichlorop-
henyl)urea;
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-[2--
fluoro-5-(trifluoromethyl)phenyl]urea;
1-[4-(4-Amino-6-methyl-furo[2,3-d]p-
yrimidin-5-yl)-phenyl]-3-(4-cyano-phenyl)-urea; and
1-[4-(4-Amino-6-methyl-furo[2,3-d]pyrimidin-5-yl)-phenyl]-3-(3
3-trifluoromethyl-phenyl)-urea.
8. A compound according to claim 2 of formula (III), 52wherein A is
selected from the group consisting of a bond, --N(R)C(O)--, and
--N(R)--C(O)--(CH.sub.2).sub.n--N(R)--; Z.sup.100 is selected from
the group consisting of --NO.sub.2, amino, substituted amino, and
optionally substituted aryl; R is hydrogen; and n is 0.
9. The compound of claim 8 wherein A is a bond; and Z.sup.100 is
selected from the group consisting of --NO.sub.2, substituted
amino, and amino.
10. The compound of claim 9 selected from the group consisting of
3-(4-nitrophenyl)isoxazolo[5,4-d]pyrimidin-4-amine; and
3-(4-aminophenyl)isoxazolo[5,4-d]pyrimidin-4-amine.
11. The compound of claim 8 wherein A is selected from the group
consisting of --N(R)C(O)--, and
--N(R)--C(O)--(CH.sub.2).sub.n--N(R)--; and Z.sup.100 is optionally
substituted aryl.
12. The compound of claim 11 selected from the group consisting of
N-[4-(4-aminoisoxazolo[5,4-d]pyrimidin-3-yl)phenyl]-N'-(3-methylphenyl)ur-
ea;
N-[4-(4-aminoisoxazolo[5,4-d]pyrimidin-3-yl)phenyl]-N'-(3-ethylphenyl)-
urea;
N-[4-(4-aminoisoxazolo[5,4-d]pyrimidin-3-yl)phenyl]-N'-(3-chlorophen-
yl)urea;
N-[4-(4-aminoisoxazolo[5,4-d]pyrimidin-3-yl)phenyl]benzamide;
N-[4-(4-aminoisoxazolo[5,4-d]pyrimidin-3-yl)phenyl]-N'-[3-(trifluoromethy-
l)phenyl]urea; and
N-[4-(4-aminoisoxazolo[5,4-d]pyrimidin-3-yl)phenyl]-N'--
[2-fluoro-5-(trifluoromethyl)phenyl]urea.
13. A compound according to claim 1, wherein X is NR.sup.1; both
R.sup.3 are each H; Y is N; Q is CR.sup.2; and there is a double
bond between Y and Q.
14. A compound according to claim 13, wherein the compound or the
pharmaceutically acceptable salt thereof is
N2-{4-[7-Amino-3-(4-piperidyl-
)-1H-pyrazolo[4,3-d]pyrimidin-1-yl]-2-methoxyphenyl}-1-methyl-1H-2-indolec-
arboxamide;
N2-{4-[7-Amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-1-y-
l]-2-methoxyphenyl}-2-fluoro-4-(trifluoromethyl)benzamide;
N1-[4-(7-Amino-1H-pyrazolo[4,3-d]pyrimidin-1-yl)-2-Methoxyphenyl]-2-fluor-
o-4-(trifluoromethyl)benzamide;
N1-{4-[7-Amino-3-(4-piperidyl)-1H-pyrazolo-
[4,3-d]pyrimidin-1-yl]-2-methoxyphenyl }-1-benzenesulfonamide;
Benzyl
N-{4-[7-amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-1-yl]-2-methoxy-
phenyl}carbamate;
N-{4-[7-Amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidi-
n-1-yl]-2-methoxyphenyl}-N-phenylurea;
N2-{4-[7-Amino-3-(1-tetrahydro-2H-4-
-pyranyl-4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-1-yl]-2-methoxyphenyl}-1-
-methyl-1H-2-indolecarboxamide;
N2-{4-[7-amino-3-(1-ethyl4-piperidyl)-1H-p-
yrazolo[4,3-d]pyrimidin-1-yl]-2-methoxyphenyl}-1-methyl-1H-2-indolecarboxa-
mide;
N1-{4-[7-Amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-1-yl]phen-
yl}-1-benzenesulfonamide;
N2-{4-[7-Amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d-
]pyrimidin-1-yl]phenyl}-1-methyl-1H-2-indolecarboxamide; or
N2-{4-[7-Amino-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-pyrazolo[4,3-d]pyrim-
idin-1-yl]-2-methoxyphenyl}-1-methyl-1H-2-indolecarboxamide.
15. A compound according to claim 1, wherein X is CR.sup.1; one of
R.sup.3 is not H; Y is N, Q is NR.sup.2; and there is a double bond
between X and Y.
16. A method of inhibiting one or more protein kinase activity in a
patient comprising administering a therapeutically effective amount
of a compound of claim 1 or a physiologically acceptable salt,
prodrug or biologically active metabolites thereof to said
patient.
17. The method of claim 16 wherein said protein kinase is selected
from the group consisting of KDR, FGFR-1, PDGFR.beta.,
PDGFR.alpha., IGF-IR, c-Met, Flt-1, Flt-4, TIE-2, TIE-1, Lck, Src,
fyn, Lyn, Blk, hck, fgr and yes.
18. A method of affecting hyperproliferative disorders in a patient
comprising administering a therapeutically effective amount of a
compound of claim 1 or a physiologically acceptable salt, prodrug
or biologically active metabolites thereof to said patient.
19. A method of affecting angiogenesis in a patient comprising
administering a therapeutically effective amount of a compound of
claim 1 or a physiologically acceptable salt, prodrug or
biologically active metabolites thereof to said patient.
20. The method of claim 16 wherein the protein kinase is a protein
serine/threonine kinase or a protein tyrosine kinase.
21. A method of treating one or more ulcers in a patient comprising
administering a therapeutically effective amount of a compound of
claim 1 or a physiologically acceptable salt, prodrug or
biologically active metabolites thereof to said patient.
22. The method of claim 21 wherein the ulcer or ulcers are caused
by a bacterial or fungal infection; or the ulcer or ulcers are
Mooren ulcers; or the ulcer or ulcers are a symptom of ulcerative
colitis.
23. A method of treating a condition in a patient comprising
administering a therapeutically effective amount of a compound of
claim 1 or a physiologically acceptable salt, prodrug or
biologically active metabolites thereof to said patient, wherein
said condition is an ocular condition, a cardiovascular condition,
a cancer, Crow-Fukase (POEMS) syndrome, a diabetic condition,
sickle cell anaemia, chronic inflammation, systemic lupus,
glomerulonephritis, synovitis, inflammatory bowel disease, Crohn's
disease, glomerulonephritis, rheumatoid arthritis, osteoarthritis,
multiple sclerosis, graft rejection, Lyme disease, sepsis, von
Hippel Lindau disease, pemphigoid, psoriasis, Paget's disease,
polycystic kidney disease, fibrosis, sarcoidosis, cirrhosis,
thyroiditis, hyperviscosity syndrome, Osler-Weber-Rendu disease,
chronic occlusive pulmonary disease, asthma or edema following
burns, trauma, radiation, stroke, hypoxia, ischemia, ovarian
hyperstimulation syndrome, preeclampsia, menometrorrhagia,
endometriosis, pulmonary hypertension, infantile hemangioma, or
infection by Herpes simplex, Herpes Zoster, human immunodeficiency
virus, parapoxvirus, protozoa or toxoplasmosis.
24. The method of claim 23 wherein the ocular condition is ocular
or macular edema, ocular neovascular disease, scleritis, radial
keratotomy, uveitis, vitritis, myopia, optic pits, chronic retinal
detachment, post-laser treatment complications, conjunctivitis,
Stargardt's disease, Eales disease, retinopathy or macular
degeneration.
25. The method of claim 23 wherein the cardiovascular condition is
atherosclerosis, restenosis, ischemia/reperfusion injury, vascular
occlusion or carotid obstructive disease.
26. The method of claim 23 wherein the cancer is a solid tumor, a
sarcoma, fibrosarcoma, osteoma, melanoma, retinoblastoma, a
rhabdomyosarcoma, glioblastoma, neuroblastoma, teratocarcinoma, an
hematopoietic malignancy, Kaposi's sarcoma, Hodgkin's disease,
lymphoma, myeloma, leukemia or malignant ascites.
27. The method of claim 23 wherein the diabetic condition is
insulin-dependent diabetes mellitus glaucoma, diabetic retinopathy
or microangiopathy.
28. A method of decreasing fertility in a patient, said method
comprising the step of administering to the patient an effective
amount of a compound of claim 1 or a physiologically acceptable
salt, prodrug or biologically active metabolite thereof.
29. The method of claim 19 wherein the compound or a
physiologically acceptable salt, prodrug or biologically active
metabolite thereof is administered in an amount effective to
promote angiogenesis or vasculogenesis.
30. The method of claim 17 wherein the protein kinase is TIE-2.
31. The method of claim 29 wherein the compound of formula (I), or
physiologically acceptable salt, prodrug or biologically active
metabolite thereof, is administered in combination with a
pro-angiogenic growth factor.
32. The method of claim 31 wherein the pro-angiogenic growth factor
is selected from the group consisiting of VEGF, VEGF-B, VEGF-C,
VEGF-D, VEGF-E, HGF, FGF-1, FGF-2, derivatives thereof and
antiiodotypic antibodies.
33. The method of claim 29 wherein the patient is suffering from
anemia, ischemia, infarct, transplant rejection, a wound, gangrene
or necrosis.
34. The method of claim 16 wherein the protein kinase activity is
involved in T cell activation, B cell activation, mast cell
degranulation, monocyte activation, the potentiation of an
inflammatory response or a combination thereof.
35. A pharmaceutical composition comprising a compound according to
claim 1 and a pharmaceutically acceptable carrier or diluent.
Description
BACKGROUND OF THE INVENTION
[0001] There are at least 400 enzymes identified as protein
kinases. These enzymes catalyze the phosphorylation of target
protein substrates. The phosphorylation is usually a transfer
reaction of a phosphate group from ATP to the protein substrate.
The specific structure in the target substrate to which the
phosphate is transferred is a tyrosine, serine or threonine
residue. Since these amino acid residues are the target structures
for the phosphoryl transfer, these protein kinase enzymes are
commonly referred to as tyrosine kinases or serine/threonine
kinases.
[0002] The phosphorylation reactions, and counteracting phosphatase
reactions, at the tyrosine, serine and threonine residues are
involved in countless cellular processes that underlie responses to
diverse intracellular signals (typically mediated through cellular
receptors), regulation of cellular functions, and activation or
deactivation of cellular processes. A cascade of protein kinases
often participate in intracellular signal transduction and are
necessary for the realization of these cellular processes. Because
of their ubiquity in these processes, the protein kinases can be
found as an integral part of the plasma membrane or as cytoplasmic
enzymes or localized in the nucleus, often as components of enzyme
complexes. In many instances, these protein kinases are an
essential element of enzyme and structural protein complexes that
determine where and when a cellular process occurs 9within a
cell.
[0003] Protein Tyrosine Kinases. Protein tyrosine kinases (PTKs)
are enzymes which catalyse the phosphorylation of specific tyrosine
residues in cellular proteins. This post-translational modification
of these substrate proteins, often enzymes themselves, acts as a
molecular switch regulating cell proliferation, activation or
differentiation (for review, see Schlessinger and Ulrich, 1992,
Neuron 9:383-391). Aberrant or excessive PTK activity has been
observed in many disease states including benign and malignant
proliferative disorders as well as diseases resulting from
inappropriate activation of the immune system (e.g., autoimmune
disorders), allograft rejection, and graft vs. host disease. In
addition, endothelial-cell specific receptor PTKs such as KDR and
Tie-2 mediate the angiogenic process, and are thus involved in
supporting the progression of cancers and other diseases involving
inappropriate vascularization (e.g., diabetic retinopathy,
choroidal neovascularization due to age-related macular
degeneration, psoriasis, arthritis, retinopathy of prematurity,
infantile hemangiomas).
[0004] Tyrosine kinases can be of the receptor-type (having
extracellular, transmembrane and intracellular domains) or the
non-receptor type (being wholly intracellular).
[0005] Receptor Tyrosine Kinases (RTKs). The RTKs comprise a large
family of transmembrane receptors with diverse biological
activities. At present, at least nineteen (19) distinct RTK
subfamilies have been identified. The receptor tyrosine kinase
(RTK) family includes receptors that are crucial for the growth and
differentiation of a variety of cell types (Yarden and Ullrich,
Ann. Rev. Biochem. 57:433-478, 1988; Ulrich and Schlessinger, Cell
61:243-254, 1990). The intrinsic function of RTKs is activated upon
ligand binding, which results in phosphorylation of the receptor
and multiple cellular substrates, and subsequently in a variety of
cellular responses (Ullrich & Schlessinger, 1990, Cell
61:203-212). Thus, receptor tyrosine kinase mediated signal
transduction is initiated by extracellular interaction with a
specific growth factor (ligand), typically followed by receptor
dimerization, stimulation of the intrinsic protein tyrosine kinase
activity and receptor trans-phosphorylation, Binding sites are
thereby created for intracellular signal transduction molecules and
lead to the formation of complexes with a spectrum of cytoplasmic
signaling molecules that facilitate the appropriate cellular
response. (e.g., cell division, differentiation, metabolic effects,
changes in the extracellular microenvironment) see Schlessinger and
Ullrich, 1992, Neuron 9:1-20.
[0006] Proteins with SH2 (src homology -2) or phosphotyrosine
binding (PTB) domains bind activated tyrosine kinase receptors and
their substrates with high affinity to propagate signals into cell.
Both of the domains recognize phosphotyrosine. (Fantl et al., 1992,
Cell 69:413-423; Songyang et al., 1994, Mol. Cell. Biol.
14:2777-2785; Songyang et al., 1993, Cell 72:767-778; and Koch et
al., 1991, Science 252:668-678; Shoelson, Curr. Opin. Chem. Biol.
(1997), 1(2), 227-234; Cowburn, Curr. Opin. Struct. Biol. (1997),
7(6), 835-838). Several intracellular substrate proteins that
associate with receptor tyrosine kinases (RTKs) have been
identified. They may be divided into two principal groups: (1)
substrates which have a catalytic domain; and (2) substrates which
lack such a domain but serve as adapters and associate with
catalytically active molecules (Songyang et al., 1993, Cell
72:767-778). The specificity of the interactions between receptors
or proteins and SH2 or PTB domains of their substrates is
determined by the amino acid residues immediately surrounding the
phosphorylated tyrosine residue. For example, differences in the
binding affinities between SH2 domains and the amino acid sequences
surrounding the phosphotyrosine residues on particular receptors
correlate with the observed differences in their substrate
phosphorylation profiles (Songyang et al., 1993, Cell 72:767-778).
Observations suggest that the function of each receptor tyrosine
kinase is determined not only by its pattern of expression and
ligand availability but also by the array of downstream signal
transduction pathways that are activated by a particular receptor
as well as the timing and duration of those stimuli. Thus,
phosphorylation provides an important regulatory step which
determines the selectivity of signaling pathways recruited by
specific growth factor receptors, as well as differentiation factor
receptors.
[0007] Several receptor tyrosine kinases such as FGFR-1, PDGFR,
TIE-2 and c-Met, and growth factors that bind thereto, have been
suggested to play a role in angiogenesis, although some may promote
angiogenesis indirectly (Mustonen and Alitalo, J. Cell Biol.
129:895-898, 1995). One such receptor tyrosine kinase, known as
Afetal liver kinase 1.congruent.(FLK-1), is a member of the type
III subclass of RTKs. An alternative designation for human FLK-1 is
Akinase insert domain-containing receptor.congruent.(KDR) (Terman
et al., Oncogene 6:1677-83, 1991). Another alternative designation
for FLK-1/KDR is Avascular endothelial cell growth factor receptor
2.congruent.(VEGFR-2) since it binds VEGF with high affinity. The
murine version of FLK-1/VEGFR-2 has also been called NYK (Oelrichs
et al, Oncogene 8(1): 11-15, 1993). DNAs encoding mouse, rat and
human FLK-1 have been isolated, and the nucleotide and encoded
amino acid sequences reported (Matthews et al., Proc. Natl. Acad.
Sci. USA, 88:9026-30, 1991; Terman et al., 1991, supra; Terman et
al., Biochem. Biophys. Res. Comm. 187:1579-86, 1992; Sarzani et
al., supra; and Millauer et al., Cell 72:835-846, 1993). Numerous
studies such as those reported in Millauer et al., supra, suggest
that VEGF and FLK-1/KDR/VEGFR-2 are a ligand-receptor pair that
play an important role in the proliferation of vascular endothelial
cells, and formation and sprouting of blood vessels, termed
vasculogenesis and angiogenesis, respectively.
[0008] Another type III subclass RTK designated Afms-like tyrosine
kinase-1.congruent.(Flt-1) is related to FLK-1/KDR (DeVries et al.
Science 255;989-991, 1992; Shibuya et al., Oncogene 5:519-524,
1990). An alternative designation for Flt-1 is Avascular
endothelial cell growth factor receptor 1.congruent.(VEGFR-1). To
date, members of the FLK-1/KDR/VEGFR-2 and Flt-1/VEGFR-1
subfamilies have been found expressed primarily on endothelial
cells. These subclass members are specifically stimulated by
members of the vascular endothelial cell growth factor (VEGF)
family of ligands (Klagsburn and D=Amore, Cytokine & Growth
Factor Reviews 7: 259-270, 1996). Vascular endothelial cell growth
factor (VEGF) binds to Flt-1 with higher affinity than to FLK-1/KDR
and is mitogenic toward vascular endothelial cells (Terman et al.,
1992, supra; Mustonen et al. supra; DeVries et al., supra). Flt-1
is believed to be essential for endothelial organization during
vascular development. Flt-1 expression is associated with early
vascular development in mouse embryos, and with neovascularization
during wound healing (Mustonen and Alitalo, supra). Expression of
Flt-1 in monocytes, osteoclasts, and osteoblasts, as well as in
adult tissues such as kidney glomeruli suggests an additional
function for this receptor that is not related to cell growth
(Mustonen and Alitalo, supra).
[0009] As previously stated, recent evidence suggests that VEGF
plays a role in the stimulation of both normal and pathological
angiogenesis (Jakeman et al., Endocrinology 133: 848-859, 1993;
Kolch et al., Breast Cancer Research and Treatment 36: 139-155,
1995; Ferrara et al., Endocrine Reviews 18(1); 4-25, 1997; Ferrara
et al., Regulation of Angiogenesis (ed. L. D. Goldberg and E. M.
Rosen), 209-232, 1997). In addition, VEGF has been implicated in
the control and enhancement of vascular permeability (Connolly, et
al., J. Biol. Chem. 264: 20017-20024, 1989; Brown et al.,
Regulation of Angiogenesis (ed. L. D. Goldberg and E. M. Rosen),
233-269, 1997). Different forms of VEGF arising from alternative
splicing of mRNA have been reported, including the four species
described by Ferrara et al. (J. Cell. Biochem. 47:211-218, 1991).
Both secreted and predominantly cell-associated species of VEGF
have been identified by Ferrara et al. supra, and the protein is
known to exist in the form of disulfide linked dimers.
[0010] Several related homologs of VEGF have recently been
identified. However, their roles in normal physiological and
disease processes have not yet been elucidated. In addition, the
members of the VEGF family are often coexpressed with VEGF in a
number of tissues and are, in general, capable of forming
heterodimers with VEGF. This property likely alters the receptor
specificity and biological effects of the heterodimers and further
complicates the elucidation of their specific functions as
illustrated below (Korpelainen and Alitalo, Curr. Opin. Cell Biol.,
159-164, 1998 and references cited therein).
[0011] Placenta growth factor (PlGF) has an amino acid sequence
that exhibits significant homology to the VEGF sequence (Park et
al., J. Biol. Chem. 269:25646-54, 1994; Maglione et al. Oncogene
8:925-31, 1993). As with VEGF, different species of PlGF arise from
alternative splicing of mRNA, and the protein exists in dimeric
form (Park et al., supra). PlGF-1 and PlGF-2 bind to Flt-1 with
high affinity, and PlGF-2 also avidly binds to neuropilin-1 (Migdal
et al, J. Biol. Chem. 273 (35): 22272-22278), but neither binds to
FLK-1/KDR (Park et al., supra). PlGF has been reported to
potentiate both the vascular permeability and mitogenic effect of
VEGF on endothelial cells when VEGF is present at low
concentrations (purportedly due to heterodimer formation) (Park et
al., supra).
[0012] VEGF-B is produced as two isoforms (167 and 185 residues)
that also appear to bind Flt-1/VEGFR-1. It may play a role in the
regulation of extracellular matrix degradation, cell adhesion, and
migration through modulation of the expression and activity of
urokinase type plasminogen activator and plasminogen activator
inhibitor 1 (Pepper et al, Proc. Natl. Acad. Sci. U.S.A. (1998),
95(20): 11709-11714).
[0013] VEGF-C was originally cloned as a ligand for VEGFR-3/Flt-4
which is primarily expressed by lymphatic endothelial cells. In its
fully processed form, VEGF-C can also bind KDR/VEGFR-2 and
stimulate proliferation and migration of endothelial cells in vitro
and angiogenesis in in vivo models ( Lymboussaki et al, Am. J.
Pathol. (1998), 153(2): 395-403; Witzenbichler et al, Am. J.
Pathol. (1998), 153(2), 381-394). The transgenic overexpression of
VEGF-C causes proliferation and enlargement of only lymphatic
vessels, while blood vessels are unaffected. Unlike VEGF, the
expression of VEGF-C is not induced by hypoxia (Ristimaki et al, J.
Biol. Chem. (1998), 273(14),8413-8418).
[0014] The most recently discovered VEGF-D is structurally very
similar to VEGF-C. VEGF-D is reported to bind and activate at least
two VEGFRs, VEGFR-3/Flt4 and KDR/VEGFR-2. It was originally cloned
as a c-fos inducible mitogen for fibroblasts and is most
prominently expressed in the mesenchymal cells of the lung and skin
(Achen et al, Proc. Natl. Acad. Sci. U.S.A. (1998), 95(2), 548-553
and references therein).
[0015] As for VEGF, VEGF-C and VEGF-D have been claimed to induce
increases in vascular permeability in vivo in a Miles assay when
injected into cutaneous tissue (PCT/US97/14696; WO98/07832,
Witzenbichler et al., supra). The physiological role and
significance of these ligands in modulating vascular
hyperpermeability and endothelial responses in tissues where they
are expressed remains uncertain.
[0016] There has been recently reported a virally encoded, novel
type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF),
which preferentially utilizes KDR/Flk-1 receptor and carries a
potent mitotic activity without heparin-binding domain (Meyer et
al, EMBO J. (1999), 18(2), 363-374; Ogawa et al, J. Biol. Chem.
(1998), 273(47), 31273-31282.). VEGF-E sequences possess 25%
homology to mammalian VEGF and are encoded by the parapoxvirus Orf
virus (OV). This parapoxvirus that affects sheep and goats and
occasionally, humans, to generate lesions with angiogenesis. VEGF-E
is a dimer of about 20 kDa with no basic domain nor affinity for
heparin, but has the characteristic cysteine knot motif present in
all mammalian VEGFs, and was surprisingly found to possess potency
and bioactivities similar to the heparin-binding VEGF165 isoform of
VEGF-A, i.e. both factors stimulate the release of tissue factor
(TF), the proliferation, chemotaxis and sprouting of cultured
vascular endothelial cells in vitro and angiogenesis in vivo. Like
VEGF165, VEGF-E was found to bind with high affinity to VEGF
receptor-2 (KDR) resulting in receptor autophosphorylation and a
biphasic rise in free intracellular Ca2+ concentrations, while in
contrast to VEGF165, VEGF-E did not bind to VEGF receptor-1
(Flt-1).
[0017] Based upon emerging discoveries of other homologs of VEGF
and VEGFRs and the precedents for ligand and receptor
heterodimerization, the actions of such VEGF homologs may involve
formation of VEGF ligand heterodimers, and/or heterodimerization of
receptors, or binding to a yet undiscovered VEGFR (Witzenbichler et
al., supra). Also, recent reports suggest neuropilin-1 (Migdal et
al, supra) or VEGFR-3/Flt-4 (Witzenbichler et al., supra), or
receptors other than KDR/VEGFR-2 may be involved in the induction
of vascular permeability (Stacker, S. A., Vitali, A., Domagala, T.,
Nice, E., and Wilks, A. F., AAngiogenesis and
Cancer.congruent.Conference, Amer. Assoc. Cancer Res., January
1998, Orlando, Fla.; Williams, Diabetelogia 40: S118-120 (1997)).
Until now, no direct evidence for the essential role of KDR in
VEGF-mediated vascular hyperpermeability has been disclosed.
[0018] The Non-Receptor Tyrosine Kinases. The non-receptor tyrosine
kinases represent a collection of cellular enzymes which lack
extracellular and transmembrane sequences. At present, over
twenty-four individual non-receptor tyrosine kinases, comprising
eleven (11) subfamilies (Src, Frk, Btk, Csk, Abl, Zap70, Fes/Fps,
Fak, Jak, Ack and LIMK) have been identified. At present, the Src
subfamily of non-receptor tyrosine kinases is comprised of the
largest number of PTKs and include Src, Yes, Fyn, Lyn, Lck, Blk,
Hck, Fgr and Yrk. The Src subfamily of enzymes has been linked to
oncogenesis and immune responses. A more detailed discussion of
non-receptor tyrosine kinases is provided in Bolen, 1993, Oncogene
8:2025-2031, which is incorporated herein by reference.
[0019] Many of the tyrosine kinases, whether an RTK or non-receptor
tyrosine kinase, have been found to be involved in cellular
signaling pathways involved in numerous pathogenic conditions,
including cancer, psoriasis, and other hyperproliferative disorders
or hyper-immune responses.
[0020] Development of Compounds to Modulate the PTKs. In view of
the surmised importance of PTKs to the control, regulation, and
modulation of cell proliferation, the diseases and disorders
associated with abnormal cell proliferation, many attempts have
been made to identify receptor and non-receptor tyrosine kinase
"inhibitors" using a variety of approaches, including the use of
mutant ligands (U.S. Pat. No. 4,966,849), soluble receptors and
antibodies (Application No. WO 94/10202; Kendall & Thomas,
1994, Proc. Natl. Acad. Sci 90:10705-09; Kim et al., 1993, Nature
362:841-844), RNA ligands (Jellinek, et al., Biochemistry
33:10450-56; Takano, et al., 1993, Mol. Bio. Cell 4:358A; Kinsella,
et al. 1992, Exp. Cell Res. 199:56-62; Wright, et al., 1992, J.
Cellular Phys. 152:448-57) and tyrosine kinase inhibitors (WO
94/03427; WO 92/21660; WO 91/15495; WO 94/14808; U.S. Pat. No.
5,330,992; Mariani, et al., 1994, Proc. Am. Assoc. Cancer Res.
35:2268).
[0021] More recently, attempts have been made to identify small
molecules which act as tyrosine kinase inhibitors. For example, bis
monocyclic, bicyclic or heterocyclic aryl compounds (PCT WO
92/20642) and vinylene-azaindole derivatives (PCT WO 94/14808) have
been described generally as tyrosine kinase inhibitors. Styryl
compounds (U.S. Pat. No. 5,217,999), styryl-substituted pyridyl
compounds (U.S. Pat. No. 5,302,606), certain quinazoline
derivatives (EP Application No. 0 566 266 A1; Expert Opin. Ther.
Pat. (1998), 8(4): 475-478), selenoindoles and selenides (PCT WO
94/03427), tricyclic polyhydroxylic compounds (PCT WO 92/21660) and
benzylphosphonic acid compounds (PCT WO 91/15495) have been
described as compounds for use as tyrosine kinase inhibitors for
use in the treatment of cancer. Anilinocinnolines (PCT WO97/34876)
and quinazoline derivative compounds (PCT WO97/22596; PCT
WO97/42187) have been described as inhibitors of angiogenesis and
vascular permeability.
[0022] In addition, attempts have been made to identify small
molecules which act as serine/threonine kinase inhibitors. For
example, bis(indolylmaleimide) compounds have been described as
inhibiting particular PKC serine/threonine kinase isoforms whose
signal transducing function is associated with altered vascular
permeability in VEGF-related diseases (PCT WO97/40830; PCT
WO97/40831).
[0023] Plk-1 Kinase Inhibitors
[0024] Plk-1 is a serine/threonine kinase which is an important
regulator of cell cycle progression. It plays critical roles in the
assembly and the dynamic function of the mitotic spindle apparatus.
Plk-1 and related kinases have also been shown to be closely
involved in the activation and inactivation of other cell cycle
regulators, such as cyclin-dependent kinases. High levels of Plk-1
expression are associated with cell proliferation activities. It is
often found in malignant tumors of various origins. Inhibitors of
Plk-1 are expected to block cancer cell proliferation by disrupting
processes involving mitotic spindles and inappropriately activated
cyclin-dependent kinases.
[0025] Cdc2/Cyclin B Kinase Inhibitors (Cdc2 is also known as
cdk1)
[0026] Cdc2/cyclin B is another serine/threonine kinase enzyme
which belongs to the cyclin-dependent kinase (cdks) family. These
enzymes are involved in the critical transition between various
phases of cell cycle progression. It is believed that uncontrolled
cell proliferation, which is the hallmark of cancer is dependent
upon elevated cdk activities in these cells. The inhibition of
elevated cdk activities in cancer cells by cdc2/cyclin B kinase
inhibitors could suppress proliferation and may restore the normal
control of cell cycle progression.
[0027] The identification of effective small compounds which
specifically inhibit signal transduction and cellular proliferation
by modulating the activity of receptor and non-receptor tyrosine
and serine/threonine kinases to regulate and modulate abnormal or
inappropriate cell proliferation, differentiation, or metabolism is
therefore desirable. In particular, the identification of methods
and compounds that specifically inhibit the function of a tyrosine
kinase which is essential for antiogenic processes or the formation
of vascular hyperpermeability leading to edema, ascites, effusions,
exudates, and macromolecular extravasation and matrix deposition as
well as associated disorders would be beneficial.
SUMMARY OF THE INVENTION
[0028] The present invention provides a compound of formula I,
2
[0029] the racemic-diastereomeric mixtures, optical isomers,
pharmaceutically-acceptable salts, prodrugs or biologically active
metabolites thereof, wherein
[0030] the dotted line in the structure of formula (I) represents
an optional double bond;
[0031] X is CR.sup.1 or NR.sup.1; Y is O, CR.sub.q or N; Q is N,
NR.sup.2 or O;
[0032] R.sup.3 for each occurrence is independently hydrogen,
hydroxy, substituted or unsubstituted alkyl or substituted or
unsubstituted alkoxy;
[0033] when X is CR.sup.1, Y is CR.sub.q, Q is O and there is a
double bond between X and Y; or when X is CR.sup.1, Y is N, Q is O
and there is a double bond between X and Y; or when X is CR.sup.1,
Y is O, Q is N and there is a double bond between Q and the
pyrimidinyl ring, then
[0034] R.sup.1 is 3
[0035] where Z.sup.100 is nitro, optionally substituted amino,
4
[0036] or a group optionally substituted with R.sub.b selected from
the group consisting of cycloalkyl, naphthyl, tetrahydronaphthyl,
benzothienyl, furanyl, thienyl, benzoxazolyl, benzothiazolyl, 5
[0037] thiazolyl, benzofuranyl, 2,3-dihydrobenzofuranyl, indolyl,
isoxazolyl, tetrahydropyranyl, tetrahydrofuranyl, piperidinyl,
pyrazolyl, pyrrolyl, oxazolyl, isothiazolyl, oxadiazolyl,
thiadiazolyl, indolinyl, indazolyl, benzoisothiazolyl,
pyrido-oxazolyl, pyrido-thiazolyl, pyrimido-oxazolyl,
pyrimido-thiazolyl and benzimidazolyl;
[0038] when a is 1 and D.sub.1, G.sub.1, J.sub.1, L.sub.1 and
M.sub.1 are each independently selected from the group consisting
of CR.sub.a and N, provided that at least two of D.sub.1, G.sub.1,
J.sub.1, L.sub.1 and M.sub.1 are CR.sub.a; or
[0039] when a is 0, and one of D.sub.1, G.sub.1, L.sub.1 and
M.sub.1 is NR.sub.a, one of D.sub.1, G.sub.1, L.sub.1 and M.sub.1
is CR.sub.a and the remainder are independently selected from the
group consisting of CR.sub.a and N;
[0040] when b is 1 and D.sub.2, G.sub.2, J.sub.2, L.sub.2 and
M.sub.2 are each independently selected from the group consisting
of CR.sub.a and N, provided that at least two of D.sub.2, G.sub.2,
J.sub.2, L.sub.2 and M.sub.2 are CR.sub.a; or
[0041] when b is 0, and one of D.sub.2, G.sub.2, L.sub.2 and
M.sub.2 is NR.sub.a, one of D.sub.2, G.sub.2, L.sub.2 and M.sub.2
CR.sub.a and the remainder are independently selected from the
group consisting of CR.sub.a and N;
[0042] R.sub.a and R.sub.b each represent one or more substituents
and are for each occurrence independently selected from the group
consisting of hydrogen, halogen, --CN, --NO.sub.2, --C(O)OH,
--C(O)H, --OH, --C(O)O-alkyl, -Z.sup.105-C(O)N(R).sub.2,
-Z.sup.105-N(R)--C(O)-Z.sup.200- ,
-Z.sup.105-N(R)--S(O).sub.2-Z.sup.200-Z.sup.105-N(R)--C(O)--N(R)-Z.sup.2-
00, R.sub.c, CH.sub.2OR.sub.c, tetrazolyl,
trifluoromethylcarbonylamino, trifluoromethylsulfonamido, and an
optionally substituted group selected from the group consisting of
carboxamido, alkyl, alkoxy, aryl, alkenyl, aryloxy, heteroaryloxy,
arylalkyl, alkynyl, amino, aminoalkyl, amido groups, heteroarylthio
and arylthio;
[0043] Z.sup.105 for each occurrence is independently a covalent
bond or (C.sub.1-C.sub.6);
[0044] Z.sup.200 for each occurrence is independently an optionally
substituted (C.sub.1-C.sub.6), optionally substituted phenyl, or
optionally substituted --(C.sub.1-C.sub.6)-phenyl;
[0045] R.sub.c for each occurrence is independently hydrogen,
optionally substituted alkyl, optionally substituted aryl,
--CH.sub.2--NR.sub.dR.sub- .e,
--W--(CH.sub.2).sub.t--NR.sub.dR.sub.e,
--W--(CH.sub.2).sub.t-Oalkyl, --W--(CH.sub.2).sub.t--S-alkyl or
--W--(CH.sub.2).sub.t--OH;
[0046] R.sub.d and R.sub.e for each occurrence are independently H,
alkyl, alkanoyl or SO.sub.2-alkyl; or R.sub.d, R.sub.e and the
nitrogen atom to which they are attached together form a five- or
six-membered heterocyclic ring;
[0047] t for each occurrence is independently an integer from 2 to
6;
[0048] W for each occurrence is independently a direct bond or O,
S, S(O), S(O).sub.2, or NR.sub.f;
[0049] R.sub.f for each occurrence is independently H or alkyl;
[0050] Z.sup.110 is a covalent bond, or an optionally substituted
(C.sub.1-C.sub.6) which is optionally substituted with one or more
substituents selected from the group consisting of alkyl, CN, OH,
halogen, NO.sub.2, COOH, optionally substituted amino and
optionally substituted phenyl;
[0051] Z.sup.111 is a covalent bond, an optionally substituted
(C.sub.1-C.sub.6) or an optionally substituted
--(CH.sub.2).sub.n-cycloal- kyl-(CH.sub.2).sub.n--; where the
optionally substituted groups are optionally substituted with one
or more substituents selected from the group consisting of alkyl,
CN, OH, halogen, NO.sub.2, COOH, optionally substituted amino and
optionally substituted phenyl;
[0052] or R.sup.1 is a substituted or unsubstituted carbocyclic or
heterocyclic ring fused with ring 2;
[0053] A is a covalent bond, --O--; --S--; --S(O).sub.p--;
--N(R)--; --N(C(O)OR)--; --N(C(O)R)--; --N(SO.sub.2R)--;
--CH.sub.2O--; --CH.sub.2S--; --CH.sub.2N(R)--; --CH(NR)--;
--CH.sub.2N(C(O)R))--; --CH.sub.2N(C(O)OR)--;
--CH.sub.2N(SO.sub.2R)--; --CH(NHR)--; --CH(NHC(O)R)--;
--CH(NHSO.sub.2R)--; --CH(NHC(O)OR)--; --CH(OC(O)R)--;
--CH(OC(O)NHR); --CH.dbd.CH--; --C(.dbd.NOR)--; --C(O)--;
--CH(OR)--; --C(O)N(R)--; --N(R)C(O)--; --N(R)S(O).sub.p--;
--OC(O)N(R)--; --N(R)--C(O)--(CH.sub.2).sub.n--N(R)--,
--N(R)C(O)O--; --N(R)--(CH.sub.2).sub.n+1--C(O)--,
--S(O).sub.pN(R)--; --O--(CR.sub.2).sub.n+1--C(O)--,
--O--(CR.sub.2).sub.n+1--O--, --N(C(O)R)S(O).sub.p--;
--N(R)S(O).sub.pN(R)--; --N(R)--C(O)--(CH.sub.2).- sub.n--O--,
--C(O)N(R)C(O)--; --S(O).sub.pN(R)C(O)--; --OS(O).sub.pN(R)--;
--N(R)S(O).sub.pO--; --N(R)S(O).sub.pC(O)--; --SO.sub.pN(C(O)R)--;
--N(R)SO.sub.pN(R)--; --C(O)O--; --N(R)P(OR.sub.g)O--;
--N(R)P(OR.sub.g)--; --N(R)P(O)(OR.sub.g)O--;
--N(R)P(O)(OR.sub.g)--; --N(C(O)R)P(OR.sub.g)O--;
--N(C(O)R)P(OR.sub.g)--; --N(C(O)R)P(O)(OR.sub.g)O--, or
--N(C(O)R)P(OR.sub.g)--;
[0054] p is 1 or2;
[0055] R for each occurrence is independently H, optionally
substituted alkyl, optionally substituted arylalkyl or optionally
substituted aryl;
[0056] R.sub.g for each occurrence is independently H, or an
optionally substituted group selected from the group consisting of
alkyl, arylalkyl, cycloalkyl and aryl;
[0057] or R, R.sub.g, the nitrogen atom and the phosphorus atom,
together form a five- or six-membered heterocyclic ring when R and
R.sub.g are in a phosphorus containing group; or
[0058] A is NRSO2 and R, R.sub.a and the nitrogen atom together
form an optionally substituted five or-six-membered heterocyclic
ring fused to ring 1;
[0059] n for each occurrence is independently an integer from 0 to
6;
[0060] R.sub.q is selected from the group consisting of hydrogen,
alkoxyalkyl, alkyl, optionally substituted arylalkyl, optionally
substituted cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted heteroaralkyl, optionally substituted
(heterocycloalkyl)alkyl, and halo; wherein the arylalkyl, the
cycloalkyl, the cycloalkylalkyl, the heteroaralkyl, and the
(heterocycloalkyl)alkyl are each optionally substituted with one,
two, three, four, or five substituents independently selected from
the group consisting of alkoxy, alkoxyalkyl, alkyl, cyano, halo,
haloalkyl, hydroxy, hydroxyalkyl and nitro; or
[0061] when X is NR.sup.1 and R.sup.3 are each H, then Y is N, Q is
CR.sup.2, there is a double bond between Y and Q, and
[0062] R.sup.1 is 6
[0063] wherein R.sub.a is H or --OMe;
[0064] A is --NH--CO--, --NH--SO.sub.2--, --NH--C(O)O--or
--NH--C(O)--NH--;
[0065] B is N-methyl-indol-2-yl, (fluoro)(trifluoromethyl)phenyl,
phenyl or benzyl;
[0066] R.sup.2 is H, 4-piperidinyl, 7
[0067] N-ethylpiperidin4-yl or 8
[0068] when X is CR.sup.1 and one of R.sup.3 is not H, then Y is N,
Q is NR.sup.2, there is a double bond between X and Y, and 9
[0069] where Z.sup.100 is nitro, optionally substituted amino,
10
[0070] or a group optionally substituted with R.sub.b selected from
the group consisting of cycloalkyl, naphthyl, tetrahydronaphthyl,
benzothienyl, furanyl, thienyl, benzoxazolyl, benzothiazolyl,
11
[0071] thiazolyl, benzofuranyl, 2,3-dihydrobenzofuranyl, indolyl,
isoxazolyl, tetrahydropyranyl, tetrahydrofuranyl, piperidinyl,
pyrazolyl, pyrrolyl, oxazolyl, isothiazolyl, oxadiazolyl,
thiadiazolyl, indolinyl, indazolyl, benzoisothiazolyl,
pyrido-oxazolyl, pyrido-thiazolyl, pyrimido-oxazolyl,
pyrimido-thiazolyl and benzimidazolyl;
[0072] when a is 1 and D.sub.1, G.sub.1, J.sub.1, L.sub.1 and
M.sub.1 are each independently selected from the group consisting
of CR.sub.a and N, provided that at least two of D.sub.1, G.sub.1,
J.sub.1, L.sub.1 and M.sub.1 are CR.sub.a; or
[0073] when a is 0, and one of D.sub.1, G.sub.1, L.sub.1 and
M.sub.1 is NR.sub.a, one of D.sub.1, G.sub.1, L.sub.1 and M.sub.1
is CR.sub.a and the remainder are independently selected from the
group consisting of CR.sub.a and N;
[0074] when b is 1 and D.sub.2, G.sub.2, J.sub.2, L.sub.2 and
M.sub.2 are each independently selected from the group consisting
of CR.sub.a and N, provided that at least two of D.sub.2, G.sub.2,
J.sub.2, L.sub.2 and M.sub.2 are CR.sub.a; or
[0075] when b is 0, and one of D.sub.2, G.sub.2, L.sub.2 and
M.sub.2 is NR.sub.a, one of D.sub.2, G.sub.2, L.sub.2 and M.sub.2
is CR.sub.a and the remainder are independently selected from the
group consisting of CR.sub.a and N;
[0076] R.sub.a and R.sub.b each represent one or more substituents
and are for each occurrence independently selected from the group
consisting of hydrogen, halogen, --CN, --NO.sub.2, --C(O)OH,
--C(O)H, --OH, --C(O)O-alkyl, -Z.sup.105-C(O)N(R).sub.2,
-Z.sup.105-N(R)--C(O)-Z.sup.200- ,
-Z.sup.105-N(R)--S(O).sub.2-Z.sup.200,
-Z.sup.105-N(R)--C(O)--N(R)-Z.sup- .200, R.sub.c, CH.sub.2OR.sub.c,
tetrazolyl, trifluoromethylcarbonylamino,
trifluoromethylsulfonamido, and an optionally substituted group
selected from the group consisting of carboxamido, alkyl, alkoxy,
aryl, alkenyl, aryloxy, heteroaryloxy, arylalkyl, alkynyl, amino,
aminoalkyl, amido groups, heteroarylthio and arylthio;
[0077] Z.sup.105 for each occurrence is independently a covalent
bond or (C.sub.1-C.sub.6);
[0078] Z.sup.200 for each occurrence is independently an optionally
substituted (C.sub.1-C.sub.6), optionally substituted phenyl, or
optionally substituted --(C.sub.1-C.sub.6)-phenyl;
[0079] R.sub.c for each occurrence is independently hydrogen,
optionally substituted alkyl, optionally substituted aryl,
--CH.sub.2--NR.sub.dR.sub- .e,
--W--(CH.sub.2).sub.t--NR.sub.dR.sub.e,
--W--(CH.sub.2).sub.t-Oalkyl, --W--(CH.sub.2).sub.t--S-alkyl or
--W--(CH.sub.2).sub.t--OH;
[0080] R.sub.d and R.sub.e for each occurrence are independently H,
alkyl, alkanoyl or SO.sub.2-alkyl; or R.sub.d, R.sub.e and the
nitrogen atom to which they are attached together form a five- or
six-membered heterocyclic ring;
[0081] t for each occurrence is independently an integer from 2 to
6;
[0082] W for each occurrence is independently a direct bond or O,
S, S(O), S(O).sub.2, or NR.sub.f;
[0083] R.sub.f for each occurrence is independently H or alkyl;
[0084] Z.sup.110 is a covalent bond, or an optionally substituted
(C.sub.1-C.sub.6) which is optionally substituted with one or more
substituents selected from the group consisting of alkyl, CN, OH,
halogen, NO.sub.2, COOH, optionally substituted amino and
optionally substituted phenyl;
[0085] Z.sup.111 is a covalent bond, an optionally substituted
(C.sub.1-C.sub.6) or an optionally substituted
--(CH.sub.2).sub.n-cycloal- kyl-(CH.sub.2).sub.n--; where the
optionally substituted groups are optionally substituted with one
or more substituents selected from the group consisting of alkyl,
CN, OH, halogen, NO.sub.2, COOH, optionally substituted amino and
optionally substituted phenyl;
[0086] or R.sup.1 is a substituted or unsubstituted carbocyclic or
heterocyclic ring fused with ring 2;
[0087] A is a covalent bond, --O--; --S--; --S(O).sub.p--;
--N(R)--; --N(C(O)OR)--; --N(C(O)R)--; --N(SO.sub.2R)--;
--CH.sub.2O--; --CH.sub.2S--; --CH.sub.2N(R)--; --CH(NR)--;
--CH.sub.2N(C(O)R))--; --CH.sub.2N(C(O)OR)--;
--CH.sub.2N(SO.sub.2R)--; --CH(NHR)--; --CH(NHC(O)R)--;
--CH(NHSO.sub.2R)--; --CH(NHC(O)OR)--; --CH(OC(O)R)--;
--CH(OC(O)NHR); --CH.dbd.CH--; --C(.dbd.NOR)--; --C(O)--;
--CH(OR)--; --C(O)N(R)--; --N(R)C(O)--; --N(R)S(O).sub.p--;
--OC(O)N(R)--; --N(R)C(O)--(CH.sub.2).sub.n--N(R)--, --N(R)C(O)O--;
--N(R)--(CH.sub.2).sub.n+1--C(O)--, --S(O).sub.pN(R)--;
--O--(CR.sub.2).sub.n+1--C(O)--, --O--(CR.sub.2).sub.n+1--O--,
--N(C(O)R)S(O).sub.p--; --N(R)S(O).sub.pN(R)--;
--N(R)--C(O)--(CH.sub.2).- sub.n--O--, --C(O)N(R)C(O)--;
--S(O).sub.pN(R)C(O)--; --OS(O).sub.pN(R)--; --N(R)S(O).sub.pO--;
--N(R)S(O).sub.pC(O)--; --SO.sub.pN(C(O)R)--; --N(R)SO.sub.pN(R)--;
--C(O)O--; --N(R)P(OR.sub.g)O--; --N(R)P(OR.sub.g)--;
--N(R)P(O)(OR.sub.g)O--; --N(R)P(O)(OR.sub.g)--;
--N(C(O)R)P(OR.sub.g)O--; --N(C(O)R)P(OR.sub.g)--;
--N(C(O)R)P(O)(OR.sub.g)O--, or --N(C(O)R)P(OR.sub.g)--;
[0088] p is 1 or 2;
[0089] R for each occurrence is independently H, optionally
substituted alkyl, optionally substituted arylalkyl or optionally
substituted aryl;
[0090] R.sub.g for each occurrence is independently H, or an
optionally substituted group selected from the group consisting of
alkyl, arylalkyl, cycloalkyl and aryl;
[0091] or R, R.sub.g, the nitrogen atom and the phosphorus atom,
together form a five- or six-membered heterocyclic ring when R and
R.sub.g are in a phosphorus containing group; or
[0092] A is NRSO2 and R, R.sub.a and the nitrogen atom together
form an optionally substituted five or-six-membered heterocyclic
ring fused to ring 1;
[0093] R.sup.2 is -Z.sup.101-Z.sup.02;
[0094] Z.sup.101 is a covalent bond, --(C.sub.1-C.sub.6)--,
--(C.sub.1-C.sub.6)--O--, --(C.sub.1-C.sub.6)--C(O)--,
--(C.sub.1-C.sub.6)--C(O)O--, --(C.sub.1-C.sub.6)--C(O)--NH--,
--(C.sub.1-C.sub.6)--C(O)--N((C.sub.1-C.sub.6))-- or an optionally
substituted phenyl group;
[0095] Z.sup.102 is hydrogen, an optionally substituted alkyl
group, an optionally substituted cycloalkyl group, an optionally
substituted saturated or unsaturated heterocyclic group, or an
optionally substituted saturated or unsaturated heterobicyclic
group;
[0096] said substituted heterocyclic or substituted heterobicyclic
group having one or more substituents each independently selected
from the group consisting of hydroxyl, cyano, optionally
substituted alkoxy, optionally substituted sulfonamido, optionally
substituted ureido, optionally substituted carboxamido; optionally
substituted amino, oxo, a saturated or unsaturated or aromatic
optionally substituted heterocyclic group;
[0097] wherein the heterocyclic group comprises one or more
nitrogen atoms, one or more oxygen atoms or a combination thereof
and where said nitrogen atoms are independently optionally
substituted by a substituted or unsubstituted alkyl, substituted or
unsubstituted aryl, or substituted or unsubstituted arylalkyl;
or
[0098] R.sup.2 is of the formula B-E;
[0099] B is hydroxy or an optionally substituted group selected
from the group consisting of cycloalkyl, azacycloalkyl, amino,
aminoalkylsulfonyl, alkoxyalkyl, alkoxy, aminoalklylcarbonyl,
alkylenyl, aminoalkyl, alkylenylcarbonyl and
aminoalkylcarbonyl;
[0100] E is an optionally substituted group selected from the group
consisting of azacycloalkyl, azacycloalkylcarbonyl,
azacycloalkylsulfonyl, azacycloalkylalkyl, heteroaryl,
heteroarylcarbonyl, heteroarylsulfonyl, heteroarylalkyl,
azacycloalkylcarbonylamino, heteroarylcarbonylamino and aryl;
and
[0101] n for each occurrence is independently an integer from 0 to
6.
[0102] A preferred compound of the foregoing compound of formula
(I), denoted preferred group A, is where X is CR.sup.1, Y is
CR.sub.q, Q is O and there is a double bond between X and Y; or X
is CR.sup.1, Y is N, Q is O and there is a double bond between X
and Y; or X is CR.sup.1, Y is O, Q is N and there is a double bond
between Q and the pyrimidinyl ring.
[0103] A preferred compound of preferred group A, denoted preferred
group B, is where the compound is of the formula (II), 12
[0104] wherein
[0105] Ris selected from the group consisting of hydrogen,
alkoxyalkyl, alkyl, optionally substituted arylalkyl, optionally
substituted cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted heteroaralkyl, optionally substituted
(heterocycloalkyl)alkyl- , and halo, wherein the arylalkyl, the
cycloalkyl, the cycloalkylalkyl, the heteroaralkyl, and the
(heterocycloalkyl)alkyl are each optionally substituted with one,
two, three, four, or five substituents independently selected from
the group consisting of alkoxy, alkoxyalkyl, alkyl, cyano, halo,
haloalkyl, hydroxy, hydroxyalkyl, and nitro;
[0106] A is selected from the group consisting of
--N(R)--C(O)--(CH.sub.2)- .sub.n--N(R)--, --N(R)--, --N(R)C(O)--,
and --N(R)S(O).sub.p--;
[0107] Z.sup.100 is selected from the group consisting of
optionally substituted aryl and optionally substituted
heteroaryl;
[0108] n is 0; p is 2; and R is hydrogen.
[0109] A preferred compound of preferred group B, denoted preferred
group C, is where R.sub.q is hydrogen.
[0110] A preferred compound of preferred group C, denoted preferred
group D, is where the compound is:
[0111]
N-[4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-methylphenyl)u-
rea;
[0112]
N-[4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methylphenyl)u-
rea;
[0113]
N-[4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2-methylphenyl)u-
rea;
[0114]
N-[4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-chlorophenyl)u-
rea;
[0115]
5-[4-(1,3-benzoxazol-2-ylamino)phenyl]furo[2,3-d]pyrimidin-4-amine;
[0116] N-[4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl]benzamide;
or
[0117]
N-[4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl]benzenesulfonamide.
[0118] Another preferred compound of preferred group B, denoted
preferred group E, is where R.sub.q is selected from the group
consisting of alkyl and halo.
[0119] A preferred compound of preferred group E, denoted preferred
group F, is where the compound is:
[0120]
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2-methy-
lphenyl)urea;
[0121]
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-methy-
lphenyl)urea;
[0122]
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]benzamide;
[0123]
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]benzenesulfo-
namide;
[0124]
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methy-
lphenyl)urea;
[0125]
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-chlor-
ophenyl)urea;
[0126]
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-metho-
xyphenyl)urea;
[0127]
N-[4-(4-amino-6-bromofuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methyl-
phenyl)urea;
[0128]
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-bromo-
phenyl)urea;
[0129]
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-ethyl-
phenyl)urea;
[0130]
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3,5-dim-
ethylphenyl)urea;
[0131]
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3,5-dic-
hlorophenyl)urea;
[0132]
N-[4-(4-amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-[2-fluor-
o-5(trifluoromethyl)phenyl]urea;
[0133]
1-[4-(4-Amino-6-methyl-furo[2,3-d]pyrimidin-5-yl)-phenyl]-3-(cyano--
phenyl)-urea; or
[0134]
1-[4-(4-Amino-6-methyl-furo[2,3-d]pyrimidin-5-yl)-phenyl]-3-(3-trif-
luoromethyl-phenyl)urea.
[0135] Another preferred compound of preferred group A, denoted
preferred group G, is where the compound is of formula (III),
13
[0136] wherein
[0137] A is selected from the group consisting of a bond,
--N(R)C(O)--, and --N(R)--C(O)--(CH.sub.2).sub.n--N(R)--;
[0138] Z.sup.100 is selected from the group consisting of
--NO.sub.2, amino, substituted amino, and optionally substituted
aryl;
[0139] R is hydrogen; and n is 0.
[0140] A preferred compound of preferred group G, denoted preferred
group H, is where A is a bond; and Z.sup.100 is selected from the
group consisting of --NO.sub.2, substituted amino, and amino.
[0141] A preferred compound of preferred group H, denoted preferred
group I, is:
[0142] 3-(4-nitrophenyl)isoxazolo[5,4-d]pyrimidin4-amine; or
3-(4-aminophenyl)isoxazolo[5,4-d]pyrimidin4-amine.
[0143] Another preferred compound of preferred group G, denoted
preferred group J, is where A is selected from the group consisting
of --N(R)C(O)--, and --N(R)--C(O)--(CH.sub.2),--N(R)--; and
Z.sup.100 is optionally substituted aryl.
[0144] A preferred compound of preferred group J, denoted preferred
group K, is:
[0145]
N-[4-(4-aminoisoxazolo[5,4-d]pyrimidin-3-yl)phenyl]-N'-(3-methylphe-
nyl)urea;
[0146]
N-[4-(4-aminoisoxazolo[5,4-d]pyrimidin-3-yl)phenyl]-N'-(3-ethylphen-
yl)urea;
[0147]
N-[4-(4-aminoisoxazolo[5,4-d]pyrimidin-3-yl)phenyl]-N'-(3-chlorophe-
nyl)urea;
[0148]
N-[4-(4-aminoisoxazolo[5,4-d]pyrimidin-3-yl)phenyl]benzamide;
[0149]
N-[4-(4-aminoisoxazolo[5,4-d]pyrimidin-3-yl)phenyl]-N'-[3-(trifluor-
omethyl)phenyl]urea; or
[0150]
N-[4-(4-aminoisoxazolo[5,4-d]pyrimidin-3-yl)phenyl]-N'-[2-fluoro-5--
(trifluoromethyl)phenyl]urea.
[0151] Another preferred compound of formula (I), denoted preferred
group L, is where X is NR.sup.1; both R.sup.3 are each H; Y is N; Q
is CR.sup.2; and there is a double bond between Y and Q.
[0152] A preferred compound of preferred group L, denoted preferred
group M, is
[0153]
N2-{4-[7-Amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-1-yl]-2--
methoxyphenyl}-1-methyl1H-2-indolecarboxamide;
[0154]
N2-{4-[7-Amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-1-yl]-2--
methoxyphenyl}-2-fluoro-4-trifluoromethyl)benzamide;
[0155]
N1-[4-(7-Amino-1H-pyrazolo[4,3-d]pyrimidin-1-yl)-2-Methoxyphenyl]-2-
-fluoro-4-(trifluoromethyl)benzamide;
[0156]
N1-{4-[7-Amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-1-yl]-2--
methoxyphenyl}-1-benzenesulfonamide;
[0157] Benzyl
N-{4-[7-amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-1--
yl]-2-methoxyphenyl}carbamate;
[0158]
N-{4-[7-Amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-1-yl]-2-m-
ethoxyphenyl }-N-phenylurea;
[0159]
N2-{4-[7-Amino-3-(1-tetrahydro-2H4-pyranyl-4-piperidyl)-1H-pyrazolo-
[4,3-d]pyrimidin-1-yl]-2-methoxyphenyl}-1-methyl-1H-2-indolecarboxamide;
[0160]
N2-{4-[7-amino-3-(1-ethyl-4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin--
1-yl]-2methoxyphenyl}-1-methyl-1H-2-indolecarboxamide;
[0161]
N1-{4-[7-Amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-1-yl]phe-
nyl}-1-benzenesulfonamide;
[0162]
N2-{4-[7-Amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-1-yl]phe-
nyl}-1-methyl-1H-2-indolecarboxamide; or
[0163]
N2-{4-[7-Amino-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-pyrazolo[4,3-d-
]pyrimidin-1-yl]-2-methoxyphenyl}-1-methyl-1H-2-indolecarboxamide.
[0164] Another preferred compound of formula (I), denoted preferred
group N, is where X is CR.sup.1; one of R.sup.3 is not H; Y is N, Q
is NR.sup.2; and there is a double bond between X and Y.
[0165] In another aspect the present invention is directed to the
use of any compound encompassed by formula (I), including the
species enumerated herein, for any of the methods described herein,
such as:
[0166] a method of inhibiting one or more protein kinase activity
in a patient comprising administering a therapeutically effective
amount of a compound of formula (I) or a physiologically acceptable
salt, prodrug or biologically active metabolites thereof to said
patient;
[0167] a method wherein said protein kinase is selected from the
group consisting of KDR, FGFR-1, PDGFR.beta., PDGFR.alpha., IGF-1R,
c-Met, Flt-1, Flt-4, TIE-2, TIE-1, Lck, Src, fyn, Lyn, Blk, hck,
fgr and yes;
[0168] a method of affecting hyperproliferative disorders in a
patient comprising administering a therapeutically effective amount
of a compound of formula (I) or a physiologically acceptable salt,
prodrug or biologically active metabolites thereof to said
patient;
[0169] a method of affecting angiogenesis in a patient comprising
administering a therapeutically effective amount of a compound of
formula (I) or a physiologically acceptable salt, prodrug or
biologically active metabolites thereof to said patient;
[0170] a method wherein the protein kinase is a protein
serine/threonine kinase or a protein tyrosine kinase;
[0171] a method of treating one or more ulcers in a patient
comprising administering a therapeutically effective amount of a
compound of formula (I) or a physiologically acceptable salt,
prodrug or biologically active metabolites thereof to said
patient;
[0172] a method wherein the ulcer or ulcers are caused by a
bacterial or fungal infection; or the ulcer or ulcers are Mooren
ulcers; or the ulcer or ulcers are a symptom of ulcerative
colitis;
[0173] a method of treating a condition in a patient comprising
administering a therapeutically effective amount of a compound of
formula (I) or a physiologically acceptable salt, prodrug or
biologically active metabolites thereof to said patient, wherein
said condition is an ocular condition, a cardiovascular condition,
a cancer, Crow-Fukase (POEMS) syndrome, a diabetic condition,
sickle cell anaemia, chronic inflammation, systemic lupus,
glomerulonephritis, synovitis, inflammatory bowel disease, Crohn's
disease, glomerulonephritis, rheumatoid arthritis, osteoarthritis,
multiple sclerosis, graft rejection, Lyme disease, sepsis, von
Hippel Lindau disease, pemphigoid, psoriasis, Paget's disease,
polycystic kidney disease, fibrosis, sarcoidosis, cirrhosis,
thyroiditis, hyperviscosity syndrome, Osler-Weber-Rendu disease,
chronic occlusive pulmonary disease, asthma or edema following
burns, trauma, radiation, stroke, hypoxia, ischemia, ovarian
hyperstimulation syndrome, preeclampsia, menometrorrhagia,
endometriosis, pulmonary hypertension, infantile hemangioma, or
infection by Herpes simplex, Herpes Zoster, human immunodeficiency
virus, parapoxvirus, protozoa or toxoplasmosis;
[0174] a method wherein the ocular condition is ocular or macular
edema, ocular neovascular disease, scleritis, radial keratotomy,
uveitis, vitritis, myopia, optic pits, chronic retinal detachment,
post-laser treatment complications, conjunctivitis, Stargardt's
disease, Eales disease, retinopathy or macular degeneration;
[0175] a method wherein the cardiovascular condition is
atherosclerosis, restenosis, ischemia/reperfusion injury, vascular
occlusion or carotid obstructive disease;
[0176] a method wherein the cancer is a solid tumor, a sarcoma,
fibrosarcoma, osteoma, melanoma, retinoblastoma, a
rhabdomyosarcoma, glioblastoma, neuroblastoma, teratocarcinoma, an
hematopoietic malignancy, Kaposi's sarcoma, Hodgkin's disease,
lymphoma, myeloma, leukemia or malignant ascites;
[0177] a method wherein the diabetic condition is insulin-dependent
diabetes mellitus glaucoma, diabetic retinopathy or
microangiopathy;
[0178] a method of decreasing fertility in a patient, said method
comprising the step of administering to the patient an effective
amount of a compound of formula (I) or a physiologically acceptable
salt, prodrug or biologically active metabolite thereof;
[0179] a method wherein the compound or a physiologically
acceptable salt, prodrug or biologically active metabolite thereof
is administered in an amount effective to promote angiogenesis or
vasculogenesis;
[0180] a method wherein the protein kinase is TIE-2;
[0181] a method wherein the compound of formula (I), or
physiologically acceptable salt, prodrug or biologically active
metabolite thereof, is administered in combination with a
pro-angiogenic growth factor;
[0182] a method wherein the pro-angiogenic growth factor is
selected from the group consisiting of VEGF, VEGF-B, VEGF-C,
VEGF-D, VEGF-E, HGF, FGF-1, FGF-2, derivatives thereof and
antiiodotypic antibodies;
[0183] a method wherein the patient is suffering from anemia,
ischemia, infarct, transplant rejection, a wound, gangrene or
necrosis; or
[0184] a method wherein the protein kinase activity is involved in
T cell activation, B cell activation, mast cell degranulation,
monocyte activation, the potentiation of an inflammatory response
or a combination thereof.
[0185] In another aspect, the present invention is directed to a
pharmaceutical composition comprising a compound of formula (I) and
a pharmaceutically acceptable carrier or diluent.
DETAILED DESCRIPTION OF THE INVENTION
[0186] Progression through the eukaryotic cell cycle is controlled
by a family of kinases called cyclin dependent kinases (CDKs)
(Myerson et al., EMBO Journal, 11:2909-2917 (1992)). The regulation
of CDK activation is complex, but requires the association of the
CDK with a member of the cyclin family of regulatory subunits
(Draetta, Trends in Cell Biology, 3:287-289 (1993)); Murray and
Kirschner, Nature, 339:275-280 (1989); Solomon et al., Molecular
Biology of the Cell, 3:13-27 (1992)). A further level of regulation
occurs through both activating and inactivating phosphorylations of
the CDK subunit (Draetta, Trends in Cell Biology, 3:287-289
(1993)); Murray and Kirschner, Nature, 339:275-280 (1989); Solomon
et al., Molecular Biology of the Cell, 3:13-27 (1992); Ducommun et
al., EMBO Journal, 10:3311-3319 (1991); Gautier et al., Nature
339:626-629 (1989); Gould and Nurse, Nature, 342:39-45 (1989); Krek
and Nigg, EMBO Journal, 10:3331-3341 (1991); Solomon et al., Cell,
63:1013-1024 (1990)). The coordinate activation and inactivation of
different cyclin/CDK complexes is necessary for normal progression
through the cell cycle (Pines, Trends in Biochemical Sciences,
18:195-197 (1993); Sherr, Cell, 73:1059-1065 (1993)). Both the
critical G1-S and G 2-M transitions are controlled by the
activation of different cyclin/CDK activities. In G1, both cyclin
D/CDK4 and cyclin E/CDK2 are thought to mediate the onset of
S-phase (Matsushima et al., Molecular & Cellular Biology,
14:2066-2076 (1994); Ohtsubo and Roberts, Science, 259:1908-1912
(1993); Quelle et al., Genes & Development, 7:1559-1571 (1993);
Resnitzky et al., Molecular & Cellular Biology, 14:1669-1679
(1994)). Progression through S-phase requires the activity of
cyclin A/CDK2 (Girard et al., Cell, 67:1169-1179 (1991); Pagano et
al., EMBO Journal, 11:961-971 (1992); Rosenblatt et al.,
Proceedings of the National Academy of Science USA, 89:2824-2828
(1992); Walker and Maller, Nature, 354:314-317 (1991); Zindy et
al., Biochemical & Biophysical Research Communications,
182:1144-1154 (1992)) whereas the activation of cyclin A/cdc2
(CDK1) and cyclin B/cdc2 are required for the onset of metaphase
(Draetta, Trends in Cell Biology, 3:287-289 (1993)); Murray and
Kirschner, Nature, 339:275-280 (1989); Solomon et al., Molecular
Biology of the Cell, 3:13-27 (1992); Girard et al., Cell,
67:1169-1179 (1991); Pagano et al., EMBO Journal, 11:961-971
(1992); Rosenblatt et al., Proceedings of the National Academy of
Science USA, 89:2824-2828 (1992); Walker and Maller, Nature,
354:314-317 (1991); Zindy et al., Biochemical & Biophysical
Research Communications, 182:1144-1154 (1992)). It is not
surprising, therefore, that the loss of control of CDK regulation
is a frequent event in hyperproliferative diseases and cancer.
(Pines, Current Opinion in Cell Biology, 4:144-148 (1992); Lees,
Current Opinion in Cell Biology, 7:773-780 (1995); Hunter and
Pines, Cell, 79:573-582 (1994)). The selective inhibition of CDKs
is therefore an object of the present invention.
[0187] The compounds of the present invention are additionally
useful in the treatment of one or more diseases afflicting mammals
which are characterized by cellular proliferation in the areas of
blood vessel proliferative disorders, fibrotic disorders, mesangial
cell proliferative disorders and metabolic diseases. Blood vessel
proliferative disorders include arthritis and restenosis. Fibrotic
disorders include hepatic cirrhosis and atherosclerosis. Mesangial
cell proliferative disorders include glomerulonephritis, diabetic
nephropathy, malignant nephrosclerosis, thrombotic microangiopathy
syndromes, organ transplant rejection and glomerulopathies.
Metabolic disorders include psoriasis, diabetes mellitus, chronic
wound healing, inflammation, neurodegenerative diseases, macular
degeneration, and diabetic retinopathy.
[0188] Inhibitors of kinases involved in mediating or maintaining
these disease states represent novel therapies for these disorders.
Examples of such kinases include, but are not limited to: (1)
inhibition of c-Src (Brickell, Critical Reviews in Oncogenesis,
3:401-406 (1992); Courtneidge, Seminars in Cancer Biology,
5:236-246 (1994), raf (Powis, Pharmacology & Therapeutics,
62:57-95 (1994)) and the cyclin-dependent kinases (CDKs) 1, 2 and 4
in cancer (Pines, Current Opinion in Cell Biology, 4:144-148
(1992); Lees, Current Opinion in Cell Biology, 7:773-780 (1995);
Hunter and Pines, Cell, 79:573-582 (1994)), (2) inhibition of CDK2
or PDGF-R kinase in restenosis (Buchdunger et al., Proceedings of
the National Academy of Science USA, 92:2258-2262 (1995)), (3)
inhibition of CDK5 and GSK3 kinases in Alzheimers (Hosoi et al.,
Journal of Biochemistry (Tokyo), 117:741-749 (1995); Aplin et al.,
Journal of Neurochemistry, 67:699-707 (1996), (4) inhibition of
c-Src kinase in osteoporosis (Tanaka et al., Nature, 383:528-531
(1996), (5) inhibition of GSK-3 kinase in type-2 diabetes
(Borthwick et al., Biochemical & Biophysical Research
Communications, 210:738-745 (1995), (6) inhibition of the p38
kinase in inflammation (Badger et al., The Journal of Pharmacology
and Experimental Therapeutics, 279:1453-1461 (1996)), (7)
inhibition of VEGF-R 1-3 and TE-1 and -2 kinases in diseases which
involve angiogenesis (Shawver et al., Drug Discovery Today, 2:50-63
(1997)), (8) inhibition of UL97 kinase in viral infections (He et
al., Journal of Virology, 71:405-411 (1997)), (9) inhibition of
CSF-1R kinase in bone and hematopoetic diseases (Myers et al.,
Bioorganic & Medicinal Chemistry Letters, 7:421-424 (1997), and
(10) inhibition of Lck kinase in autoimmune diseases and transplant
rejection (Myers et al., Bioorganic & Medicinal Chemistry
Letters, 7:417-420 (1997)).
[0189] It is additionally possible that inhibitors of certain
kinases may have utility in the treatment of diseases when the
kinase is not misregulated, but it nonetheless essential for
maintenance of the disease state. In this case, inhibition of the
kinase activity would act either as a cure or palliative for these
diseases. For example, many viruses, such as human papilloma virus,
disrupt the cell cycle and drive cells into the S-phase of the cell
cycle (Vousden, FASEB Journal, 7:8720879 (1993)). Preventing cells
from entering DNA synthesis after viral infection by inhibition of
essential S-phase initiating activities such as CDK2, may disrupt
the virus life cycle by preventing virus replication. This same
principle may be used to protect normal cells of the body from
toxicity of cycle-specific chemotherapeutic agents (Stone et al.,
Cancer Research, 56:3199-3202 (1996); Kohn et al., Journal of
Cellular Biochemistry, 54:44-452 (1994)). Inhibition of CDKs 2 or 4
will prevent progression into the cycle in normal cells and limit
the toxicity of cytotoxics which act in S-phase, G2 or mitosis.
Furthermore, CDK2/cyclin E activity has also been shown to regulate
NF-kB. Inhibition of CDK2 activity stimulates NF-kB-dependent gene
expression, an event mediated through interactions with the p300
coactivator (Perkins et al., Science, 275:523-527 (1997)). NF-kB
regulates genes involved in inflammatory responses (such as
hematopoetic growth factors, chemokines and leukocyte adhesion
molecules) (Baeuerle and Henkel, Annual Review of Immunology,
12:141-179 (1994)) and may be involved in the suppression of
apoptotic signals within the cell (Beg and Baltimore, Science,
274:782-784 (1996); Wang et al., Science, 274:784-787 (1996); Van
Antwerp et al., Science, 274:787-789 (1996)). Thus, inhibition of
CDK2 may suppress apoptosis induced by cytotoxic drugs via a
mechanism which involves NF-kB. This therefore suggests that
inhibition of CDK2 activity may also have utility in other cases
where regulation of NF-kB plays a role in etiology of disease. A
further example may be take from fungal infections: Aspergillosis
is a common infection in immune-compromised patients (Armstrong,
Clinical Infectious Diseases, 16:1-7 (1993)). Inhibition of the
Aspergillus kinases Cdc2/CDC28 or Nim A (Osmani et al., EMBO
Journal, 10:2669-2679 (1991); Osmani et al., Cell, 67:283-291
(1991)) may cause arrest or death in the fungi, improving the
therapeutic outcome for patients with these infections.
[0190] The following are the preferred substituents of a compound
of formula (I). Preferably, R.sub.a and R.sub.b are each
independently F, Cl, Br, I, CH.sub.3, NO.sub.2, OCF.sub.3,
OCH.sub.3, CN, CO.sub.2CH.sub.3, CF.sub.3, t-butyl, pyridyl,
carboxyl, or an optionally substituted group selected from the
group consisting of oxazolyl, benzyl, benzenesulfonyl, phenoxy,
phenyl, amino, tetrazolyl, styryl, arylthio and heteroarylthio;
CH.sub.2OR.sub.c, wherein R.sub.c is hydrogen or optionally
substituted alkyl or aryl; and --W--(CH.sub.2).sub.t--NR.sub.d-
R.sub.e, wherein t is an integer from about 1 to about 6; W is a
direct bond, O, S, S(O), S(O).sub.2, or NR.sub.f, wherein R.sub.f
is H or alkyl and R.sub.d and R.sub.e are independently H, alkyl,
alkanoyl or SO.sub.2-alkyl; or R.sub.d, R.sub.e and the nitrogen
atom to which they are attached together form a five- or
six-membered heterocyclic ring.
[0191] In one embodiment, R.sub.2 is an oxacycloalkyl group of the
formula 14
[0192] wherein n is 1, 2 or 3.
[0193] In another embodiment, R.sub.2 is of the formula 15
[0194] where m is 0, 1, 2 or 3 and R.sub.g is H or
--(CH.sub.2).sub.pN(R.s- ub.4)R.sub.5, where p is an integer from
about 2 to about 6. R.sub.4 and R.sub.5 are each, independently, H,
azabicycloalkyl or Y-Z, wherein Y is selected from the group
consisting of --C(O)--, --(CH.sub.2).sub.p--,--S(- O).sub.2--,
--C(O)O--, --SO.sub.2NH--, --CONH--, (CH.sub.2).sub.qO--,
--(CH.sub.2).sub.qNH--, and --(CH.sub.2).sub.qS(O).sub.r--; wherein
p is an integer from 0 to about 6, q is an integer from 0 to about
6, and 0, 1 or 2; and Z is a substituted or unsubstituted alkyl,
amino, aryl, heteroaryl or heterocycloalkyl group or R.sub.4,
R.sub.5 and the nitrogen atom together form a 3, 4, 5, 6 or
7-membered, substituted or unsubstituted heterocyclic or
heterobicyclic group.
[0195] In another embodiment, R.sub.2 is of the formula 16
[0196] wherein m is 1, 2 or 3. a and b ar each, independently, an
integer from 0 to about, except that when the two substituents are
attached to the same carbon atom, a is from 1 to about 6. Q is
NR.sub.4R.sub.5 or --OR.sub.6. Each R.sub.4 and R.sub.5 is,
independently, H, azabicycloalkyl or Y-Z, wherein Y is selected
from the group consisting of --C(O)--, --(CH.sub.2).sub.p--,
--S(O).sub.2--, --C(O)O--, --SO.sub.2NH--, --CONH--,
(CH.sub.2).sub.qO--, --(CH.sub.2).sub.qNH--, and
--(CH.sub.2).sub.qS(O).sub.r--; where p is an integer from 0 to
about 6, q is an integer from 0 to about 6, and r is 0, 1 or 2; and
Z is a substituted or unsubstituted alkyl, amino, aryl, heteroaryl
or heterocycloalkyl group. R.sub.4, R.sub.5 and the nitrogen atom
can also together form a 3, 4, 5, 6 or 7-membered, substituted or
unsubstituted heterocyclic or heterobicyclic group.
[0197] In another embodiment, R.sub.2 is of the formula 17
[0198] where n is 1, 2 or 3; and R.sub.4 is H, azabicycloalkyl or
Y-Z, wherein Y is selected from the group consisting of --C(O)--,
(CH.sub.2).sub.p--, --S(O).sub.2--, --C(O)O--, --SO.sub.2NH--,
--CONH--, (CH.sub.2).sub.qO, --(CH.sub.2).sub.qNH--, and
--(CH.sub.2).sub.qS(O).sub- .r--; wherein p is an integer from 0 to
about 6, q is an integer from 0 to about 6, and r is 0, 1 or 2; and
Z is a substituted or unsubstituted alkyl, amino, aryl, heteroaryl
or heterocycloalkyl group.
[0199] In another embodiment, R.sub.2 is of the formula 18
[0200] where m is 0, 1, 2 or 3. R.sub.5 is H, azabicycloalkyl or
Y-Z, where Y is selected from the group consisting of --C(O)--,
--(CH.sub.2).sub.p--, --S(O).sub.2--, --C(O)O--, --SO.sub.2NH--,
--CONH--, --(CH.sub.2).sub.qO--, --(CH.sub.2).sub.qNH--, and
--(CH.sub.2).sub.qS(O).sub.r--; where p is an integer from 0 to
about 6, q is an integer from 0 to about 6, and r is 0, 1 or 2; and
Z is a substituted or unsubstituted alkyl, amino, aryl, heteroaryl
or heterocycloalkyl group. R.sub.6 represents one or more
substituents independently selected from the group consisting of
hydrogen, hydroxy, oxo and substituted or unsubstituted alkyl,
aryl, heteroaryl, alkoxycarbonyl, alkoxyalkyl, aminocarbonyl,
alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, aminoalkyl and
arylalkyl groups, provided that the carbon atoms adjacent to the
nitrogen atom are not substituted by a hydroxy group.
[0201] In another embodiment, R.sub.2 is of the formula 19
[0202] wherein R.sub.4 is H, azabicycloalkyl or Y-Z, wherein Y is
selected from the group consisting of --C(O)--, --(CH2).sub.p--,
--S(O).sub.2--, --C(O)O--, --SO.sub.2NH--, --CONH--,
(CH.sub.2).sub.qO--, --(CH.sub.2).sub.qNH--, and
--(CH.sub.2).sub.qS(O).sub.r--; wherein p is an integer from 0 to
about 6, q is an integer from 0 to about 6, and r is 0, 1 or 2; and
Z is a substituted or unsubstituted alkyl, amino, aryl, heteroaryl
or heterocycloalkyl group.
[0203] In another embodiment, R.sub.2 is of the formula 20
[0204] where m is an integer from 1 to about 6; and R.sub.4 and
R.sub.5 are each, independently, H, azabicycloalkyl or Y-Z, wherein
Y is selected from the group consisting of --C(O)--,
(CH.sub.2).sub.p--, --S(O).sub.2--, --C(O)O--, --SO.sub.2NH--,
--CONH--, (CH.sub.2).sub.qO--, --(CH.sub.2).sub.qNH--, and
--(CH.sub.2).sub.qS(O).sub.r--; wherein p is an integer from 0 to
about 6, q is an integer from 0 to about 6, and r is 0, 1 or 2; and
Z is a substituted or unsubstituted alkyl, amino, aryl, heteroaryl
or heterocycloalkyl group. R.sub.4, R.sub.5 and the nitrogen atom
can also together form a 3, 4, 5, 6 or 7-membered, substituted or
unsubstituted heterocyclic or heterobicyclic group.
[0205] In another embodiment, R.sub.2 is of the formula 21
[0206] where n is an integer from 0 to about 4; and r is 0 or 1.
When r is 0, m is an integer from 0 to 6. When r is 1, m is an
integer from 1 to 6. Q is --NR.sub.4R.sub.5 or --OR.sub.6. Each
R.sub.4 and R.sub.5 is, independently, H, azabicycloalkyl or Y-Z,
wherein Y is selected from the group consisting of --C(O)--,
--(CH.sub.2).sub.p--, --S(O).sub.2--, --C(O)O--, --SO.sub.2NH--,
--CONH--, (CH.sub.2).sub.qO--, --(CH.sub.2).sub.qNH--, and
--(CH.sub.2)S(O).sub.r--; wherein p is an integer from 0 to about
6, q is an integer from 0 to about 6, and r is 0, 1 or 2; and Z is
a substituted or unsubstituted alkyl, amino, aryl, heteroaryl or
heterocycloalkyl group. R.sub.4, R.sub.5 and the nitrogen atom can
also together form a 3, 4, 5 or 6-membered, substituted or
unsubstituted heterocyclic group. R.sub.6 is hydrogen or a
substituted or unsubstituted alkyl group.
[0207] In another embodiment, R.sub.2 is of the formula 22
[0208] where n is an integer from 0 to about 4 and m is an integer
from 0 to about 6. R.sub.4 is H, azabicycloalkyl or Y-Z, wherein Y
is selected from the group consisting of --C(O)--,
--(CH.sub.2).sub.p--, --S(O).sub.2--, --C(O)O--, --SO.sub.2NH--,
--CONH--, (CH.sub.2).sub.qO--, --(CH.sub.2).sub.qNH--, and
--(CH.sub.2).sub.qS(O).sub.r--; p is an integer from 0 to about 6,
q is an integer from 0 to about 6, and r is 0, 1 or 2; and Z is a
substituted or unsubstituted alkyl, amino, aryl, heteroaryl or
heterocycloalkyl group. R.sub.6 is hydrogen or a substituted or
unsubstituted alkyl group.
[0209] In embodiments of R.sub.2 described above which include an
--N(R.sub.4)R.sub.5 group, this group can form a heterocyclic group
of the formula 23
[0210] where R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11,
R.sub.12, R.sub.13 and R.sub.14 are each, independently, lower
alkyl or hydrogen; or at least one pair of substituents R.sub.7 and
R.sub.8; R.sub.9 and R.sub.10; R.sub.11, and R.sub.12; or R.sub.13
and R.sub.14 together are an oxygen atom; or at least one of
R.sub.7 and R.sub.9 is cyano, CONHR.sub.15, COOR.sub.15,
CH.sub.2OR.sub.15 or CH.sub.2NR.sub.15(R.sub.1- 6), where R.sub.15
and R.sub.16 are each, independently, H, azabicycloalkyl or Y-Z,
wherein Y is selected from the group consisting of --C(O)--,
--(CH.sub.2).sub.p--, --S(O).sub.2--, --C(O)O--, --SO.sub.2NH--,
--CONH--, (CH.sub.2).sub.qO--, --(CH.sub.2).sub.qNH--, and
--(CH.sub.2).sub.qS(O).sub.r--; wherein p is an integer from 0 to
about 6, q is an integer from 0 to about 6, and r is 0, 1 or 2; and
Z is a substituted or unsubstituted alkyl, amino, aryl, heteroaryl
or heterocycloalkyl group; or R.sub.15, R.sub.16 and the nitrogen
atom together form a 3, 4, 5, 6 or 7-membered, substituted or
unsubstituted heterocyclic or heterobicyclic group; X is O, S, SO,
SO.sub.2, CH.sub.2, CHOR.sub.17 or NR17, wherein R.sub.17 is
hydrogen, substituted or unsubstituted alkyl, aryl, arylalkyl,
--C(NH)NH.sub.2, --C(O)R.sub.17, or --C(O)OR.sub.18, wherein
R.sub.18 is hydrogen, substituted or unsubstituted alkyl, aryl or
arylalkyl; and t is 0 or 1.
[0211] R.sub.4, R.sub.5 and the nitrogen atom can also together
form a heterocyclic group of the formula 24
[0212] where R.sub.19 and R.sub.20 are each, independently,
hydrogen or lower alkyl; or R.sub.19 and R.sub.20 together are an
oxygen atom. R.sub.21 and R.sub.22 are each, independently, H
azabicycloalkyl or Y-Z, wherein Y is selected from the group
consisting of --C(O)--, --(CH.sub.2).sub.p--, --S(O).sub.2--,
--C(O)O--, --SO.sub.2NH--, --CONH--, (CH.sub.2).sub.qO--,
--(CH.sub.2).sub.qNH--, and --(CH.sub.2).sub.qS(O).sub.r--; wherein
p is an integer from 0 to about 6, q is an integer from 0 to about
6, and r is 0, 1 or 2; and Z is a substituted or unsubstituted
alkyl, amino, aryl, heteroaryl or heterocycloalkyl group. R.sub.21,
R.sub.22 and the nitrogen atom can also together form a 3, 4, 5 or
6-membered, substituted or unsubstituted heterocyclic group. m is
an integer from 1 to about 6; and n is an integer from 0 to about
6.
[0213] R.sub.4, R.sub.5 and the nitrogen atom can also together
form a heterocyclic group of the formula 25
[0214] where m is an integer from 1 to 6. R.sub.23 is CH.sub.2OH,
NRR', C(O)NR'R or COOR, where R and R' are each independently
hydrogen or a substituted or unsubstituted alkyl, aryl or arylalkyl
group.
[0215] R.sub.4, R.sub.5 and the nitrogen atom can also together
form a heterocyclic group of the formula 26
[0216] where R.sub.24 is a substituted or unsubstituted alkyl, aryl
or arylalkyl group, carboxyl, cyano, C(O)OR.sub.25,
CH.sub.2OR.sub.25, CH.sub.2NR.sub.26R.sub.27 or C(O)NHR.sub.26.
R.sub.25 is a substituted or unsubstituted alkyl, aryl, arylalkyl,
heterocyclic or heteroaryl group. R.sub.26 and R.sub.27 are each,
independently, H, azabicycloalkyl or Y-Z, wherein Y is selected
from the group consisting of --C(O)--, --(CH.sub.2).sub.p--,
--S(O).sub.2--, --C(O)O--, --SO.sub.2NH--, --CONH--,
(CH.sub.2).sub.qO--, --(CH.sub.2).sub.qNH--, and
--(CH.sub.2).sub.qS(O).sub.r--; wherein p is an integer from 0 to
about 6, q is an integer from 0 to about 6, and r is 0, 1 or 2; and
Z is a substituted or unsubstituted alkyl, amino, aryl, heteroaryl
or heterocycloalkyl group. R.sub.26, R.sub.27 and the nitrogen atom
can also together form a 3, 4, 5 or 6-membered, substituted or
unsubstituted heterocyclic group.
[0217] In one subset of compounds of formula (I), at least one of
R.sub.4 and R.sub.5 is of the formula Y-Z, where Z is of the
formula 27
[0218] where T is C(O), S, SO, SO.sub.2, CHOR or NR, wherein R is
hydrogen or a substituted or unsubstituted alkyl, aryl or arylalkyl
group; and n is 0, 1 or 2.
[0219] In another embodiment, at least one of R.sub.4 and R.sub.5
is of the formula Y-Z, where Z is --N(R.sub.28)R.sub.29, and
R.sub.28 and R.sub.29 are each, independently, substituted or
unsubstituted carboxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl,
alkylsulfonyl, alkylcarbonyl or cyanoalkyl. R.sub.28 and R.sub.29,
together with the nitrogen atom, can also form a five- or
six-membered heterocyclic group.
[0220] In yet another embodiment, at least one of R.sub.4 and
R.sub.5 is of the formula Y-Z, where Z is of the formula
N(R.sub.30)R.sub.31. R.sub.30 and R.sub.31 are each, independently,
hydrogen, alkyl, alkoxycarbonyl, alkoxyalkyl, hydroxyalkyl,
aminocarbonyl, cyano, alkylcarbonyl or arylalkyl.
[0221] In another embodiment, at least one of R and R.sub.5 is Y-Z,
where Z is of the formula 28
[0222] Each X is, independently, CH or N. R.sub.32 is hydrogen,
cyano or a substituted or unsubstituted alkyl, alkoxycarbonyl,
alkoxyalkyl, hydroxyalkyl, amninocarbonyl, alkylcarbonyl or
arylalkyl group.
[0223] One of R.sub.4 and R.sub.5 can also be Y-Z where Z is of the
formula 29
[0224] where g is 0 or 1; and T is C(O), O, S, SO, SO.sub.2,
CH.sub.2, CHOR.sub.17 or NR17. R.sub.17 is hydrogen, substituted or
unsubstituted alkyl, aryl, arylalkyl, --C(NH)NH.sub.2,
--C(O)R.sub.18, C(O)NH.sub.2 or --C(O)OR.sub.18, where R.sub.18 is
hydrogen, substituted or unsubstituted alkyl, aryl or arylalkyl.
R.sub.32 is hydrogen, cyano or a substituted or unsubstituted
alkyl, alkoxycarbonyl, alkoxyalkyl, hydroxyalkyl, aminocarbonyl,
alkylcarbonyl or arylalkyl group.
[0225] One of R.sub.4 and R.sub.5 can also be Y-Z, where Z is of
the formula 30
[0226] where g is 0, 1 or 2; and R.sub.32 is hydrogen, cyano or a
substituted or unsubstituted alkyl, alkoxycarbonyl, alkoxyalkyl,
hydroxyalkyl, aminocarbonyl, alkylcarbonyl or arylalkyl group.
[0227] Z can also be of the formula 31
[0228] where g is 0, 1, 2 or 3, and T is O, S, SO, SO.sub.2,
CH.sub.2, CHOR.sub.17 or NR.sub.17. R.sub.17 is hydrogen,
substituted or unsubstituted alkyl, aryl, arylalkyl,
--C(NH)NH.sub.2, --C(O)R.sub.17, or --C(O)OR.sub.18, wherein
R.sub.18 is hydrogen, substituted or unsubstituted alkyl, aryl or
arylalkyl. R.sub.32 is hydrogen, cyano or a substituted or
unsubstituted alkyl, alkoxycarbonyl, alkoxyalkyl, hydroxyalkyl,
aminocarbonyl, alkylcarbonyl or arylalkyl group.
[0229] One of R.sub.4 and R.sub.5 can also be Y-Z, wherein Z is of
the formula 32
[0230] Where R.sub.32 is hydrogen, cyano or substituted or
unsubstituted alkyl, alkoxycarbonyl, alkoxyalkyl, hydroxyalkyl,
aminocarbonyl, alkylcarbonyl , thioalkoxy or arylalkyl; and
R.sub.33 is hydrogen or substituted or unsubstituted alkyl,
alkoxycarbonyl, alkoxyalkyl, aminocarbonyl, perhaloalkyl, alkenyl,
alkylcarbonyl or arylalkyl.
[0231] In another subset of the compounds of formula (I), R.sub.2
is of the formula 33
[0232] where m is 0 or 1; R.sub.34, R.sub.35, R.sub.36, R.sub.37,
R.sub.38, R.sub.39, R.sub.40 and R.sub.41 are each, independently,
methyl or hydrogen; or at least one pair of substituents R.sub.34
and R.sub.35; R.sub.36 and R.sub.37; R.sub.38 and R.sub.39; or
R.sub.40 and R.sub.41 together are an oxygen atom. R.sub.42 is H,
azabicycloalkyl or Y-Z, wherein Y is selected from the group
consisting of --C(O)--, --(CH.sub.2).sub.p--, --S(O).sub.2--,
--C(O)O--, --SO.sub.2NH--, --CONH--, (CH.sub.2).sub.qO--,
--(CH.sub.2).sub.qNH--, and --(CH.sub.2).sub.qS(O).sub.r--; wherein
p is an integer from 0 to about 6, q is an integer from 0 to about
6, and r is 0, 1 or 2; and Z is a substituted or unsubstituted
alkyl, amino, aryl, heteroaryl or heterocycloalkyl group.
[0233] In a preferred embodiment, R.sub.42 is of the formula 34
[0234] Where u is 0 or 1; R.sub.43, R.sub.44, R.sub.45, R.sub.46,
R.sub.47, R.sub.48, R.sub.49 and R.sub.50 are each, independently,
methyl or hydrogen; or at least one pair of substituents R.sub.43
and R.sub.44; R.sub.45 and R.sub.46; R.sub.47 and R48; or
R.sub.49and R.sub.50 together are an oxygen atom. R.sub.51 is H,
azabicycloalkyl or V-L, where V is selected from the group
consisting of --C(O)--, --(CH.sub.2).sub.p--, --S(O).sub.2--,
--C(O)O--, --SO.sub.2NH--, --CONH--, (CH.sub.2).sub.qO--,
--(CH.sub.2).sub.qNH--, and --(CH.sub.2).sub.qS(O).sub.r--; wherein
p is an integer from 0 to about 6, q is an integer from 0 to about
6, and r is 0, 1 or 2; and L is a substituted or unsubstituted
alkyl, amino, aryl, heteroaryl or heterocycloalkyl group.
[0235] In another subset of the compounds of formula (I), R.sub.2
is of the formula 35
[0236] Where h, i, j, k and l are independently 0 or 1; R.sub.52,
R.sub.53, R.sub.54, R.sub.55, R.sub.56, R.sub.57, R.sub.R.sub.58,
R.sub.59, R.sub.g and R.sub.h are R.sub.56 and R.sub.57; or
R.sub.58 and R.sub.59 together are an oxygen atom. R.sub.60 is H,
azabicycloalkyl or Y-Z, wherein Y is selected from the group
consisting of --C(O)--, --(CH.sub.2).sub.p--, --S(O).sub.2--,
--C(O)O--, --SO.sub.2NH--, --CONH--, (CH.sub.2).sub.qO--,
--(CH.sub.2).sub.qNH--, and --(CH.sub.2).sub.qS(O).sub.r--; wherein
p is an integer from 0 to about 6, q is an integer from 0 to about
6, and r is 0, 1 or 2; and Z is a substituted or unsubstituted
alkyl, amino, aryl, heteroaryl or heterocycloalkyl group. In one
embodiment, R.sub.60 is of the formula 36
[0237] Where v is 0 or 1; R.sub.61, R.sub.62, R.sub.63, R.sub.64,
R.sub.65, R.sub.66, R.sub.67 and R.sub.68 are each, independently,
lower alkyl or hydrogen; or at least one pair of substituents
R.sub.61and R.sub.62; R.sub.63 and R.sub.64; R.sub.65 and R.sub.66;
and R.sub.67 and R.sub.68 together are an oxygen atom; and R.sub.69
is H, azabicycloalkyl or V-L, where V is selected from the group
consisting of --C(O)--, --(CH.sub.2).sub.p--, --S(O).sub.2--,
--C(O)O--, --SO.sub.2NH--, --CONH--, (CH.sub.2).sub.qO--,
--(CH.sub.2).sub.qNH--, and --(CH.sub.2).sub.qS(O).sub.r--; wherein
p is an integer from 0 to about 6, q is an integer from 0 to about
6, and r is 0, 1 or 2; and L is a substituted or unsubstituted
alkyl, amino, aryl, heteroaryl or heterocycloalkyl group.
[0238] Compounds of formula (I) may exist as salts with
pharmaceutically acceptable acids. The present invention includes
such salts. Examples of such salts include hydrochlorides,
hydrobromides, sulfates, methanesulfonates, nitrates, maleates,
acetates, citrates, fumarates, tartrates (eg (+)-tartrates,
(-)-tartrates or mixtures thereof including racemnic mixtures),
succinates, benzoates and salts with amino acids such as glutamic
acid. These salts may be prepared by methods known to those skilled
in the art.
[0239] Certain compounds of formula (I) which have acidic
substituents may exist as salts with pharmaceutically acceptable
bases. The present invention includes such salts. Example of such
salts include sodium salts, potassium salts, lysine salts and
arginine salts. These salts may be prepared by methods known to
those skilled in the art.
[0240] Certain compounds of formula (I) and their salts may exist
in more than one crystal form and the present invention includes
each crystal form and mixtures thereof.
[0241] Certain compounds of formula (I) and their salts may also
exist in the form of solvates, for example hydrates, and the
present invention includes each solvate and mixtures thereof.
[0242] Certain compounds of formula (I) may contain one or more
chiral centres, and exist in different optically active forms. When
compounds of formula (I) contain one chiral centre, the compounds
exist in two enantiomeric forms and the present invention includes
both enantiomers and mixtures of enantiomers, such as racemic
mixtures. The enantiomers may be resolved by methods known to those
skilled in the art, for example by formation of diastereoisomeric
salts which may be separated, for example, by crystallization;
formation of diastereoisomeric derivatives or complexes which may
be separated, for example, by crystallization, gas-liquid or liquid
chromatography; selective reaction of one enantiomer with an
enantiomer-specific reagent, for example enzymatic esterification;
or gas-liquid or liquid chromatography in a chiral environment, for
example on a chiral support for example silica with a bound chiral
ligand or in the presence of a chiral solvent. It will be
appreciated that where the desired enantiomer is converted into
another chemical entity by one of the separation procedures
described above, a further step is required to liberate the desired
enantiomeric form. Alternatively, specific enantiomers may be
synthesized by asymmetric synthesis using optically active
reagents, substrates, catalysts or solvents, or by converting one
enantiomer into the other by asymmetric transformation.
[0243] When a compound of formula (I) contains more than one chiral
centre it may exist in diastereoisomeric forms. The
diastereoisomeric pairs may be separated by methods known to those
skilled in the art, for example chromatography or crystallization
and the individual enantiomers within each pair may be separated as
described above. The present invention includes each
diastereoisomer of compounds of formula (I) and mixtures
thereof.
[0244] Certain compounds of formula (I) may exist in different
tautomeric forms or as different geometric isomers, and the present
invention includes each tautomer and/or geometric isomer of
compounds of formula (I) and mixtures thereof.
[0245] Certain compounds of formula (I) may exist in different
stable conformational forms which may be separable. Torsional
asymmetry due to restricted rotation about an asymmetric single
bond, for example because of steric hindrance or ring strain, may
permit separation of different conformers. The present invention
includes each conformational isomer of compounds of formula (I) and
mixtures thereof.
[0246] Certain compounds of formula (I) may exist in zwitterionic
form and the present invention includes each zwitterionic form of
compounds of formula (I) and mixtures thereof. Heteroaromatic
groups, as used herein, include heteroaryl ring systems (e.g., for
purposes of exemplification, which should not be construed as
limiting the scope of this invention: thienyl, pyridyl, pyrazole,
isoxazolyl, thiadiazolyl, oxadiazolyl, indazolyl, furans, pyrroles,
imidazoles, pyrazoles, triazoles, pyrimidines, pyrazines,
thiazoles, isothiazoles, oxazolyl or tetrazoles) and heteroaryl
ring systems in which a carbocyclic aromatic ring, carbocyclic
non-aromatic ring or heteroaryl ring is fused to one or more other
heteroaryl rings (e.g., for purposes of exemplification, which
should not be construed as limiting the scope of this invention:
benzo(b)thienyl, benzimidazolyl, benzoxazolyl, benzothiazolyl,
benzothiadiazolyl, benzoxadiazolyl, indole, tetrahydroindole,
azaindole, indazole, quinoline, imidazopyridine, quinazoline
purine, pyrrolo[2,3-d]pyrimidine, pyrazolo[3,4-d]pyrimidine) and
their N-oxides. Substituted heteroaryl groups are preferably
substituted with one or more substituents each independently
selected from the group consisting of a halogen, hydroxy, alkyl,
alkoxy, alkyl-O--C(O)--, alkoxyalkyl, a heterocycloalkyl group,
optionally substituted phenyl, nitro, amino, mono-substituted amino
or di-substituted amino.
[0247] A heterocyclic (heterocyclyl) group, as used herein, refers
to a heterocyclic group that is unsaturated, partially saturated or
saturated.
[0248] A heterobicyclic group, as used herein, refers to a bicyclic
group having one or more heteroatoms, which is saturated, partially
unsaturated or unsaturated.
[0249] An arylalkyl group, as used herein, is an aromatic
substituent that is linked to a compound by an aliphatic group
having from one to about six carbon atoms. A preferred arylalkyl
group is a benzyl group.
[0250] An heteroaralkyl group, as used herein, is a heteroaromatic
substituent that is linked to a compound by an aliphatic group
having from one to about six carbon atoms.
[0251] A heterocycloalkyl group, as used herein, is a non-aromatic
ring system that has 3 to 8 atoms and includes at least one
heteroatom, such as nitrogen, oxygen, or sulfur.
[0252] As used herein, a (heterocycloalkyl)alkyl group is a
heterocycloalkyl group attached to the parent molecule through an
alkyl group.
[0253] As used herein, a cycloalkyl group is a saturated or
partially unsaturated monocyclic, bicyclic, or tricyclic
hydrocarbon ring system having three to twelve carbon atoms.
[0254] As used herein, a cycloalkylalkyl group is a cycloalkyl
group attached to the parent molecule through an alkyl group.
[0255] As used herein, aliphatic groups or notations such as
"(C.sub.0-C.sub.6)" include straight chained, branched or cyclic
hydrocarbons which are completely saturated or which contain one or
more units of unsaturation. When the group is a C.sub.0 it means
that the moiety is not present or in other words is a bond.
[0256] As used herein, an alkoxyalkyl group is an alkoxy group that
is attached to the parent molecule through an alkyl group.
Preferred are alkoxy groups of 1 to 6 carbon atoms and alkyl groups
of 1 to 6 carbon atoms.
[0257] As used herein, aromatic groups (or aryl groups) include
aromatic carbocyclic ring systems (e.g. phenyl) and fused
polycyclic aromatic ring systems (e.g. naphthyl and
1,2,3,4-tetrahydronaphthyl.)
[0258] As used herein, the term "natural amino acid" refers to the
twenty-three natural amino acids known in the art, which are as
follows (denoted by their three letter acronym): Ala, Arg, Asn,
Asp, Cys, Cys-Cys, Glu, Gln, Gly, His, Hyl, Hyp, Ile, Leu, Lys,
Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val. The term non-natural
amino acid refers to compounds of the formula
NH.sub.2--(C(X).sub.2).sub.n--COOH, which are alpha- (when n is 1)
or beta- (when n is 2) amino acids where X for each occurrence is
independently any side chain moiety recognized by those skilled in
the art; examples of non-natural amino acids include, but are not
limited to: hydroxyproline, homoproline, 4-amino-phenylalanine,
.beta.-(2-naphthyl)alanine, norleucine, cyclohexylalanine,
.beta.-(3-pyridinyl)alanine, .beta.-(4-pyridinyl)alanine,
.alpha.-aminoisobutyric acid, urocanic acid,
N,N-tetramethylamidino-histi- dine, N-methyl-alanine,
N-methyl-glycine, N-methyl-glutamic acid, tert-butylglycine,
.alpha.-aminobutyric acid, tert-butylalanine, ornithine,
.alpha.-aminoisobutyric acid, .beta.-alanine, .gamma.-aminobutyric
acid, 5-aminovaleric acid, 12-aminododecanoic acid,
2-aminoindane-2-carboxylic acid, etc. and the derivatives thereof,
especially where the amine nitrogen has been mono- or
di-alkylated.
[0259] As used herein, many moieties or substituents are termed as
being either "substituted or unsubstituted" or "optionally
substituted". When a moiety is modified by one of these terms, it
denotes that any portion of the moiety that is known to one skilled
in the art as being available for substitution can be substituted,
which includes one or more substituents, where if more than one
substituent then each substituent is independently selected. Such
means for substitution are well-known in the art and/or taught by
the instant disclosure. For purposes of exemplification, which
should not be construed as limiting the scope of this invention,
some examples of groups that are substituents are: alkyl groups
(which itself can also be substituted, such as CF.sub.3), alkoxy
group (which itself can be substituted, such as OCF.sub.3), a
halogen or halo group (F, Cl, Br, I), hydroxy, nitro, oxo, CN, COH,
COOH, amino, N-alkylamino or N,N-dialkylamino (in which the alkyl
groups can also be substituted), esters (--C(O)--OR, where R is
groups such as alkyl, aryl, etc., which can be substituted), aryl
(most preferred is phenyl, which can be substituted) and arylalkyl
(which can be substituted).
[0260] The compounds of this invention have antiangiogenic
properties. These antiangiogenic properties are due at least in
part to the inhibition of protein tyrosine kinases essential for
angiogenic processes. For this reason, these compounds can be used
as active agents against such disease states as arthritis,
atherosclerosis, restenosis, psoriasis, hemangiomas, myocardial
angiogenesis, coronary and cerebral collaterals, ischemic limb
angiogenesis, ischemia/reperfusion injury, wound healing, peptic
ulcer Helicobacter related diseases, virally-induced angiogenic
disorders, fractures, Crow-Fukase syndrome (POEMS), preeclampsia,
menometrorrhagia, cat scratch fever, rubeosis, neovascular glaucoma
and retinopathies such as those associated with diabetic
retinopathy, retinopathy of prematurity, or age-related macular
degeneration. In addition, some of these compounds can be used as
active agents against solid tumors, malignant ascites, von Hippel
Lindau disease, hematopoietic cancers and hyperproliferative
disorders such as thyroid hyperplasia (especially Grave's disease),
and cysts (such as hypervascularity of ovarian stroma
characteristic of polycystic ovarian syndrome (Stein-Leventhal
syndrome) and polycystic kidney disease since such diseases require
a proliferation of blood vessel cells for growth and/or
metastasis.
[0261] Further, some of these compounds can be used as active
agents against burns, chronic lung disease, stroke, polyps,
anaphylaxis, chronic and allergic inflammation, delayed-type
hypersensitivity, ovarian hyperstimulation syndrome, brain
tumor-associated cerebral edema, high-altitude, trauma or hypoxia
induced cerebral or pulmonary edema, ocular and macular edema,
ascites, glomerulonephritis and other diseases where vascular
hyperpermeability, effusions, exudates, protein extravasation, or
edema is a manifestation of the disease. The compounds will also be
useful in treating disorders in which protein extravasation leads
to the deposition of fibrin and extracellular matrix, promoting
stromal proliferation (e.g. keloid, fibrosis, cirrhosis and carpal
tunnel syndrome). Increased VEGF production potentiates
inflammatory processes such as monocyte recruitment and activation.
The compounds of this invention will also be useful in treating
inflammatory disorders such as inflammatory bowel disease (IBD) and
Crohn's disease.
[0262] VEGF's are unique in that they are the only angiogenic
growth factors known to contribute to vascular hyperpermeability
and the formation of edema. Indeed, vascular hyperpermeability and
edema that is associated with the expression or administration of
many other growth factors appears to be mediated via VEGF
production. Inflammatory cytokines stimulate VEGF production.
Hypoxia results in a marked upregulation of VEGF in numerous
tissues, hence situations involving infarct, occlusion, ischemia,
anemia, or circulatory impairment typically invoke VEGF/VPF
mediated responses. Vascular hyperpermeability, associated edema,
altered transendothelial exchange and macromolecular extravasation,
which is often accompanied by diapedesis, can result in excessive
matrix deposition, aberrant stromal proliferation, fibrosis, etc.
Hence, VEGF-mediated hyperpermeability can significantly contribute
to disorders with these etiologic features.
[0263] Because blastocyst implantation, placental development and
embryogenesis are angiogenesis dependent, certain compounds of the
invention are useful as contraceptive agents and antifertility
agents.
[0264] It is envisaged that the disorders listed above are mediated
to a significant extent by protein tyrosine kinase activity
involving the KDR/VEGFR-2 and/or the Flt-1/VEGFR-1 and/or TIE-2
tyrosine kinases. By inhibiting the activity of these tyrosine
kinases, the progression of the listed disorders is inhibited
because the angiogenic or vascular hyperpermeability component of
the disease state is severely curtailed. The action of certain
compounds of this invention, by their selectivity for specific
tyrosine kinases, result in a minimization of side effects that
would occur if less selective tyrosine kinase inhibitors were used.
Certain compounds of the invention are also effective inhibitors of
FGFR, PDGFR, c-Met and IGF-1-R. These receptor kinases can directly
or indirectly potentiate angiogenic and hyperproliferative
responses in various disorders, hence their inhibition can impede
disease progression.
[0265] Tie-2 (TEK) is a member of a recently discovered family of
endothelial cell specific receptor tyrosine kinases which is
involved in critical angiogenic processes, such as vessel
branching, sprouting, remodeling, maturation and stability. Tie-2
is the first mammalian receptor tyrosine kinase for which both
agonist ligand(s) (e.g., Angiopoietin1 ("Ang1"), which stimulates
receptor autophosphorylation and signal transduction), and
antagonist ligand(s) (e.g., Angiopoietin2 ("Ang2")), have been
identified. Knock-out and transgenic manipulation of the expression
of Tie-2 and its ligands indicates tight spatial and temporal
control of Tie-2 signaling is essential for the proper development
of new vasculature. The current model suggests that stimulation of
Tie-2 kinase by the Ang1 ligand is directly involved in the
branching, sprouting and outgrowth of new vessels, and recruitment
and interaction of periendothelial support cells important in
maintaining vessel integrity and inducing quiescence. The absence
of Ang1 stimulation of Tie-2 or the inhibition of Tie-2
autophosphorylation by Ang2, which is produced at high levels at
sites of vascular regression, may cause a loss in vascular
structure and matrix contacts resulting in endothelial cell death,
especially in the absence of growth/survival stimuli. The situation
is however more complex, since at least two additional Tie-2
ligands (Ang3 and Ang4) have recently been reported, and the
capacity for heterooligomerization of the various agonistic and
antagonistic angiopoietins, thereby modifying their activity, has
been demonstrated. Targeting Tie-2 ligand-receptor interactions as
an antiangiogenic therapeutic approach is thus less favored and a
kinase inhibitory strategy preferred.
[0266] The soluble extracellular domain of Tie-2 ("ExTek") can act
to disrupt the establishment of tumor vasculature in a breast tumor
xenograft and lung metastasis models and in tumor-cell mediated
ocular neovasculatization. By adenoviral infection, the in vivo
production of mg/ml levels ExTek in rodents may be achieved for
7-10 days with no adverse side effects. These results suggest that
disruption of Tie-2 signaling pathways in normal healthy animals
may be well tolerated. These Tie-2 inhibitory responses to ExTek
may be a consequence sequestration of ligand(s) and/or generation
of a nonproductive heterodimer with full-length Tie-2.
[0267] Recently, significant upregulation of Tie-2 expression has
been found within the vascular synovial pannus of arthritic joints
of humans, consistent with a role in the inappropriate
neovascularization. This finding suggests that Tie-2 plays a role
in the progression of rheumatoid arthritis. Point mutations
producing constitutively activated forms of Tie-2 have been
identified in association with human venous malformation disorders.
Tie-2 inhibitors are, therefore, useful in treating such disorders,
and in other situations of inappropriate neovascularization.
[0268] The compounds of this invention have inhibitory activity
against protein kinases. That is, these compounds modulate signal
transduction by protein kinases. Compounds of this invention
inhibit protein kinases from serine/threonine and tyrosine kinase
classes. In particular, these compounds selectively inhibit the
activity of the KDR/FLK-1/VEGFR-2 tyrosine kinases. Certain
compounds of this invention also inhibit the activity of additional
tyrosine kinases such as Flt-1/VEGFR-1, Flt-4/VEGFR-3, Tie-1,
Tie-2, FGFR, PDGFR, IGF-1R, c-Met, Src-subfamily kinases such as
Lck, hck, fgr, Src, fyn, yes, etc. Additionally, some compounds of
this invention significantly inhibit serine/threonine kinases such
as PKC, MAP kinases, erk, CDKs, Plk-1, or Raf-1 which play an
essential role in cell proliferation and cell-cycle progression.
The potency and specificity of the generic compounds of this
invention towards a particular protein kinase can often be altered
and optimized by variations in the nature, number and arrangement
of the substituents (i.e., R.sub.1, R.sub.2, R.sub.3, A and ring 1)
and conformational restrictions. In addition the metabolites of
certain compounds may also possess significant protein kinase
inhibitory activity.
[0269] The compounds of this invention, when administered to
individuals in need of such compounds, inhibit vascular
hyperpermeability and the formation of edema in these individuals.
These compounds act, it is believed, by inhibiting the activity of
KDR tyrosine kinase which is involved in the process of vascular
hyperpermeability and edema formation. The KDR tyrosine kinase may
also be referred to as FLK-1 tyrosine kinase, NYK tyrosine kinase
or VEGFR-2 tyrosine kinase. KDR tyrosine kinase is activated when
vascular endothelial cell growth factor (VEGF) or another
activating ligand (such as VEGF-C, VEGF-D, VEGF-E or HIV Tat
protein) binds to a KDR tyrosine kinase receptor which lies on the
surface of vascular endothelial cells. Following such KDR tyrosine
kinase activation, hyperpermeability of the blood vessels occurs
and fluid moves from the blood stream past the blood vessel walls
into the interstitial spaces, thereby forming an area of edema.
Diapedesis also often accompanies this response. Similarly,
excessive vascular hyperpermeability can disrupt normal molecular
exchange across the endothelium in critical tissues and organs
(e.g., lung and kidney), thereby causing macromolecular
extravasation and deposition. Following this acute response to KDR
stimulation which is believed to facilitate the subsequent
angiogenic process, prolonged KDR tyrosine kinase stimulation
results in the proliferation and chemotaxis of vascular endothelial
cells and formation of new vessels. By inhibiting KDR tyrosine
kinase activity, either by blocking the production of the
activating ligand, by blocking the activating ligand binding to the
KDR tyrosine kinase receptor, by preventing receptor dimerization
and transphosphorylation, by inhibiting the enzyme activity of the
KDR tyrosine kinase (inhibiting the phosphorylation function of the
enzyme) or by some other mechanism that interrupts its downstream
signaling (D. Mukhopedhyay et al., Cancer Res. 58:1278-1284 (1998)
and references therein), hyperpermeability, as well as associated
extravasation, subsequent edema formation and matrix deposition,
and angiogenic responses, may be inhibited and minimized.
[0270] One group of preferred compounds of this invention have the
property of inhibiting KDR tyrosine kinase activity without
significantly inhibiting Flt-1 tyrosine kinase activity (Flt-1
tyrosine kinase is also referred to as VEGFR-1 tyrosine kinase).
Both KDR tyrosine kinase and Flt-1 tyrosine kinase are activated by
VEGF binding to KDR tyrosine kinase receptors and to Flt-1 tyrosine
kinase receptors, respectively. Certain preferred compounds of this
invention are unique because they inhibit the activity of one
VEGF-receptor tyrosine kinase (KDR) that is activated by activating
ligands but do not inhibit other receptor tyrosine kinases, such as
Flt-1, that are also activated by certain activating ligands. In
this manner, certain preferred compounds of this invention are,
therefore, selective in their tyrosine kinase inhibitory
activity.
[0271] In one embodiment, the present invention provides a method
of treating a protein kinase-mediated condition in a patient,
comprising administering to the patient a therapeutically or
prophylactically effective amount of one or more compounds of
formula (I).
[0272] A "protein kinase-mediated condition" or a "condition
mediated by protein kinase activity" is a medical condition, such
as a disease or other undesirable physical condition, the genesis
or progression of which depends, at least in part, on the activity
of at least one protein kinase. The protein kinase can be, for
example, a protein tyrosine kinase or a protein serine/threonine
kinase.
[0273] The patient to be treated can be any animal, and is
preferably a mammal, such as a domesticated animal or a livestock
animal. More preferably, the patient is a human.
[0274] A "therapeutically effective amount" is an amount of a
compound of formula (I) or a combination of two or more such
compounds, which inhibits, totally or partially, the progression of
the condition or alleviates, at least partially, one or more
symptoms of the condition. A therapeutically effective amount can
also be an amount which is prophylactically effective. The amount
which is therapeutically effective will depend upon the patient's
size and gender, the condition to be treated, the severity of the
condition and the result sought. For a given patient, a
therapeutically effective amount can be determined by methods known
to those of skill in the art.
[0275] The method of the present invention is useful in the
treatment of protein kinase-mediated conditions, such as any of the
conditions described above. In one embodiment, the protein
kinase-mediated condition is characterized by undesired
angiogenesis, edema, or stromal deposition. For example, the
condition can be one or more ulcers, such as ulcers caused by
bacterial or fungal infections, Mooren ulcers and ulcerative
colitis. The condition can also be due to a microbial infection,
such as Lyme disease, sepsis, septic shock or infections by Herpes
simplex, Herpes Zoster, human immunodeficincy virus, protozoa,
toxoplasmosis or parapoxvirus; an angiogenic disorders, such as von
Hippel Lindau disease, polycystic kidney disease, pemphigoid,
Paget's disease and psoriasis; a reproductive condition, such as
endometriosis, ovarian hyperstimulation syndrome, preeclampsia or
menometrorrhagia; a fibrotic and edemic condition, such as
sarcoidosis, fibrosis, cirrhosis, thyroiditis, hyperviscosity
syndrome systemic, Osler-Weber-Rendu disease, chronic occlusive
pulmonary disease, asthma, and edema following burns, trauma,
radiation, stroke, hypoxia or ischemia; or an
inflammatory/immunologic condition, such as systemic lupus, chronic
inflammation, glomerulonephritis, synovitis, inflammatory bowel
disease, Crohn's disease, rheumatoid arthritis, osteoarthritis,
multiple sclerosis and graft rejection. Suitable protein
kinase-mediated conditions also include sickle cell anaemia,
osteoporosis, osteopetrosis, tumor-induced hypercalcemia and bone
metastases. Additional protein kinase-mediated conditions which can
be treated by the method of the present invention include ocular
conditions such as ocular and macular edema, ocular neovascular
disease, scleritis, radial keratotomy, uveitis, vitritis, myopia,
optic pits, chronic retinal detachment, post-laser complications,
conjunctivitis, Stargardt's disease and Eales disease, in addition
to retinopathy and macular degeneration.
[0276] The compounds of the present invention are also useful in
the treatment of cardiovascular conditions such as atherosclerosis,
restenosis, vascular occlusion and carotid obstructive disease.
[0277] The compounds of the present invention are also useful in
the treatment of cancer related indications such as solid tumors,
sarcomas (especially Ewing's sarcoma and osteosarcoma),
retinoblastoma, rhabdomyosarcomas, neuroblastoma, glioblastoma,
hematopoietic malignancies, including leukaemia and lymphoma,
tumor-induced pleural or pericardial effusions, and malignant
ascites.
[0278] The compounds of the present invention are also useful in
the treatment of pulmonary hypertension, especially in patients
with thromboembolic disease (J Thorac Cardiovasc Surg, 2001, 122
(1), p. 65-73), Crow-Fukase (POEMS) syndrome and diabetic
conditions such as glaucoma, diabetic retinopathy and
microangiopathy.
[0279] The Src, Tec, Jak, Map, Csk, NFKB and Syk families of
kinases play pivotal roles in the regulation of immune function.
The Src family currently includes Fyn, Lck, Fgr, Fes, Lyn, Src,
Yrk, Fyk, Yes, Hck, and Blk. The Syk family is currently understood
to include only Zap and Syk. The TEC family includes Tec, Btk, Rlk
and Itk. The Janus family of kinases is involved in the
transduction of growth factor and proinflammatory cytokine signals
through a number of receptors. Although BTK and ITK, members of the
Tec family of kinases, play a less well understood role in
immunobiology, their modulation by an inhibitor may prove
therapeutically beneficial. The Csk family is currently understood
to include Csk and Chk. The kinases RIP, IRAK-1, IRAK-2, NIK, p38
MAP kinases, Jnk, IKK-1 and IKK-2 are involved in the signal
transduction pathways for key pro-inflammatory cytokines, such as
TNF and IL-1. By virtue of their ability to inhibit one or more of
these kinases, compounds of formula (I) may function as
immunomodulatory agents useful for the maintenance of allografts,
the treatment of autoimmune disorders and treatment of sepsis and
septic shock. Through their ability to regulate the migration or
activation of T cells, B-cells, mast cells, monocytes and
neutrophils, these compounds could be used to treat such autoimmune
diseases and sepsis. Prevention of transplant rejection, either
host versus graft for solid organs or graft versus host for bone
marrow, are limited by the toxicity of currently available
immunosuppressive agents and would benefit from an efficacious drug
with improved therapeutic index. Gene targeting experiments have
demonstrated the essential role of Src in the biology of
osteoclasts, the cells responsible for bone resorption. Compounds
of formula (I), through their ability to regulate Src, may also be
useful in the treatment of osteoporosis, osteopetrosis, Paget's
disease, tumor-induced hypercalcemia and in the treatment of bone
metastases.
[0280] A number of protein kinases have been demonstrated to be
protooncogenes. Chromosome breakage (at the ltk kinase break point
on chromosome 5), translocation as in the case of the Abl gene with
BCR (Philadelphia chromosome), truncation in instances such as
c-Kit or EGFR, or mutation (e.g., Met) result in the creation of
dysregulated proteins converting them from protooncogene to
oncogene products. In other tumors, oncogenesis is driven by an
autocrine or paracrine ligand/growth factor receptor interactions.
Members of the src-family kinases are typically involved in
downstream signal transduction thereby potentiating the oncogenesis
and themselves may become oncogenic by over-expression or mutation.
By inhibiting the protein kinase activity of these proteins the
disease process may be disrupted. Vascular restenosis may involve
FGF and/or PDGF--promoted smooth muscle and endothelial cell
proliferation. The ligand stimulation of FGFR, PDGFR, IGF1-R and
c-Met in vivo is proangiogenic, and potentiates angiogenesis
dependent disorders. Inhibition of FGFr, PDGFr, c-Met, or IGF1-R
kinase activities individually or in combination may be an
efficacious strategy for inhibiting these phenomena. Thus compounds
of formula (I) which inhibit the kinase activity of normal or
aberrant c-kit, c-met, c-fms, src-family members, EGFr, erbB2,
erbB4, BCR-Abl, PDGFr, FGFr, IGF1-R and other receptor or cytosolic
tyrosine kinases may be of value in the treatment of benign and
neoplastic proliferative diseases.
[0281] In many pathological conditions (for example, solid primary
tumors and metastases, Kaposi's sarcoma, rheumatoid arthritis,
blindness due to inappropriate ocular neovascularization, psoriasis
and atherosclerosis) disease progression is contingent upon
persistent angiogenesis. Polypeptide growth factors often produced
by the disease tissue or associated inflammatory cells, and their
corresponding endothelial cell specific receptor tyrosine kinases
(e.g., KDR/VEGFR-2, Flt-1/VEGFR-1, Tie-2/Tek and Tie) are essential
for the stimulation of endothelial cell growth, migration,
organization, differentiation and the establishment of the
requisite new functional vasculature. As a result of the vascular
permeability factor activity of VEGF in mediating vascular
hyperpermeability, VEGF-stimulation of a VEGFR kinase is also
believed to play an important role in the formation of tumor
ascites, cerebral and pulmonary edema, pleural and pericardial
effusions, delayed-type hypersensitivity reactions, tissue edema
and organ dysfunction following trauma, burns, ischemia, diabetic
complications, endometriosis, adult respiratory distress syndrome
(ARDS), post-cardiopulmonary bypass-related hypotension and
hyperpermeability, and ocular edema leading to glaucoma or
blindness due to inappropriate neovascularization. In addition to
VEGF, recently identified VEGF-C and VEGF-D, and virally-encoded
VEGF-E or HIV-Tat protein can also cause a vascular
hyperpermeability response through the stimulation of a VEGFR
kinase. KDR/EGFR-2 and/or Tie-2 are expressed also in a select
population of hematopoietic stem cells. Certain members of this
population are pluripotent in nature and can be stimulated with
growth factors to differentiate into endothelial cells and
participate in vasculogenetic angiogenic processes. For this reason
these have been called Endothelial Progenitor Cells (EPCs) (J.
Clin. Investig. 103: 1231-1236 (1999)). In some progenitors, Tie-2
may play a role in their recruitment, adhesion, regulation and
differentiation (Blood, 4317-4326 (1997)). Certain agents according
to formula (I) capable of blocking the kinase activity of
endothelial cell specific kinases could therefore inhibit disease
progression involving these situations.
[0282] Vascular destabilization of the antagonist ligand of Tie-2
(Ang2) is believed to induce an unstable "plastic" state in the
endothelium. In the presence of high VEGF levels a robust
angiogenic response may result; however, in the absence of VEGF or
a VEGF-related stimulus, frank vessel regression and endothelial
apoptosis can occur (Genes and Devel. 13: 1055-1066 (1999)). In an
analogous manner a Tie-2 kinase inhibitor can be proangiogenic or
antiangiogenic in the presence or absence of a VEGF-related
stimulus, respectively.
[0283] The compounds of formula (I) or a salt thereof or
pharmaceutical compositions containing a therapeutically effective
amount thereof may be used in the treatment of protein
kinase-mediated conditions, such as benign and neoplastic
proliferative diseases and disorders of the immune system, as
described above. For example, such diseases include autoimmune
diseases, such as rheumatoid arthritis, thyroiditis, type 1
diabetes, multiple sclerosis, sarcoidosis, inflammatory bowel
disease, Crohn's disease, myasthenia gravis and systemic lupus
erythematosus; psoriasis, organ transplant rejection (eg. kidney
rejection, graft versus host disease), benign and neoplastic
proliferative diseases, human cancers such as lung, breast,
stomach, bladder, colon, pancreas, ovarian, prostate and rectal
cancer and hematopoietic malignancies (leukemia and lymphoma), and
diseases involving inappropriate vascularization for example
diabetic retinopathy, retinopathy of prematurity, choroidal
neovascularization due to age-related macular degeneration, and
infantile hemangiomas in human beings. In addition, such inhibitors
may be useful in the treatment of disorders involving VEGF mediated
edema, ascites, effusions, and exudates, including for example
macular edema, cerebral edema, acute lung injury and adult
respiratory distress syndrome (ARDS).
[0284] The compounds of the present invention may also be useful in
the prophylaxis of the above diseases.
[0285] It is envisaged that the disorders listed above are mediated
to a significant extent by protein tyrosine kinase activity
involving the VEGF receptors (e.g. KDR, Flt-1 and/or Tie-2). By
inhibiting the activity of these receptor tyrosine kinases, the
progression of the listed disorders is inhibited because the
angiogenic component of the disease state is severely curtailed.
The action of the compounds of this invention, by their selectivity
for specific tyrosine kinases, result in a minimization of side
effects that would occur if less selective tyrosine kinase
inhibitors were used.
[0286] In another aspect the present invention provides compounds
of formula (I) as defined initially above for use as medicaments,
particularly as inhibitors of protein kinase activity for example
tyrosine kinase activity, serine kinase activity and threonine
kinase activity. In yet another aspect the present invention
provides the use of compounds of formula (I) as defined initially
above in the manufacture of a medicament for use in the inhibition
of protein kinase activity.
[0287] In this invention, the following definitions are
applicable:
[0288] "Physiologically acceptable salts" refers to those salts
which retain the biological effectiveness and properties of the
free bases and which are obtained by reaction with inorganic acids
such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric
acid, phosphoric acid or organic acids such as sulfonic acid,
carboxylic acid, organic phosphoric acid, methanesulfonic acid,
ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, lactic
acid, tartaric acid and the like.
[0289] Phamaceutical Formulations
[0290] The compounds of this invention can be administered to a
human patient by themselves or in pharmaceutical compositions where
they are mixed with suitable carriers or excipient(s) at doses to
treat or ameliorate vascular hyperpermeability, edema and
associated disorders. Mixtures of these compounds can also be
administered to the patient as a simple mixture or in suitable
formulated pharmaceutical compositions. A therapeutically effective
dose further refers to that amount of the compound or compounds
sufficient to result in the prevention or attenuation of
inappropriate neovascularization, progression of hyperproliferative
disorders, edema, VEGF-associated hyperpermeability and/or
VEGF-related hypotension. Techniques for formulation and
administration of the compounds of the instant application may be
found in "Remington's Pharmaceutical Sciences," Mack Publishing
Co., Easton, Pa., latest edition.
[0291] Routes of Administration
[0292] Suitable routes of administration may, for example, include
oral, eyedrop, rectal, transmucosal, topical, or intestinal
administration; parenteral delivery, including intramuscular,
subcutaneous, intramedullary injections, as well as intrathecal,
direct intraventricular, intravenous, intraperitoneal, intranasal,
or intraocular injections.
[0293] Alternatively, one may administer the compound in a local
rather than a systemic manner, for example, via injection of the
compound directly into an edematous site, often in a depot or
sustained release formulation.
[0294] Furthermore, one may administer the drug in a targeted drug
delivery system, for example, in a liposome coated with endothelial
cell-specific antibody.
[0295] Composition/Formulation
[0296] The pharmaceutical compositions of the present invention may
be manufactured in a manner that is itself known, e.g., by means of
conventional mixing, dissolving, granulating, dragee-making,
levigating, emulsifying, encapsulating, entrapping or lyophilizing
processes.
[0297] Pharmaceutical compositions for use in accordance with the
present invention thus may be formulated in conventional manner
using one or more physiologically acceptable carriers comprising
excipients and auxiliaries which facilitate processing of the
active compounds into preparations which can be used
pharmaceutically. Proper formulation is dependent upon the route of
administration chosen.
[0298] For injection, the agents of the invention may be formulated
in aqueous solutions, preferably in physiologically compatible
buffers such as Hanks's solution, Ringer's solution, or
physiological saline buffer. For transmucosal administration,
penetrants appropriate to the barrier to be permeated are used in
the formulation. Such penetrants are generally known in the
art.
[0299] For oral administration, the compounds can be formulated
readily by combining the active compounds with pharmaceutically
acceptable carriers well known in the art. Such carriers enable the
compounds of the invention to be formulated as tablets, pills,
dragees, capsules, liquids, gels, syrups, slurries, suspensions and
the like, for oral ingestion by a patient to be treated.
Pharmaceutical preparations for oral use can be obtained by
combining the active compound with a solid excipient, optionally
grinding a resulting mixture, and processing the mixture of
granules, after adding suitable auxiliaries, if desired, to obtain
tablets or dragee cores. Suitable excipients are, in particular,
fillers such as sugars, including lactose, sucrose, mannitol, or
sorbitol; cellulose preparations such as, for example, maize
starch, wheat starch, rice starch, potato starch, gelatin, gum
tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium
carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If
desired, disintegrating agents may be added, such as the
cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt
thereof such as sodium alginate.
[0300] Dragee cores are provided with suitable coatings. For this
purpose, concentrated sugar solutions may be used, which may
optionally contain gum arabic, talc, polyvinyl pyrrolidone,
carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer
solutions, and suitable organic solvents or solvent mixtures.
Dyestuffs or pigments may be added to the tablets or dragee
coatings for identification or to characterize different
combinations of active compound doses.
[0301] Pharmaceutical preparations which can be used orally include
push-fit capsules made of gelatin, as well as soft, sealed capsules
made of gelatin and a plasticizer, such as glycerol or sorbitol.
The push-fit capsules can contain the active ingredients in
admixture with filler such as lactose, binders such as starches,
and/or lubricants such as talc or magnesium stearate and,
optionally, stabilizers. In soft capsules, the active compounds may
be dissolved or suspended in suitable liquids, such as fatty oils,
liquid paraffin, or liquid polyethylene glycols. In addition,
stabilizers may be added. All formulations for oral administration
should be in dosages suitable for such administration.
[0302] For buccal administration, the compositions may take the
form of tablets or lozenges formulated in conventional manner.
[0303] For administration by inhalation, the compounds for use
according to the present invention are conveniently delivered in
the form of an aerosol spray presentation from pressurized packs or
a nebuliser, with the use of a suitable propellant, e.g.,
dichlorodifluoromethane, trichlorofluoromethane,
dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In
the case of pressurized aerosol the dosage unit may be determined
by providing a valve to deliver a metered amount. Capsules and
cartridges of e.g. gelatin for use in an inhaler or insufflator may
be formulated containing a powder mix of the compound and a
suitable powder base such as lactose or starch.
[0304] The compounds can be formulated for parenteral
administration by injection, e.g. bolus injection or continuous
infusion. Formulations for injection may be presented in unit
dosage form, e.g. in ampoules or in multi-dose containers, with an
added preservative. The compositions may take such forms as
suspensions, solutions or emulsions in oily or aqueous vehicles,
and may contain formulatory agents such as suspending, stabilizing
and/or dispersing agents.
[0305] Pharmaceutical formulations for parenteral administration
include aqueous solutions of the active compounds in water-soluble
form. Additionally, suspensions of the active compounds may be
prepared as appropriate oily injection suspensions. Suitable
lipophilic solvents or vehicles include fatty oils such as sesame
oil, or synthetic fatty acid esters, such as ethyl oleate or
triglycerides, or liposomes. Aqueous injection suspensions may
contain substances which increase the viscosity of the suspension,
such as sodium carboxymethyl cellulose, sorbitol, or dextran.
Optionally, the suspension may also contain suitable stabilizers or
agents which increase the solubility of the compounds to allow for
the preparation of highly concentrated solutions.
[0306] Alternatively, the active ingredient may be in powder form
for constitution with a suitable vehicle, e.g., sterile
pyrogen-free water, before use.
[0307] The compounds may also be formulated in rectal compositions
such as suppositories or retention enemas, e.g., containing
conventional suppository bases such as cocoa butter or other
glycerides.
[0308] In addition to the formulations described previously, the
compounds may also be formulated as a depot preparation. Such long
acting formulations may be administered by implantation (for
example subcutaneously or intramuscularly or by intramuscular
injection). Thus, for example, the compounds may be formulated with
suitable polymeric or hydrophobic materials (for example as an
emulsion in an acceptable oil) or ion exchange resins, or as
sparingly soluble derivatives, for example, as a sparingly soluble
salt.
[0309] An example of a pharmaceutical carrier for the hydrophobic
compounds of the invention is a cosolvent system comprising benzyl
alcohol, a nonpolar surfactant, a water-miscible organic polymer,
and an aqueous phase. The cosolvent system may be the VPD
co-solvent system. VPD is a solution of 3% w/v benzyl alcohol, 8%
w/v of the nonpolar surfactant polysorbate 80, and 65% w/v
polyethylene glycol 300, made up to volume in absolute ethanol. The
VPD co-solvent system (VPD:5W) consists of VPD diluted 1:1 with a
5% dextrose in water solution. This co-solvent system dissolves
hydrophobic compounds well, and itself produces low toxicity upon
systemic administration. Naturally, the proportions of a co-solvent
system may be varied considerably without destroying its solubility
and toxicity characteristics. Furthermore, the identity of the
co-solvent components may be varied: for example, other
low-toxicity nonpolar surfactants may be used instead of
polysorbate 80; the fraction size of polyethylene glycol may be
varied; other biocompatible polymers may replace polyethylene
glycol, e.g. polyvinyl pyrrolidone; and other sugars or
polysaccharides may substitute for dextrose.
[0310] Alternatively, other delivery systems for hydrophobic
pharmaceutical compounds may be employed. Liposomes and emulsions
are well known examples of delivery vehicles or carriers for
hydrophobic drugs. Certain organic solvents such as
dimethysulfoxide also may be employed, although usually at the cost
of greater toxicity. Additionally, the compounds may be delivered
using a sustained-release system, such as semipermeable matrices of
solid hydrophobic polymers containing the therapeutic agent.
Various sustained-release materials have been established and are
well known by those skilled in the art. Sustained-release capsules
may, depending on their chemical nature, release the compounds for
a few weeks up to over 100 days. Depending on the chemical nature
and the biological stability of the therapeutic reagent, additional
strategies for protein stabilization may be employed.
[0311] The pharmaceutical compositions also may comprise suitable
solid or gel phase carriers or excipients. Examples of such
carriers or excipients include but are not limited to calcium
carbonate, calcium phosphate, various sugars, starches, cellulose
derivatives, gelatin, and polymers such as polyethylene
glycols.
[0312] Many of the compounds of the invention may be provided as
salts with pharmaceutically compatible counterions.
Pharmaceutically compatible salts may be formed with many acids,
including but not limited to hydrochloric, sulfuric, acetic,
lactic, tartaric, malic, succinic, etc. Salts tend to be more
soluble in aqueous or other protonic solvents than are the
corresponding free base forms.
[0313] Effective Dosage
[0314] Pharmaceutical compositions suitable for use in the present
invention include compositions wherein the active ingredients are
contained in an effective amount to achieve its intended purpose.
More specifically, a therapeutically effective amount means an
amount effective to prevent development of or to alleviate the
existing symptoms of the subject being treated. Determination of
the effective amounts is well within the capability of those
skilled in the art.
[0315] For any compound used in the method of the invention, the
therapeutically effective dose can be estimated initially from
cellular assays. For example, a dose can be formulated in cellular
and animal models to achieve a circulating concentration range that
includes the IC.sub.50 as determined in cellular assays (i.e., the
concentration of the test compound which achieves a half-maximal
inhibition of a given protein kinase activity). In some cases it is
appropriate to determine the IC.sub.50 in the presence of 3 to 5%
serum albumin since such a determination approximates the binding
effects of plasma protein on the compound. Such information can be
used to more accurately determine useful doses in humans. Further,
the most preferred compounds for systemic administration
effectively inhibit protein kinase signaling in intact cells at
levels that are safely achievable in plasma.
[0316] A therapeutically effective dose refers to that amount of
the compound that results in amelioration of symptoms in a patient.
Toxicity and therapeutic efficacy of such compounds can be
determined by standard pharmaceutical procedures in cell cultures
or experimental animals, e.g., for determining the maximum
tolerated dose (MTD) and the ED.sub.50 (effective dose for 50%
maximal response). The dose ratio between toxic and therapeutic
effects is the therapeutic index and it can be expressed as the
ratio between MTD and ED.sub.50. Compounds which exhibit high
therapeutic indices are preferred. The data obtained from these
cell culture assays and animal studies can be used in formulating a
range of dosage for use in humans. The dosage of such compounds
lies preferably within a range of circulating concentrations that
include the ED.sub.50 with little or no toxicity. The dosage may
vary within this range depending upon the dosage form employed and
the route of administration utilized. The exact formulation, route
of administration and dosage can be chosen by the individual
physician in view of the patient's condition. (See e.g. Fingl et
al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1
p1). In the treatment of crises, the administration of an acute
bolus or an infusion approaching the MTD may be required to obtain
a rapid response.
[0317] Dosage amount and interval may be adjusted individually to
provide plasma levels of the active moiety which are sufficient to
maintain the kinase modulating effects, or minimal effective
concentration (MEC). The MEC will vary for each compound but can be
estimated from in vitro data; e.g. the concentration necessary to
achieve 50-90% inhibition of protein kinase using the assays
described herein. Dosages necessary to achieve the MEC will depend
on individual characteristics and route of administration. However,
HPLC assays or bioassays can be used to determine plasma
concentrations.
[0318] Dosage intervals can also be determined using the MEC value.
Compounds should be administered using a regimen which maintains
plasma levels above the MEC for 10-90% of the time, preferably
between 30-90% and most preferably between 50-90% until the desired
amelioration of symptoms is achieved. In cases of local
administration or selective uptake, the effective local
concentration of the drug may not be related to plasma
concentration.
[0319] The amount of composition administered will, of course, be
dependent on the subject being treated, on the subject's weight,
the severity of the affliction, the manner of administration and
the judgment of the prescribing physician.
[0320] Packaging
[0321] The compositions may, if desired, be presented in a pack or
dispenser device which may contain one or more unit dosage forms
containing the active ingredient. The pack may for example comprise
metal or plastic foil, such as a blister pack. The pack or
dispenser device may be accompanied by instructions for
administration. Compositions comprising a compound of the invention
formulated in a compatible pharmaceutical carrier may also be
prepared, placed in an appropriate container, and labeled for
treatment of an indicated condition.
[0322] In some formulations it may be beneficial to use the
compounds of the present invention in the form of particles of very
small size, for example as obtained by fluid energy milling.
[0323] The use of compounds of the present invention in the
manufacture of pharmaceutical compositions is illustrated by the
following description. In this description the term "active
compound" denotes any compound of the invention but particularly
any compound which is the final product of one of the preceding
Examples.
[0324] a) Capsules
[0325] In the preparation of capsules, 10 parts by weight of active
compound and 240 parts by weight of lactose can be de-aggregated
and blended. The mixture can be filled into hard gelatin capsules,
each capsule containing a unit dose or part of a unit dose of
active compound.
[0326] b) Tablets
[0327] Tablets can be prepared from the following ingredients.
[0328] Parts by weight
[0329] Active compound 10
[0330] Lactose 190
1 Maize starch 22 Polyvinylpyrrolidone 10 Magnesium stearate 3
[0331] The active compound, the lactose and some of the starch can
be de-aggregated, blended and the resulting mixture can be
granulated with a solution of the polyvinyl-pyrrolidone in ethanol.
The dry granulate can be blended with the magnesium stearate and
the rest of the starch. The mixture is then compressed in a
tabletting machine to give tablets each containing a unit dose or a
part of a unit dose of active compound.
[0332] c) Enteric coated tablets
[0333] Tablets can be prepared by the method described in (b)
above. The tablets can be enteric coated in a conventional manner
using a solution of 20% cellulose acetate phthalate and 3% diethyl
phthalate in ethanol:dichloromethane (1:1).
[0334] d) Suppositories
[0335] In the preparation of suppositories, 100 parts by weight of
active compound can be incorporated in 1300 parts by weight of
triglyceride suppository base and the mixture formed into
suppositories each containing a therapeutically effective amount of
active ingredient.
[0336] In the compositions of the present invention the active
compound may, if desired, be associated with other compatible
pharmacologically active ingredients. For example, the compounds of
this invention can be administered in combination with one or more
additional pharmaceutical agents that inhibit or prevent the
production of VEGF or angiopoietins, attenuate intracellular
responses to VEGF or angiopoietins, block intracellular signal
transduction, inhibit vascular hyperpermeability, reduce
inflammation, or inhibit or prevent the formation of edema or
neovascularization. The compounds of the invention can be
administered prior to, subsequent to or simultaneously with the
additional pharmaceutical agent, whichever course of administration
is appropriate. The additional pharmaceutical agents include but
are not limited to anti-edemic steroids, NSAIDS, ras inhibitors,
anti-TNF agents, anti-IL1 agents, antihistamines, PAF-antagonists,
COX-1 inhibitors, COX-2 inhibitors, NO synthase inhibitors, Akt/PTB
inhibitors, IGF-1R inhibitors, PKC inhibitors and PI3 kinase
inhibitors. The compounds of the invention and the additional
pharmaceutical agents act either additively or synergistically.
Thus, the administration of such a combination of substances that
inhibit angiogenesis, vascular hyperpermeability and/or inhibit the
formation of edema can provide greater relief from the deletrious
effects of a hyperproliferative disorder, angiogenesis, vascular
hyperpermeability or edema than the administration of either
substance alone. In the treatment of malignant disorders
combinations with antiproliferative or cytotoxic chemotherapies or
radiation are anticipated.
[0337] The present invention also comprises the use of a compound
of formula (I) as a medicament.
[0338] A further aspect of the present invention provides the use
of a compound of formula (I) or a salt thereof in the manufacture
of a medicament for treating vascular hyperpermeability,
angiogenesis-dependent disorders, proliferative diseases and/or
disorders of the immune system in mammals, particularly human
beings.
[0339] The present invention also provides a method of treating
vascular hyperpermeability, inappropriate neovascularization,
proliferative diseases and/or disorders of the immune system which
comprises the administration of a therapeutically effective amount
of a compound of formula (I) to a mammal, particularly a human
being, in need thereof.
[0340] The in vitro potency of compounds in inhibiting these
protein kinases may be determined by the procedures detailed
below.
[0341] The potency of compounds can be determined by the amount of
inhibition of the phosphorylation of an exogenous substrate (e.g.,
synthetic peptide (Z. Songyang et al., Nature. 373:536-539) by a
test compound relative to control.
[0342] KDR Tyrosine Kinase Production Using Baculovirus System:
[0343] The coding sequence for the human KDR intra-cellular domain
(aa789-1354) was generated through PCR using cDNAs isolated from
HUVEC cells. A poly-His6 sequence was introduced at the N-terminus
of this protein as well. This fragment was cloned into transfection
vector pVL1393 at the Xba 1 and Not 1 site. Recombinant baculovirus
(BV) was generated through co-transfection using the BaculoGold
Transfection reagent (PharMingen). Recombinant BV was plaque
purified and verified through Western analysis. For protein
production, SF-9 cells were grown in SF-900-II medium at
2.times.106/ml, and were infected at 0.5 plaque forming units per
cell (MOI). Cells were harvested at 48 hours post infection.
[0344] Purification of KDR
[0345] SF-9 cells expressing (His).sub.6KDR(aa789-1354) were lysed
by adding 50 ml of Triton X-100 lysis buffer (20 mM Tris, pH 8.0,
137 mM NaCl, 10% glycerol, 1% Triton X-100, 1 nmM PMSF, 10
.mu.g/rnl aprotinin, 1 .mu.g/ml leupeptin) to the cell pellet from
1L of cell culture. The lysate was centrifuged at 19,000 rpm in a
Sorval SS-34 rotor for 30 min at 4E C. The cell lysate was applied
to a 5 ml NiCl.sub.2 chelating sepharose column, equilibrated with
50 mM HEPES, pH7.5, 0.3 M NaCl. KDR was eluted using the same
buffer containing 0.25 M imidazole. Column fractions were analyzed
using SDS-PAGE and an ELISA assay (below) which measures kinase
activity. The purified KDR was exchanged into 25 mM HEPES, pH7.5,
25 mM NaCl, 5 mM DTT buffer and stored at -80E C.
[0346] Human Tie-2 Kinase Production and Purification
[0347] The coding sequence for the human Tie-2 intra-cellular
domain (aa775-1124) was generated through PCR using cDNAs isolated
from human placenta as a template. A poly-His.sub.6 sequence was
introduced at the N-terminus and this construct was cloned into
transfection vector pVL 1939 at the Xba 1 and Not 1 site.
Recombinant BV was generated through co-transfection using the
BaculoGold Transfection reagent (PharMingen). Recombinant BV was
plaque purified and verified through Western analysis. For protein
production, SF-9 insect cells were grown in SF-900-II medium at
2.times.106/ml, and were infected at MOI of 0.5. Purification of
the His-tagged kinase used in screening was analogous to that
described for KDR.
[0348] Human Flt-i Tyrosine Kinase Production and Purification
[0349] The baculoviral expression vector pVL1393 (Phar Mingen, Los
Angeles, Calif.) was used. A nucleotide sequence encoding poly-His6
was placed 5' to the nucleotide region encoding the entire
intracellular kinase domain of human Flt-1 (amino acids 786-1338).
The nucleotide sequence encoding the kinase domain was generated
through PCR using cDNA libraries isolated from HUVEC cells. The
histidine residues enabled affinity purification of the protein as
a manner analogous to that for KDR and ZAP70. SF-9 insect cells
were infected at a 0.5 multiplicity and harvested 48 hours post
infection.
[0350] EGFR Tyrosine Kinase Source
[0351] EGFR was purchased from Sigma (Cat #E-3641; 500 units/50
.mu.l) and the EGF ligand was acquired from Oncogene Research
Products/Calbiochem (Cat #PF011-100).
[0352] Expression of ZAP70
[0353] The baculoviral expression vector used was pVL1393.
(Pharmingen, Los Angeles, Calif.) The nucleotide sequence encoding
amino acids M(H)6 LVPR.sub.9S was placed 5' to the region encoding
the entirety of ZAP70 (amino acids 1-619). The nucleotide sequence
encoding the ZAP70 coding region was generated through PCR using
cDNA libraries isolated from Jurkat immortalized T-cells. The
histidine residues enabled affinity purification of the protein
(vide infra). The LVPR.sub.9S bridge constitutes a recognition
sequence for proteolytic cleavage by thrombin, enabling removal of
the affinity tag from the enzyme. SF-9 insect cells were infected
at a multiplicity of infection of 0.5 and harvested 48 hours post
infection.
[0354] Extraction and purification of ZAP70
[0355] SF-9 cells were lysed in a buffer consisting of 20 mM Tris,
pH 8.0, 137 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM PMSF, 1
.mu.g/ml leupeptin, 10 jg/ml aprotinin and 1 mM sodium
orthovanadate. The soluble lysate was applied to a chelating
sepharose HiTrap column (Pharmacia) equilibrated in 50 mM HEPES, pH
7.5, 0.3 M NaCl. Fusion protein was eluted with 250 mM imidazole.
The enzyme was stored in buffer containing 50 mM HEPES, pH 7.5, 50
mM NaCl and 5 mM DTT.
[0356] Protein kinase source
[0357] Lck, Fyn, Src, Blk, Csk, and Lyn, and truncated forms
thereof may be commercially obtained ( e.g. from Upstate
Biotechnology Inc. (Saranac Lake, N.Y.) and Santa Cruz
Biotechnology Inc. (Santa Cruz, Calif.)) or purified from known
natural or recombinant sources using conventional methods.
[0358] Enzyme Linked Immunosorbent Assay (ELISA) For PTKs
[0359] Enzyme linked immunosorbent assays (ELISA) were used to
detect and measure the presence of tyrosine kinase activity. The
ELISA were conducted according to known protocols which are
described in, for example, Voller, et al., 1980, "Enzyme-Linked
immunosorbent Assay," In: Manual of Clinical Immunology, 2d ed.,
edited by Rose and Friedman, pp 359-371 Am. Soc. of Microbiology,
Washington, D.C.
[0360] The disclosed protocol was adapted for determining activity
with respect to a specific PTK. For example, preferred protocols
for conducting the ELISA experiments is provided below. Adaptation
of these protocols for determining a compound's activity for other
members of the receptor PTK family, as well as non-receptor
tyrosine kinases, are well within the abilities of those in the
art. For purposes of determining inhibitor selectivity, a universal
PTK substrate (e.g., random copolymer of poly(Glu.sub.4 Tyr),
20,000-50,000 MW) was employed together with ATP (typically 5
.mu.M) at concentrations approximately twice the apparent Km in the
assay.
[0361] The following procedure was used to assay the inhibitory
effect of compounds of this invention on KDR, Flt-1, Flt-4, Tie-1,
Tie-2, EGFR, FGFR, PDGFR, IGF-1-R, c-Met, Lck, hck, Blk, Csk, Src,
Lyn, fgr, Fyn and ZAP70 tyrosine kinase activity:
[0362] Buffers and Solutions:
[0363] PGTPoly (Glu,Tyr) 4:1
[0364] Store powder at -20.degree. C. Dissolve powder in phosphate
buffered saline (PBS) for 50 mg/ml solution.
[0365] Store 1 ml aliquots at -20.degree. C. When making plates
dilute to 250 .mu.g/ml in Gibco PBS.
[0366] Reaction Buffer: 100 mM Hepes, 20 mM MgCl.sub.2, 4 mM
MnCl.sub.2, 5 mM DTT, 0.02% BSA, 200 .mu.M
[0367] NaVO.sub.4, pH 7.10
[0368] ATP: Store aliquots of 100 mM at -20.degree. C. Dilute to 20
.mu.M in water
[0369] Washing Buffer: PBS with 0.1% Tween 20
[0370] Antibody Diluting Buffer: 0.1% bovine serum albumin (BSA) in
PBS
[0371] TMB Substrate: mix TMB substrate and Peroxide solutions 9:1
just before use or use K-Blue
[0372] Substrate from Neogen
[0373] Stop Solution: 1M Phosphoric Acid
[0374] Procedure
[0375] 1. Plate Preparation:
[0376] Dilute PGT stock (50 mg/ml, frozen) in PBS to a 250
.mu.g/ml. Add 125 .mu.l per well of Corning modified flat bottom
high affinity ELISA plates (Corning #25805-96). Add 125,.mu.l PBS
to blank wells. Cover with sealing tape and incubate overnight
37.degree. C. Wash 1.times. with 250 .mu.l washing buffer and dry
for about 2 hrs in 37.degree. C. dry incubator.
[0377] Store coated plates in sealed bag at 4.degree. C. until
used.
[0378] 2. Tyrosine Kinase Reaction:
[0379] Prepare inhibitor solutions at a 4.times. concentration in
20% DMSO in water.
[0380] Prepare reaction buffer
[0381] Prepare enzyme solution so that desired units are in 50
.mu.l, e.g. for KDR make to 1 ng/.mu.l for a total of 50 ng per
well in the reactions. Store on ice.
[0382] Make 4.times. ATP solution to 20 .mu.M from 100 mM stock in
water. Store on ice.
[0383] Add 50 .mu.l of the enzyme solution per well (typically 5-50
ng enzyme/well depending on the specific activity of the
kinase)
[0384] Add 25 .mu.l 4.times. inhibitor
[0385] Add 25 .mu.l 4.times. ATP for inhibitor assay
[0386] Incubate for 10 minutes at room temperature
[0387] Stop reaction by adding 50,.mu.l 0.05N HCl per well
[0388] Wash plate
[0389] Final Concentrations for Reaction: 5 .mu.M ATP, 5% DMSO
[0390] 3. Antibody Binding
[0391] Dilute 1 mg/ml aliquot of PY20-HRP (Pierce) antibody (a
phosphotyrosine antibody) to 50 ng/ml in 0.1% BSA in PBS by a 2
step dilution (100.times., then 200.times.)
[0392] Add 100 .mu.l Ab per well. Incubate 1 hr at room temp.
Incubate 1 hr at 4C.
[0393] Wash 4.times. plate
[0394] 4. Color reaction
[0395] Prepare TMB substrate and add 100 .mu.l per well
[0396] Monitor OD at 650 nm until 0.6 is reached
[0397] Stop with 1M Phosphoric acid. Shake on plate reader.
[0398] Read OD immediately at 450 nm
[0399] Optimal incubation times and enzyme reaction conditions vary
slightly with enzyme preparations and are determined empirically
for each lot.
[0400] For Lck, the Reaction Buffer utilized was 100 mM MOPSO, pH
6.5, 4 MM MnCl.sub.2, 20 mM MgCl.sub.2, 5 mM DTT, 0.2% BSA, 200 mM
NaVO.sub.4 under the analogous assay conditions.
[0401] Compounds of formula (I) may have therapeutic utility in the
treatment of diseases involving both identified, including those
not mentioned herein, and as yet unidentified protein tyrosine
kinases which are inhibited by compounds of formula (I).
[0402] Cdc2 Source
[0403] The human recombinant enzyme and assay buffer may be
obtained commercially (New England Biolabs, Beverly, Mass. USA) or
purified from known natural or recombinant sources using
conventional methods.
[0404] Cdc2 Assay
[0405] A protocol that can be used is that provided with the
purchased reagents with minor modifications. In brief, the reaction
is carried out in a buffer consisting of 5 mM Tris pH 7.5, 100 mM
NaCl, 1 mM EGTA, 2mM DTT, 0.01% Brij, 5% DMSO and 10 mM MgCl.sub.2
(commercial buffer) supplemented with fresh 300 .mu.M ATP (31
.mu.Ci/ml) and 30 jg/ml histone type IIIss final concentrations. A
reaction volume of 80 .mu.L, containing units of enzyme, is run for
20 minutes at 25 degrees C. in the presence or absence of
inhibitor. The reaction is terminated by the addition of 120 .mu.L
of 10% acetic acid. The substrate is separated from unincorporated
label by spotting the mixture on phosphocellulose paper, followed
by 3 washes of 5 minutes each with 75 mM phosphoric acid. Counts
are measured by a betacounter in the presence of liquid
scintillant.
[0406] PKC Kinase Source
[0407] The catalytic subunit of PKC may be obtained commercially
(Calbiochem).
[0408] PKC Kinase Assay
[0409] A radioactive kinase assay is employed following a published
procedure (Yasuda, I., Kirshimoto, A., Tanaka, S., Tominaga, M.,
Sakurai, A., Nishizuka, Y. Biochemical and Biophysical Research
Communication 3:166, 1220-1227 (1990)). Briefly, all reactions are
performed in a kinase buffer consisting of 50 mM Tris-HCl pH7.5, 10
mM MgCl.sub.2, 2 mM DTT, 1 mM EGTA, 100 .mu.M ATP, 8 .mu.M peptide,
5% DMSO and .sup.33P ATP (8 Ci/mM). Compound and enzyme are mixed
in the reaction vessel and the reaction is initiated by addition of
the ATP and substrate mixture. Following termination of the
reaction by the addition of 10 .mu.L stop buffer (5 mM ATP in 75 mM
phosphoric acid), a portion of the mixture is spotted on
phosphocellulose filters. The spotted samples are washed 3 times in
75 mM phosphoric acid at room temperature for 5 to 15 minutes.
Incorporation of radiolabel is quantified by liquid scintillation
counting.
[0410] Erk2 Enzyme Source
[0411] The recombinant murine enzyme and assay buffer may be
obtained commercially (New England Biolabs, Beverly Mass. USA) or
purified from known natural or recombinant sources using
conventional methods.
[0412] Erk2 Enzyme Assay
[0413] In brief, the reaction is carried out in a buffer consisting
of 50 mM Tris pH 7.5, 1 mM EGTA, 2 mM DTT, 0.01% Brij, 5% DMSO and
10 mM MgCl.sub.2 (commercial buffer) supplemented with fresh 100
.mu.M ATP (31 .mu.Ci/ml) and 30 .mu.M myelin basic protein under
conditions recommended by the supplier. Reaction volumes and method
of assaying incorporated radioactivity are as described for the PKC
assay (vide supra).
[0414] In Vitro Models for T-cell Activation
[0415] Upon activation by mitogen or antigen, T-cells are induced
to secrete IL-2, a growth factor that supports their subsequent
proliferative phase. Therefore, one may measure either production
of IL-2 from or cell proliferation of, primary T-cells or
appropriate T-cell lines as a surrogate for T-cell activation. Both
of these assays are well described in the literature and their
parameters well documented (in Current Protocols in Immunology, Vol
2, 7.10.1-7.11.2).
[0416] In brief, T-cells may be activated by co-culture with
allogenic stimulator cells, a process termed the one-way mixed
lymphophocyte reaction. Responder and stimulator peripheral blood
mononuclear cells are purified by Ficoll-Hypaque gradient
(Pharmacia) per directions of the manufacturer. Stimulator cells
are mitotically inactivated by treatment with mitomycin C (Sigma)
or gamma irradiation. Responder and stimulator cells are
co-cultured at a ratio of two to one in the presence or absence of
the test compound. Typically 10.sup.5 responders are mixed with
5.times.10.sup.4 stimulators and plated (200 .mu.l volume) in a U
bottom microtiter plate (Costar Scientific). The cells are cultured
in RPMI 1640 supplemented with either heat inactivated fetal bovine
serum (Hyclone Laboratories) or pooled human AB serum from male
donors, 5.times.10.sup.-5 M 2mercaptoethanol and 0.5% DMSO, The
cultures are pulsed with 0.5 .mu.Ci of .sup.3H thymidine (Amersham)
one day prior to harvest (typically day three). The cultures are
harvested (Betaplate harvester, Wallac) and isotope uptake assessed
by liquid scintillation (Betaplate, Wallac).
[0417] The same culture system may be used for assessing T-cell
activation by measurement of IL-2 production. Eighteen to
twenty-four hours after culture initiation, the supernatants are
removed and the IL-2 concentration is measured by ELISA (R and D
Systems) following the directions of the manufacturer.
[0418] In-vivo Models of T-Cell Activation
[0419] The in vivo efficacy of compounds can be tested in animal
models known to directly measure T-cell activation or for which
T-cells have been proven the effectors. T-cells can be activated in
vivo by ligation of the constant portion of the T-cell receptor
with a monoclonal anti-CD3 antibody (Ab). In this model, BALB/c
mice are given 10 .mu.g of anti-CD3 Ab intraperitoneally two hours
prior to exsanguination. Animals to receive a test drug are
pre-treated with a single dose of the compound one hour prior to
anti-CD3 Ab administration. Serum levels of the proinflammatory
cytokines interferon-.gamma. (IFN-.gamma.) and tumor necrosis
factor-.alpha.(TNF-.alpha.), indicators of T-cell activation, are
measured by ELISA. A similar model employs in vivo T-cell priming
with a specific antigen such as keyhole limpet hemocyanin (KLH)
followed by a secondary in vitro challenge of draining lymph node
cells with the same antigen. As previously, measurement of cytokine
production is used to assess the activation state of the cultured
cells. Briefly, C57BL/6 mice are immunized subcutaneously with 100
.mu.g KLH emulsified in complete Freund's adjuvant (CFA) on day
zero. Animals are pre-treated with the compound one day prior to
immunization and subsequently on days one, two and three post
immunization. Draining lymph nodes are harvested on day 4 and their
cells cultured at 6.times.10.sup.6 per ml in tissue culture medium
(RPMI 1640 supplemented with heat inactivated fetal bovine serum
(Hyclone Laboratories) 5.times.10.sup.-5 M 2-mercaptoethanol and
0.5% DMSO) for both twenty-four and forty-eight hours. Culture
supematants are then assessed for the autocrine T-cell growth
factor Interleukin-2 (IL-2) and/or IFN-.gamma. levels by ELISA.
[0420] Lead compounds can also be tested in animal models of human
disease. These are exemplified by experimental auto-immune
encephalomyelitis (EAE) and collagen-induced arthritis (CIA). EAE
models which mimic aspects of human multiple sclerosis have been
described in both rats and mice (reviewed FASEB J. 5:2560-2566,
1991; murine model: Lab. Invest. 4(3):278, 1981; rodent model:J.
Immunol 146(4): 1163-8, 1991 ). Briefly, mice or rats are immunized
with an emulsion of myelin basic protein (MBP), or neurogenic
peptide derivatives thereof, and CFA. Acute disease can be induced
with the addition of bacterial toxins such as bordetella pertussis.
Relapsing/remitting disease is induced by adoptive transfer of
T-cells from MBP/peptide immunized animals.
[0421] CIA may be induced in DBA/1 mice by immunization with type
II collagen (J. Immunol: 142(7):2237-2243). Mice will develop signs
of arthritis as early as ten days following antigen challenge and
may be scored for as long as ninety days after immunization. In
both the EAE and CIA models, a compound may be administered either
prophylactically or at the time of disease onset. Efficacious drugs
should reduce severity and/or incidence.
[0422] Certain compounds of this invention which inhibit one or
more angiogenic receptor PTK, and/or a protein kinase such as lck
involved in mediating inflammatory responses can reduce the
severity and incidence of arthritis in these models.
[0423] Compounds can also be tested in mouse allograft models,
either skin (reviewed in Ann. Rev. Immunol., 10:333-58, 1992;
Transplantation: 57(12): 1701-17D6, 1994) or heart (Am. J. Anat.:
113:273, 1963). Briefly, full thickness skin grafts are
transplanted from C57BL/6 mice to BALB/c mice. The grafts can be
examined daily, beginning at day six, for evidence of rejection. In
the mouse neonatal heart transplant model, neonatal hearts are
ectopically transplanted from C57BL/6 mice into the ear pinnae of
adult CBA/J mice. Hearts start to beat four to seven days post
transplantation and rejection may be assessed visually using a
dissecting microscope to look for cessation of beating.
[0424] Cellular Receptor PTK Assays
[0425] The following cellular assay was used to determine the level
of activity and effect of the different compounds of the present
invention on KDR/VEGFR2. Similar receptor PTK assays employing a
specific ligand stimulus can be designed along the same lines for
other tyrosine kinases using techniques well known in the art.
[0426] VEGF-Induced KDR Phosphorylation in Human Umbilical Vein
Endothelial Cells (HUVEC) as Measured by Western Blots:
[0427] 1. HUVEC cells (from pooled donors) can be purchased from
Clonetics (San Diego, Calif.) and cultured according to the
manufacturer directions. Only early passages (3-8) are used for
this assay. Cells are cultured in 100 mm dishes (Falcon for tissue
culture; Becton Dickinson; Plymouth, England) using complete EBM
media (Clonetics).
[0428] 2. For evaluating a compound's inhibitory activity, cells
are trypsinized and seeded at 0.5-1.0.times.10.sup.5 cells/well in
each well of 6-well cluster plates (Costar; Cambridge, Mass.).
[0429] 3. 3-4 days after seeding, plates are typically 90-100%
confluent. Medium is removed from all the wells, cells are rinsed
with 5-10 ml of PBS and incubated 18-24h with 5 ml of EBM base
media with no supplements added (i.e., serum starvation).
[0430] 4. Serial dilutions of inhibitors are added in 1 ml of EBM
media (25 .mu.M, 5 .mu.M, or 1 .mu.M final concentration to cells
and incubated for one hour at 37 C. Human recombinant VEGF.sub.165
(R & D Systems) is then added to all the wells in 2 ml of EBM
medium at a final concentration of 50 ng/ml and incubated at 37 C.
for 10 minutes. Control cells untreated or treated with VEGF only
are used to assess background phosphorylation and phosphorylation
induction by VEGF.
[0431] All wells are then rinsed with 5-10 ml of cold PBS
containing 1 mM Sodium Orthovanadate (Sigma) and cells are lysed
and scraped in 200 .mu.l of RIPA buffer (50 mM Tris-HCl) pH7, 150
mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1 mM EDTA) containing
protease inhibitors (PMSF 1 mM, aprotinin 1 .mu.g/ml, pepstatin 1
.mu.g/ml, leupeptin 1 .mu.g/ml, Na vanadate 1 mM, Na fluoride 1 mM)
and 1 .mu.g/ml of Dnase (all chemicals from Sigma Chemical Company,
St Louis, Mo.). The lysate is spun at 14,000 rpm for 30 min, to
eliminate nuclei.
[0432] Equal amounts of proteins are then precipitated by addition
of cold (-20 C.) Ethanol (2 volumes) for a minimum of 1 hour or a
maximum of overnight. Pellets are reconstituted in Laemli sample
buffer containing 5%-mercaptoethanol (BioRad; Hercules, Calif.) and
boiled for 5 min. The proteins are resolved by polyacrylamide gel
electrophoresis (6%, 1.5mm Novex, San Deigo, Calif.) and
transferred onto a nitrocellulose membrane using the Novex system.
After blocking with bovine serum albumin (3%), the proteins are
probed overnight with anti-KDR polyclonal antibody (C20, Santa Cruz
Biotechnology; Santa Cruz, Calif.) or with anti-phosphotyrosine
monoclonal antibody (4G10, Upstate Biotechnology, Lake Placid,
N.Y.) at 4 C. After washing and incubating for 1 hour with
HRP-conjugated F(ab).sub.2 of goat anti-rabbit or goat-anti-mouse
IgG the bands are visualized using the emission chemiluminescience
(ECL) system (Amersham Life Sciences, Arlington Height, Ill.).
[0433] In Vivo Uterine Edema Model
[0434] This assay measures the capacity of compounds to inhibit the
acute increase in uterine weight in mice which occurs in the first
few hours following estrogen stimulation. This early onset of
uterine weight increase is known to be due to edema caused by
increased permeability of uterine vasculature. Cullinan-Bove and
Koss (Endocrinology (1993), 133:829-837) demonstrated a close
temporal relationship of estrogen-stimulated uterine edema with
increased expression of VEGF mRNA in the uterus. These results have
been confirmed by the use of neutralizing monoclonal antibody to
VEGF which significantly reduced the acute increase in uterine
weight following estrogen stimulation (WO 97/42187). Hence, this
system can serve as a model for in vivo inhibition of VEGF
signalling and the associated hyperpermeability and edema.
[0435] Materials: All hormones can be purchased from Sigma (St.
Louis, Mo.) or Cal Biochem (La Jolla, Calif.) as lyophilized
powders and prepared according to supplier instructions. Vehicle
components (DMSO, Cremaphor EL) can be purchased from Sigma (St.
Louis, Mo.). Mice (Balb/c, 8-12 weeks old) can be purchased from
Taconic (Germantown, N.Y.) and housed in a pathogen-free animal
facility in accordance with institutional Animal Care and Use
Committee Guidelines.
[0436] Method:
2 Day 1: Balb/c mice are given an intraperitoneal (i.p.) injection
of 12.5 units of pregnant mare's serum gonadotropin (PMSG). Day 3:
Mice receive 15 units of human chorionic gonadotropin (hCG) i.p.
Day 4: Mice are randomized and divided into groups of 5-10. Test
compounds are administered by i.p., i.v. or p.o. routes depending
on solubility and vehicle at doses ranging from 1-100 mg/kg.
Vehicle control group receive vehicle only and two groups are left
untreated.
[0437] Thirty minutes later, experimental, vehicle and 1 of the
untreated groups are given an i.p. injection of 17-estradiol (500
.mu.g/kg). After 2-3 hours, the animals are sacrificed by CO.sub.2
inhalation. Following a midline incision, each uterus was isolated
and removed by cutting just below the cervix and at the junctions
of the uterus and oviducts. Fat and connective tissue were removed
with care not to disturb the integrity of the uterus prior to
weighing (wet weight). Uteri are blotted to remove fluid by
pressing between two sheets of filter paper with a one liter glass
bottle filled with water. Uteri are weighed following blotting
(blotted weight). The difference between wet and blotted weights is
taken as the fluid content of the uterus. Mean fluid content of
treated groups is compared to untreated or vehicle treated groups.
Significance is determined by Student's test. Non-stimulated
control group is used to monitor estradiol response.
[0438] Certain compounds of this invention which are inhibitors of
angiogenic receptor tyrosine kinases can also be shown active in a
Matrigel implant model of neovascularization. The Matrigel
neovascularization model involves the formation of new blood
vessels within a clear marble of extracellular matrix implanted
subcutaneously which is induced by the presence of proangiogenic
factor producing tumor cells (for examples see: Passaniti, A., et
al, Lab. Investig. (1992), 67(4), 519-528; Anat. Rec. (1997),
249(1), 63-73; Int. J. Cancer (1995), 63(5), 694-701; 15(11),
1857-6). The model preferably runs over 34days and endpoints
include macroscopic visual/image scoring of neovascularization,
microscopic microvessel density determinations, and hemoglobin
quantitation (Drabkin method) following removal of the implant
versus controls from animals untreated with inhibitors. The model
may alternatively employ bFGF or HGF as the stimulus.
[0439] The teachings of all references, including journal articles,
patents and published patent applications, are incorporated herein
by reference in their entirety.
[0440] The following examples are for illustrative purposes and are
not to be construed as limiting the scope of the present
invention.
[0441] Preparation 1
[0442] 4-Nitro-1H-5-pyrazolecarboxamide
[0443] A suspension of 4-nitro-1H-5-pyrazolocarboxylic acid (10.0
g, 64 mmol) in dichloromethane (150 mL) was treated with oxalyl
chloride (8.9 g, 71 mmol) and a few drops of N,N-dimethylformamide.
The mixture was stirred at ambient temperature for 18 hours. The
solvent was removed under reduced pressure then the residue was
dissolved in acetone (40 mL). The solution was cooled in an ice
bath then a solution of 30% aqueous ammonium hydroxide (60 mL) was
added slowly while maintaining the temperature of the mixture below
10.degree. C. The mixture was warmed to ambient temperature then
diluted with water (60 mL). The acetone was removed by evaporation
under reduced pressure and the resulting slurry was cooled in an
ice bath then the precipitate was collected by filtration and
washed with water. The material thus collected was dried under high
vacuum to yield the title compound (9 g, 90%) as a white solid:
.sup.1H NMR (DMSO-d.sub.6, 400 MHz) .delta.14.1 (bs, 1H), 8.70 (s,
1H), 8.05 (s, 1H), 7.82 (s, 1H); RP-HPLC (Hypersil HS C18, 5 .mu.m,
100A, 250.times.4.6 mm; 5%-100% acetonitrile-0.05 M ammonium
acetate over 25 min, 1 mL/min) t.sub.r 5.82 min;
MS:MH.sup.+157.1.
[0444] Preparation 2
[0445] 4-Nitro-1H-5-pyrazolecarbonitrile
[0446] A suspension of 4-nitro-1H-5-pyrazolocarboxamide (7.80 g, 50
mmol) in dichloromethane (300 mL) and pyridine (30 mL) was treated
with a solution of phosgene in toluene (20%, 50 mL). The mixture
was stirred for 16 hours at ambient temperature then water (20 mL)
was slowly added to the mixture, followed by 6 N aqueous
hydrochloric acid (50 mL) and brine (15 mL). The mixture was
extracted with dichloromethane (5.times.50 mL) and ethyl acetate
(3.times.50 mL). The organic solutions were combined and dried over
magnesium sulfate, filtered and the filtrate concentrated to a
volume of about 150 mL then it was extracted with 1N aqueous
hydrochloric acid (25 mL) and then brine (15 mL). The organic layer
was dried over magnesium sulfate then filtered and the filtrate
concentrated under reduced pressure to yield the title compound as
a tan solid (6.36 g, 92%): .sup.1H NMR (DMSO-d.sub.6, 400 MHz)
.delta.14.99 bs, 1H), 9.15 (s, 1H); RP-HPLC (Hypersil HS C18, 5
.mu.m, 100A, 250.times.4.6 mm; 5%-100% acetonitrile-0.05 M ammonium
acetate over 25 min, 1 mL/min) t.sub.r 12.05 min;
MS:MH.sup.+137.0.
[0447] Preparation 3
[0448] 1H-Pyrazolo[4,3-d]pyrimidin-7-amine
[0449] 4-Nitro-1H-5-pyrazolocarbonitrile (6.25 g, 45.3 mmol) in
ethanol (100 mL) was treated with 10% Palladium on carbon (0.50 g)
and hydrogenated in a Parr shaker at 50 psi for 18 hours. The
catalyst was removed by filtration through a pad of diatomaceous
earth. The filtrate was then treated with formamidine acetate (37.7
g, 0.363 mol) then the mixture was heated at reflux for one hour.
The mixture was cooled and then approximately 50 mL of the solvent
was removed under reduced pressure. The precipitate which formed
was isolated by filtration and washed with ethyl acetate
(3.times.25 mL) then discarded. The filtrate was concentrated under
reduced pressure to a volume of approximately 40 mL. The mixture
was heated to dissolve all of the material then applied to a silica
gel column which was eluted with ethyl acetate/methanol (8:2). The
appropriate fractions were concentrated to give the title compound
(3.85 g, 61%) which contained 18 % formamidine acetate by weight as
determined by .sup.1H NMR: .sup.1H NMR (DMSO-d.sub.6, 400 MHz)
.delta.13.3 bs, 1H), 8.15 (s, 1H) 8.07 (s, 1H), 7.47 (bs, 2H);
RP-HPLC (Hypersil HS C18, 5 .mu.m, 100A, 250.times.4.6 mm; 5%-100%
acetonitrile-0.05 M ammonium acetate over 25 min, 1 mL/min) t.sub.r
4.95 min; MS:MH.sup.+136.1, M-H.sup.+134.1.
[0450] Preparation 4
[0451] 3-Iodo-1H-pyrazolo[4,3-d]pyrimidin-7-amine
[0452] 1H-Pyrazolo[4,3-d]pyrimidin-7-amine (82% pure, 2.85 g, 17.3
mmol) in N,N-dimethylformamide (40 mL) was treated with
N-iodosuccinimide (3.8 g, 16.9 mmol). The mixture was heated in an
80.degree. C. oil bath for 1.5 hours then cooled and concentrated
under reduced pressure. Ethanol (20 mL) and water (10 mL) was added
to the residue then stirred and cooled in an ice bath. The
precipitate was collected by filtration and washed with water. The
filtrate was concentrated under reduced pressure then water (20 mL)
was added and the solid was again collected by filtration and
washed with water. The solids thus isolated were combined and dried
under high vacuum to give the desired title compound as a brown
powder: .sup.1H NMR (DMSO-d.sub.6, 400 MHz) .delta.13.2 (s, 1H),
8.21 (s, 1H), 7.39 (bs, 2H); RP-HPLC (Hypersil HS C18, 5 .mu.m,
100A, 250.times.4.6 mm; 5%-100% acetonitrile-0.05 M ammonium
acetate over 25 min, 1 mL/min) t.sub.r 8.58 min; MS:MH.sup.+262.0,
M-H.sup.+259.9.
[0453] Preparation 5
[0454] 4-Fluoro-2-methoxy-1 -nitrobenzene
[0455] A mixture of 5-fluoro-2-nitrophenol (3.0 g, 19.1 mmol),
potassium carbonate (2.50 g, 21.0 mmol) and dimethyl sulfate (2.65
g, 21.0 mmol) in acetone was stirred at ambient temperature for 24
hours. The solvents were removed under reduced pressure and then
water (30 mL) and dichloromethane (30 mL) was added to the residue.
The combined organics solutions were dried over magnesium sulfate
then filtered and the filtrate concentrated under reduced pressure
to provide an oil. This was purified by flash chromatography on
silica gel using dichloromethane/heptane (7:3) as an eluent to
provide the title compound as a crystalline solid (3.24 g, 100%):
.sup.1H NMR (CDCl.sub.3, 400 MHz) .delta.7.96 (M, 1H), 6.80 (m,
1H), 6.73 (m, 1H), 3.96 (s, 3H); RP-HPLC (Hypersil HS C18, 5 .mu.m,
100A, 250.times.4.6 mm; 5%-100% acetonitrile-0.05 M ammonium
acetate over 25 min, 1 mL/min) t.sub.r 17.82 min;
MS:MH.sup.+172.2.
[0456] Preparation 6
[0457] tert-Butyl
4{[(trifluoromethyl)sulfonyl]oxy}-1,2,3,6-tetrahydro-1-p-
yridinecarboxylate
[0458] The title compound was synthesized according to the method
disclosed in Wustrow, D. J., Wise, L. D., Synthesis, 1991, pg
993-995, which is incorporated herein by reference in its
entirety.
[0459] Preparation 7
[0460]
tert-Butyl4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-t-
etrahydro-1-pyridinecarboxylate
[0461] A mixture of tert-butyl
4{[(trifluoromethyl)sulfonyl]oxy}-1,2,3,6-t-
etrahydro-1-pyridinecarboxylate (1.8 g, 2.42 mmol), pinacol diboron
(1.4 g, 5.44 mmol), potassium acetate (1.6 g, 16.32 mmol) and
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex
with dichloromethane (0.27 g, 0.33 mmol) in N,N-dimethylformamide
(30 mL) was heated in an 85.degree. C. oil bath for 17 hours. The
solvent was evaporated under reduced pressure then the residue was
triturated with dichloromethane (30 mL). The mixture was filtered
through a bed of diatomaceous earth then the solvents were
evaporated under reduced pressure and the residue purified by flash
chromatography on silica gel with heptane/ethyl acetate (8:2) as an
eluent. The appropriate fractions were concentrated under reduced
pressure to provide the title compound as a crystalline solid (0.87
g, 52%); TLC R.sub.F 0.44, heptane/ethyl acetate (8:2), visualized
by PMA/heat, Silica Gel 60 F.sub.254 plates; .sup.1H NMR
(CDCl.sub.3, 400 MHz) .delta.6.46 (m, 1H), 3.94 (m, 2H), 3.43 (m,
2), 2.21 (m, 2H), 1.45 (s, 9H), 1.26 (s, 12H).
[0462] Preparation 8
[0463]
3-Iodo-1-(3-methoxy-4-nitrophenyl)-1H-pyrazolo[4,3-d]pyrimidin-7-am-
ine
[0464] A mixture of 3-iodo-1H-pyrazolo[4,3-d]pyrimidin-7-amine (500
mg, 1.92 mmol) and 4-fluoro-2-methoxy-1-nitrobenzene (360 mg, 2.11
mmol) in N,N-dimethylformamide (5 mL) was treated with 60% sodium
hydride in oil (92 mg, 2.30 mmol) then heated in an 85.degree. C.
oil bath for 17 hours. The solvent was removed by evaporation under
reduced pressure then the residue was dissolved in a minimum of hot
N,N-dimethylformamide and applied to a silica gel column and eluted
with ethyl acetate to provide the title compound (405 mg, 51%) as a
yellow solid after concentration of the appropriate fractions:
.sup.1H NMR (DMSO-d.sub.6, 400 MHz) .delta.8.38 (s, 1H), 8.10 (d,
1H), 7.47 (s, 1H), 7.30 (m, 1H), 7.15 (bs, 2H), 3.98 (s, 3H);
RP-HPLC (Hypersil HS C18, 5 .mu.m, 100A, 250.times.4.6 mm; 5%-100%
acetonitrile-0.05 M amrnonium acetate over 25 min, 1 mL/min)
t.sub.r 16.17 min; MS:MH.sup.+413.1, M-H.sup.+411.1.
[0465] Preparation 9
[0466] tert-Butyl4-17-amino-1
-(3-methoxy4-nitrophenyl)-1H-pyrazolo[4,3-d]-
pyrimidin-3-yl]-1,2,3,6-tetrahydro-1 -pyridinecarboxylate
[0467] A mixture of 3-iodo-1
-(3-methoxy4-nitrophenyl)-1H-pyrazolo[4,3-d]p- yrimidin-7-amine
(300 mg, 0.728 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1-
,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydro-1-pyridinecarboxylate
(270 mg, 0.874 mmol), sodium carbonate (185 mg, 1.75 mmol) and
tetrakis(triphenylphosphine)palladium(0) (50 mg, 0.044 mmol) in
1,2-dimethoxy ethane (6 mL) and water (3 mL) was heated in an
85.degree. C. oil bath for 1.75 hours. tert-Butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxa-
borolan-2-yl)-1,2,3,6-tetrahydro-1-pyridinecarboxylate (45 mg,
0.146 mmol) was added to the mixture and then it was heated in the
85.degree. C. oil bath for another 16 hours. The solvents were
evaporated under reduced pressure then the residue was partitioned
between water (10 mL) and ethyl acetate (15 mL). The layers were
separated and then the aqueous layer was extracted with ethyl
acetate (10 mL), dichloromethane (20 mL) and then a 10% solution of
methanol in dichloromethane (20 mL). The organic solutions thus
obtained were combined and evaporated to a residue which was
purified by flash chromatography on silica gel using ethyl acetate
as an eluent to provide the title compound as a yellow solid (205
mg, 60%):
[0468] .sup.1H NMR (DMSO-d.sub.6, 400 MHz) .delta.8.40 (s, 1H),
8.10 (d, 1H), 7.50 (m, 1H), 7.42 (s, 1H), 7.31 (d,1H), 7.1 (bs,
2H), 4.13 (m, 2H), 3.99 (s, 3H), 3.58 (m, 2H), 2.67 (m, 2H), 1.44
(s, 9H) RP-HPLC (Hypersil HS C18, 5 .mu.m. 100A, 250.times.4.6 mm;
5%-100% acetonitrile-0.05 M ammonium acetate over 25 min, 1 mL/min)
t.sub.r 21.42 min; MS:M-H.sup.+466.3.
[0469] Preparation 10
[0470] tert-Butyl
4-[7-amino-1-(4-amino-3-methoxyphenyl)-1H-pyrazolo[4,3-d-
]pyrimidin-3-yl]-1-piperidinecarboxylate
[0471] A mixture of tert-butyl
4-[7-amino-1-(3-methoxy-4-nitrophenyl)-1H-p-
yrazolo[4,3-d]pyrimidin-3-yl]-1,2,3,6-tetrahydro-1-pyridinecarboxylate
(200 mg, 0.428 mmol) and 10% palladium on carbon (100 mg) in
methanol (20 mL) and hydrogenated in a Parr shaker at 55 psi for 18
hours. The catalyst was removed by filtration through a pad of
diatomaceous earth and the filtrate concentrated under reduced
pressure then the residue was dissolved methanol (20 mL). Platinum
(IV) oxide (100 mg) was added and the mixture was hydrogenated in a
Parr shaker at 55 psi for 30 hours. The catalyst was removed by
filtration through a pad of diatomaceous earth and the filtrate
concentrated under reduced pressure to provide the title compound
as a brown solid (175 mg, 93%):.sup.1H NMR (DMSO-d.sub.6, 400 MHz)
.delta.8.22 (s, 1H), 6.96 (d, 1H), 6.84 (d, 1H), 6.74 (d,1H), 6.5
(bs, 2H), 5.75 (bs, 2H), 4.03 (m, 2H), 3.76 (s, 3H), 3.22 (m, 1H),
2.93 (m, 2H), 1.7-2.1 (m, 4H), 1.42 (s,9H) RP-HPLC (Hypersil HS
C18, 5 .mu.m, 100A, 250.times.4.6 mm; 5%-100% acetonitrile-0.05 M
ammonium acetate over 25 min, 1 mL/min) t.sub.r 16.93 min;
MS:MH.sup.+440.2.
EXAMPLE 1
[0472]
N2-{4-[7-Amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-1-yl]-2--
methoxyphenyl}-1-methyl-1H-2-indolecarboxamide
[0473] tert-Butyl
4-[7-amino-1-(4-amino-3-methoxyphenyl)-1H-pyrazolo[4,3-d-
]pyrimidin-3-yl]-1-piperidinecarboxylate (75 mg, 0.171 mmol) was
dissolved in dichloromethane (5 mL) and pyridine (0.5 mL) then the
mixture was cooled to 5.degree. C. in an ice bath. 1-Methylindole
carbonyl chloride (0.188 mmol) in dichloromethane (1 mL) was added
then the mixture was stirred for 10 minutes. The solvents were
removed by evaporation under reduced pressure then the residue was
dissolved in acetone (3 mL) and 6 N aqueous hydrochloric acid (6
mL). The mixture was heated in an 85.degree. C. oil bath for 1
hour. The solvents were removed under reduced pressure and the
material purified by preparative reverse phase chromatography.
Lyophilization afforded a white powder (65 mg) which was treated
with dichloromethane (25 mL) and 5 N aqueous sodium hydroxide (10
mL). The layers were separated and then the aqueous layer was
extracted with dichloromethane (2.times.10 ml). The organic
solutions were combined and dried over magnesium sulfate then
filtered. The filtrate was concentrated to give the title compound
(30 mg) as a white solid: .sup.1H NMR (DMSO-d.sub.6, 400 MHz)
.delta.9.48 (s, 1H), 8.29 (s, 1H), 8.10 (d, 1H), 7.71 (d, 1H), 7.58
(d, 1H), 7.36 (m, 2H), 7.27 (s, 1H), 7.15 (m, 2H), 6.59 (bs, 2H),
4.04 (s, 3H), 3.89 (s, 3H), 3.19 (m, 1H), 3.07 (m, 2H), 2,63 (m,
2H), 1.87 (m, 4H); RP-HPLC (Hypersil HS C18, 5 .mu.m, 100A,
250.times.4.6 mm; 5%-100% acetonitrile-0.05 M ammonium acetate over
25 min, 1 mL/min) t.sub.r 15.03 min; MS:MH.sup.+497.3,
M-H.sup.+495.2.
EXAMPLE 2
[0474]
N2-{4-[7-Amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-1-yl]-2--
methoxyphenyl}-2-fluoro4-(trifluoromethyl)benzamide
[0475] The title compound (25 mg) was prepared from tert-Butyl
4-[7-amino-1-(4-amino-3-methoxyphenyl-1H-pyrazolo[4,3-d]pyrimidin-3-yl]-1-
-piperidinecarboxylate (75 mg, 0.171 mmol) and
2-fluoro-4-(trifluoromethyl- )benzoyl chloride in the manner
described for the preparation of
N2-{4-[7-amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-1-yl]-2-methox-
yphenyl}-1-methyl-1H-2-indolecarboxamide: .sup.1H NMR
(DMSO-d.sub.6, 400MHz) .delta.9.94 (bs, 1H), 8.29 (m, 2H), 7.98 (t,
1H), 7.90 (d, 1H0, 7.74 (d, 1H), 7.26 (d, 1H), 7.15 (m, 1H), 6.6
(bs, 2H), 3.93 (s, 3H), 3.18 (m, 1H), 3.06 (m, 2H), 2.66 (m, 2H0,
1.87-1.97 (m, 4H); RP-HPLC (Hypersil HS C18, 5 .mu.m, 100A,
250.times.4.6 mm; 5%-100% acetonitrile-0.05 M ammonium acetate over
25 min, 1 mL/min) t.sub.r 15.38 min; MS:MH.sup.+530.2,
M-H.sup.+528.2.
EXAMPLE 3
[0476]
1-(4-Amino-3-methoxyphenyl)-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-7-am-
ine
[0477]
3-Iodo-1-(3-methoxy4-nitrophenyl)-1H-pyrazolo[4,3-d]pyrimidin-7-ami-
ne (300 mg, 0.728 mmol) in ethanol (10 mL) and water (5 mL) was
heated in an 80.degree. C. oil bath then sodium dithionite (635 mg,
3.64 mmol) was added. After 18 hours the solvents were removed by
evaporation under reduced pressure and the material was purified by
preparative reverse phase chromatography. Lyophilization afforded
135 mg of material which was dissolved in N,N-dimethylformamide and
applied to a column of basic ion exchange resin and eluted with
methanol. The eluent was concentrated under reduced pressure to
provide the title compound (80 mg) : .sup.1H NMR (DMSO-d.sub.6, 400
MHz) .delta.8.28 (s, 1H), 7.01 (s, 1H), 6.96 (d, 1H), 6.76 (d, 1H),
5.28 (bs, 2H), 3.80 (s, 3H); RP-HPLC (Hypersil HS C18, 5 .mu.m,
100A, 250.times.4.6 mm; 5%-100% acetonitrile-0.05 M ammonium
acetate over 25 min, 1 mL/min) t.sub.r 13.08 min;
MS:MH.sup.+383.1.
EXAMPLE 4
[0478]
N1-[4-(7-Amino-1H-pyrazolo[4,3-d]pyrimidin-1-yl)-2-Methoxyphenyl]-2-
-fluoro-4-(trifluoromethyl)benzamide acetate
[0479]
1-(4-Amino-3-methoxyphenyl)-3-iodo-1H-pyrazolo[4,3-d]pyrimidin-7-am-
ine (80 mg, 0.209 mmol) in dichloromethane (5 mL) and pyridine (0.5
mL) was cooled to 5.degree. C. in an ice bath then
2-fluoro-4-(trifluoromethy- l)benzoyl chloride (52 mg, 0.230 mmol)
was added dropwise. The solution was warmed to ambient temperature
for 30 minutes then the solvents were removed by evaporation. The
residue was dissolved in methanol (10 mL), 10% palladium on carbon
(50 mg) was added and the mixture was hydrogenated at atmospheric
pressure and 60.degree. C. for 1 hour. The catalyst was removed by
filtration through a pad of diatomaceous earth then the filtrate
was concentrated and the material purified by preparative reverse
phase chromatography. Lyophilization yielded the title compound (25
mg) as a white solid: .sup.1H NMR (DMSO-d.sub.6, 400 MHz)
.delta.9.98 (s, 1H), 8.32 (m, 3H), 7.99 (t, 1H), 7.89 (d, 1H), 7.75
(d, 1H), 7.32 (d, 1H), 7.18 (m, 1H), 6.7 (bs, 2H) 3.93 (s, 3H),
1.60 (s, 3H); RP-HPLC (Hypersil HS C18, 5 ,.mu.m, 100A,
250.times.4.6 mm; 5%-100% acetonitrile-0.05 M ammonium acetate over
25 min, 1 mL/min) t.sub.r 18.75 min; MS:MH.sup.+447.1,
M-H.sup.+445.1.
EXAMPLE 5
[0480] N1-{4-[7-Amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-l
-yl]-2-methoxyphenyl}-1-benzenesulfonamide bisacetate
[0481] The title compound was prepared from tert-Butyl
4-[7-amino-1-(4-amino-3-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-3-yl]--
1 -piperidinecarboxylate and benzenesulfonyl chloride in the manner
described for the preparation of
N2-{4-[7-amino-3-(4-piperidyl)-1H-pyrazo-
lo[4,3-d]pyrimidin-1-yl]-2-methoxyphenyl}-1
-methyl-1H-2-indolecarboxamide- : .sup.1H NMR (DMSO-d.sub.6, 400
MHz) .delta.8.2 (s, 1H), 7.73 (m, 2H), 7.38 (m, 3H), 7.12 (d, 1H),
6.80 (s, 1H), 6.68 (m, 1H), 3.67 (s, 3H), 3.15 (m, @H), 2.69 (m,
2H), 1.7-2.0 (m, 13H); RP-HPLC (Hypersil HS C18, 5 .mu.m, 100A,
250.times.4.6 mm; 5%-100% acetonitrile-0.05 M ammonium acetate over
25 min, 1 mL/min) t.sub.r 11.93 min; MS:MH.sup.+480.2,
M-H.sup.+378.1.
EXAMPLE 6
[0482] Benzyl
N-{4-[7-amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-1--
yl]-2-methoxyphenyl}carbamate bisacetate
[0483] The title compound was prepared from tert-Butyl
4-[7-amino-1-(4-amino-3-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-3-yl]--
1 -piperidinecarboxylate and benzyl chloroformate in the manner
described for the preparation of
N2-{4-[7-amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]p-
yrimidin-1-yl]-2-methoxyphenyl}-1-methyl-1H-2-indolecarboxamide:
.sup.1H NMR (DMSO-d.sub.6, 400 MHz) .delta.8.9 (bs, 1H), 8.27 (s,
1H), 7.89 (d, 1H), 7.3-7.4 (m, 5H), 7.17 (s, 1H), 7.06 (d, 1H), 6.6
(bs, 2H), 5.18 (s, 2H), 3.86 (s, 3H), 3.18 (m, 1H), 3.08 (m, 2H),
2.69 (m, 2H), 1.87-1.98 (m, 2H), 1.76 (s, 6H); RP-HPLC (Hypersil HS
C18, 5 .mu.m, 100A, 250.times.4.6 mm; 5%-100% acetonitrile-0.05 M
ammonium acetate over 25 min, 1 mL/min) t.sub.r 14.27 min;
MS:MH.sup.+474.2, M-H.sup.+472.2.
EXAMPLE 7
[0484]
N-{4-[7-Amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-1-yl]-2-m-
ethoxyphenyl}-N-phenylurea
[0485] The title compound was prepared from tert-Butyl
4-[7-amino-1-(4-amino-3-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-3-yl]--
1-piperidinecarboxylate and phenyl isocyanate in the manner
described for the preparation of
N2-{4-[7-amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrim-
idin-1-yl]-2-methoxyphenyl}-1-methyl-1H-2-indolecarboxamide:
.sup.1H NMR (DMSO-d.sub.6, 400 MHz) .delta.9.40 (s, 1H), 8.44 (s,
1H), 8.33 (d, 1H), 8.23 (s, 1H), 7.47 (d, 2H), 7.31 (m, 2H), 7.19
(s, 1H), 7.06 (m, 1H), 7.00 (m, 1H), 6.5 (bs, 2H), 3.95 (s, 3H),
3-3.2 (m, 3H), 2.71 (m, 2H), 1.9-2.0 (m, 4H); RP-HPLC (Hypersil HS
C18, 5 .mu.m, 100A, 250.times.4.6 mm; 5%-100% acetonitrile-0.05 M
armonium acetate over 25 min, 1 mL/min) t.sub.r 13.02 min;
MS:MH.sup.+459.1, M-H.sup.+457.2.
EXAMPLE 8
[0486]
N2-{4-[7-Amino-3-(1-tetrahydro-2H4-4pyranyl-4-piperidyl)-1H-pyrazol-
o[4,3-d]pyrimidin-1-yl]2-methoxyphenyl}-1-methyl-1H-2-indolecarboxamide
maleate
[0487] A mixture of
N2-{4-[7-amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrim-
idin-1-yl]-2-methoxyphenyl}-1-methyl-1H-2-indolecarboxamide (320
mg, 0.645 mmol), tetrahydro-4H-pyran-4-one (129 mg, 1.29 mmol) and
sodium triacetoxyborohydride (275 mg, 1.29 mmol) in
1,2-dichloroethane (15 mL) was heated at 75.degree. C. for 3 hours.
The mixture was treated with saturated aqueous sodium bicarbonate
(20 mL) and the layers were separated. The aqueous layer was
extracted with dichloromethane (3.times.20 mL) then the combined
organic solutions were dried over magnesium sulfate, filtered and
the filtrate concentrated under reduced pressure. The residue was
purified by flash chromatography on silica gel then the material
(190 mg) was heated to reflux in a mixture of ethyl acetate (10 mL)
and ethanol (1 mL). Maleic acid (85 mg) in ethyl acetate (4 mL) was
added to the mixture, which was then heated at reflux for 30 min.
The mixture was cooled to ambient temperature then the solid was
collected by filtration to yield the title compound (220 mg):
.sup.1H NMR (DMSO-d.sub.6, 400 MHz) ,9.49 (s, 1H), 9.15 (bs, 1H),
8.33 (s, 1H), 8.13 (d, 1H), 7.71 (d, 1H), 7.59 (d, 1H), 7.35 (m,
3H), 7.28 (s, 1H), 7.16 (m, 2H), 6.8 (bs, 2H), 6.02 (s, 2H), 4.04
(s, 3H), 3.99 (m, 1H), 3.94 (s, 1H), 3.2-3.6 (m, 8H), 2.31 (m, 4H),
2.0 (m, 2H), 1.70 (m, 2H); RP-HPLC (Hypersil HS C18, 5 .mu.m, 100A,
250.times.4.6 mm; 5%-100% acetonitrile-0.05 M ammonium acetate over
25 min, 1 mL/min) t.sub.r 15.63 min; MS:MH.sup.+581.2,
M-H.sup.+579.2.
EXAMPLE 9
[0488]
N2-{4-[7-amino-3-(1-ethyl-4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin--
1-yl]-2methoxyphenyl}-1-methyl-1H-2-indolecarboxamide maleate
[0489] The title compound was prepared from
N2-{4-[7-amino-3-(4-piperidyl)-
-1H-pyrazolo[4,3-d]pyrimidin-1-yl]-2-methoxyphenyl}-1-methyl-1H-2-indoleca-
rboxamide and acetaldehyde in the manner described for the
preparation
N2-{4-[7-amino-3-(1-tetrahydro-2H-4-pyranyl-4-piperidyl)-.sup.1H-pyrazolo-
[4,3-d]pyrimidin-1-yl]-2-methoxyphenyl}-1-methyl-1H-2-indolecarboxamide
maleate: .sup.1H NMR (DMSO-d.sub.6, 400 MHz) ,9.49 (s, 1H0, 9.10
(bs, 1H), 8.33 (s, 1H), 8.13 (s, 1H), 7.71 (d, 1H), 7.59(d, 1H),
7.28-7.35 (m, 3H), 7.15 (m, 2H), 6.80 (bs, 2H0, 6.01 (s, 2H), 4.04
(s, 3H), 3.94 (s, 3H), 3.62 (m, 2H), 3.38 (m, 1H), 3.16 (m, 4H),
2.26 (m, 4H), 1.27 (t, 3H); RP-HPLC (Hypersil HS C18, 5 .mu.m,
100A, 250.times.4.6 mm; 5%-100% acetonitrile-0.05 M ammonium
acetate over 25 min, 1 mL/min) t.sub.r 15.77 min; MS:MH.sup.+525.0,
M-H.sup.+523.0.
[0490] Preparation 11
[0491]
3-Iodo-1-(4-nitrophenyl)-1H-pyrazolo[4.3-d]pyrimidin-7-amine
[0492] The title compound was prepared from
3-iodo-1H-pyrazolo[4,3-d]pyrim- idin-7-amine and
1-fluoro-4-nitrobenzene as described for the preparation of
3-iodo-1-(3-methoxy-4-nitrophenyl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine
.sup.1H NMR (DMSO-d6, 400 MHz) .delta.8.40-8.50 (m, 3H), 7.79 (d,
2H) 7.11 (bs, 2H); RP-HPLC (Hypersil HS C18, 5 .mu.m, 100A,
250.times.4.6 mm; 5%-100% acetonitrile-0.05 M ammonium acetate over
25 min, 1 mL/min) t.sub.r 15.98 min.
[0493] Preparation 12
[0494] tert-Butyl
4-[7-amino-1-(4-nitrophenyl)-1H-pyrazolo[4,3-d]pyrimidin-
e-3-yl]-1,2,3,6-tetrahydro-1-pyridinecarboxylate
[0495] The title compound was prepared from
3-iodo-1-(4-nitrophenyl)-1H-py- razolo[4,3-d]pyrimidin-7-amine and
tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-
-dioxaborolan-2-yl)-1,2,3,6-tetrahydro-1-pyridinecarboxylate in the
manner described for the preparation of tert-butyl
4-[7-amino-1-(3-methoxy-4-nit-
rophenyl)-1H-pyrazolo[4,3-d]pyrimidin-3-yl]-1,2,3,6-tetrahydro-1
-pyridinecarboxylate:.sup.1H NMR (DMSO-d6, 400 MHz) .delta.8.44 (m,
3H0, 7.76 (d, 2H), 7.53 (m, 1H), 7.05 (bs, 2H), 4.13 (m, 2H), 3.58
(m, 2H), 2.67 (m, 2H), 1.44 (s, 9H); RP-HPLC (Hypersil HS C18, 5
.mu.m, 100A, 250.times.4.6 mm; 5%-100% acetonitrile-0.05 M ammonium
acetate over 25 min, 1 mL/mnin) t.sub.r 21.70 min;
MS:MH.sup.+438.1, M-H.sup.+436.1.
[0496] Preparation 13
[0497] tert-Butyl 4-[7-amino-1
-(4-aminophenyl)-1H-pyrazolo[4,3-d]pyrimidi-
ne-3-yl]-1-piperidinecarboxylate
[0498] The title compound was prepared from tert-butyl
4-[7-amino-1-(4-nitrophenyl)-1H-pyrazolo[4,3-d]pyrimidine-3-yl]-1,2,3,6-t-
etrahydro-1-pyridinecarboxylate in the same manner as described for
the preparation of tert-butyl
4-[7-amino-1-(4-amino-3-methoxyphenyl)-1H-pyraz-
olo[4,3-d]pyrimidin-3-yl]-1-piperidinecarboxylate: RP-HPLC
(Hypersil HS C18, 5 .mu.m, 100A, 250.times.4.6 mm; 5%-100%
acetonitrile-0.05 M ammonium acetate over 25 min, 1 mL/min) t.sub.r
16.07 min; MS:MH.sup.+410.2.
EXAMPLE 10
[0499]
N1-{4-[7-Amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-1-yl]phe-
nyl}-1-benzenesulfonamide bisacetate
[0500] The title compound was prepared from tert-butyl
4-[7-amino-1-(4-aminophenyl)-1H-pyrazolo[4,3-d]pyrimidine-3-yl]-1-piperid-
inecarboxylate and benzenesulfonyl chloride in the manner described
for the preparation of
N2-{4-[7-amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrim-
idin-1-yl]-2-methoxyphenyl}-1-methyl-1H-2-indolecarboxamide:
.sup.1H NMR (DMSO-d.sub.6, 400 MHz), .delta.8.22 (s, 1H0, 7.75 (m,
2H), 7.45 (m, 3H), 7.14 (d, 2H), 7.02 (d, 2H), 6.5 (bs, 1H),
3.0-3.3 (m, 3H), 2.77 (m, 2H), 2.0 (m, 4H), 1.89 (s, 6H); RP-HPLC
(Hypersil HS C18, 5 .mu.m, 100A, 250.times.4.6 mm; 5%-100%
acetonitrile-0.05 M ammonium acetate over 25 min, 1 mL/min) t.sub.r
11.63 min; MS:MH.sup.+450.0, M-H.sup.+448.0.
EXAMPLE 11
[0501]
N2-{4-l7-Amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrimidin-1-yl]phe-
nyl}-1-methyl-1H-2-indolecarboxamide
[0502] The title compound was prepared from tert-butyl
4-[7-amino-1-(4-aminophenyl)-1H-pyrazolo[4,3-d]pyrimidine-3-yl]-1-piperid-
inecarboxylate and 1-methylindole carbonyl chloride in the manner
described for the preparation of
N2-{4-[7-amino-3-(4-piperidyl)-1H-pyrazo-
lo[4,3-d]pyrimidin-1-yl]-2-methoxyphenyl}-1
-methyl-1H-2-indolecarboxamide- : .sup.1H NMR (DMSO-d.sub.6, 400
MHz) .delta.10.85 (s, 1H), 8.28 (s, 1H), 8.03 (d, 2H), 7.74 (d,
1H), 7.58 (d, 1H), 7.53 (d, 2H), 7.37 (s, 1H), 7.34 (t, 1H), 7.15
(t, 1H), 6.5 (bs, 1.4H), 4.04 (s, 3H), 3.19 (m, 1H), 3.10 (m, 2H),
2.70 (m, 2), 1.84-2.0 (m, 4H); RP-HPLC (Hypersil HS C18, 5 .mu.m,
100A, 250.times.4.6 mm; 5%-100% acetonitrile-0.05 M ammonium
acetate over 25 min, 1 mL/min) t.sub.r 14.42 min; MS:MH.sup.+467.1,
M-H.sup.+465.1.
EXAMPLE 12
[0503]
N2-{4-[7-Amino-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-pyrazolo[4,3-d-
]pyrimidin-1-yl]-2-methoxyphenyl}-1-methyl-1H-2-indolecarboxamide
bisacetate
[0504] The title compound was prepared by hydrogenation of a
methanolic solution of tert-butyl
4-[7-amino-1-(3-methoxy4-nitrophenyl)-1H-pyrazolo[-
4,3-d]pyrimidin-3-yl]-1,2,3,6-tetrahydro-1-pyridinecarboxylate in
the presence of 10% Pd--C at 55 psi of hydrogen for 12 hours to
provide tert-butyl 4-[7-amino-1
-(4-amino-3-methoxyphenyl)-1H-pyrazolo[4,3-d]pyri-
midine-3-yl]-1,2,3,6-tetrahydro-1-pyridinecarboxylate which was
then reacted with 1-Methylindole carbonyl chloride in the manner
described for the preparation of
N2-{4-[7-amino-3-(4-piperidyl)-1H-pyrazolo[4,3-d]pyrim-
idin-1-yl]-2-methoxyphenyl}-1-methyl-1H-2-indolecarboxamide:
.sup.1H NMR (DMSO-d.sub.6, 400 MHz) 59.49 (bs, 1H), 8.35 (s, 1H),
8.12 (d, 1H), 7.71 (d, 1H), 7.60 (m, 1H), 7.46 (m, 1H), 7.32 (m,
3H), 7.16 (m, 2H), 4.04 (s, 3H), 3.94 (s, 3H), 3.50 (m, 2H), 2.96
(m, 2H), 2.54 (m, 2H), 1.88 (s, 6H); RP-HPLC (Hypersil HS C18, 5
.mu.m, 100A, 250.times.4.6 mm; 5%-100% acetonitrile-0.05 M ammonium
acetate over 25 min, 1 mL/min) t.sub.r 15.42 min; MS:MH.sup.+495.2,
M-H.sup.+493.3.
EXAMPLE 13
[0505]
N-[4-(4-Aminofuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-methylphenyl)u-
rea
EXAMPLE 13A
[0506] 2-Hydroxy-1 -(4-nitrophenyl)ethanone
[0507] A mixture of 2-bromo-1-(4-nitrophenyl)ethanone (5 g, 20.5
mmol) and silver nitrate (5 g, 29.4 mmol) in water (250 mL) and
acetone (150 mL) was heated to reflux for 4 hours then cooled to
room temperature. The suspension was filtered and the filtrate was
extracted twice with dichloromethane. The combined extracts were
dried (Na.sub.2SO.sub.4), filtered, and concentrated. The
concentrate was purified by flash column chromatography on silica
gel with 2:1 hexanes/ethyl acetate to provide 3.7 g (50%) of the
desired product. R.sub.f=0.4 (1:1 hexanes/ethyl acetate).
EXAMPLE 13B
[0508] 2-Amino-4-(4-nitrophenyl)-3-furonitrile
[0509] A mixture of Example 13A (5 g, 27.6 mmol) and malononitrile
(2.74 g, 41.4 mmol) in methanol (8.6 mL) at room temperature was
treated with diethylamine (1.43 mL, 13.8 mmol), stirred for 1 hour,
and poured into water. The resulting suspension was filtered and
the filter cake was washed with water then purified by flash column
chromatography on silica gel with 1:1 ethyl acetate/hexanes to
provide 5 g (80%) of the desired product. MS (DCI) m/e 247
(M+NH4).sup.+.
EXAMPLE 13C
[0510] N'-[3-Cyano4-(4-nitrophenyl)-2-furyl]imidoformamide
[0511] A mixture of Example 13B (2 g, 8.7 mmol) and ammonium
sulfate (115 mg, 0.87 mmol) in triethylformate (40 mL) was heated
to reflux for 4 hours, cooled to -20 .degree. C., treated with 2M
ammonia in ethanol (80 mL, 160 mmol), warmed to room temperature,
and stirred for 5 hours. The resulting precipitate was collected by
vacuum filtration, washed with water and ethanol, and dried to
provide 2.2 g (98%) of the desired product. MS (ESI(-)) m/e 255
(M-H).sup.-.
EXAMPLE 13D
[0512] 5-(4-Nitrophenyl)furo[2,3-d]pyrimidin-4-amine
[0513] A suspension of Example 13C (120 mg, 0.47 mmol) in
1,2-dichlorobenzene (5 mL) was heated in a Smith Synthesizer
microwave at 250 .degree. C. for 15 minutes, diluted with THF, and
concentrated. The concentrate was purified by flash column
chromatography on silica gel with 5% methanol/dichloromethane to
provide 98 mg (82%) of the desired product. MS (ESI(-)) m/e 255
(M-H).sup.-; .sup.1H NMR (DMSO-d.sub.6) .delta.8.37-8.33 (m, 2H),
8.29 (s, 2H), 8.19 (s, 1H), 7.80-7.75 (m, 2H), 6.80 (br s, 2H);
Anal. Calcd. for C.sub.12H.sub.8N.sub.4O.sub.3: C, 56.25; H, 3.15;
N, 21.87. Found: C, 56.32; H, 3.17; N, 21.86. 37
EXAMPLE 13E
[0514] 5-(4-Aminophenyl)furo[2,3-d]pyrimidin-4-amine
[0515] A mixture of Example 13D (140 mg, 0.55 mmol) and NH4CI (30
mg, 0.55 mmol) in 2:1 ethanol/water (9 mL) was heated to 50
.degree. C., treated with iron powder (61 mg, 1.1 mmol), heated to
80.degree. C. for 2 hours, cooled to room temeperature, filtered
through diatomaceous earth (Celite.RTM.), and concentrated. The
concentrate was purified by flash column chromatography on silica
gel with 2:1 hexanes/ethyl acetate to provide 95 mg (77%) of the
desired product. MS (ESI(+)) m/e 227 (M+H).sup.+.
EXAMPLE 13F
[0516]
N-[4-(4-Aminofuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(4-methylphenyl)u-
rea
[0517] A 0 .degree. C. suspension of Example 13E (50 mg, 0.22 mmol)
in dichloromethane (3 mL) was treated with p-tolylisocyanate (0.031
mL, 0.24 mmol), warmed to room temperature, and stirred overnight.
The resulting precipiate was collected by vacuum filtration, washed
with dichloromethane, and dried to provide 55 mg (70%) of the
desired product. MS (ESI(+)) m/e 360 (M+H).sup.+; .sup.1H NMR
(DMSO-d.sub.6) .delta.8.80 (s, 1H), 8.60 (s, 1H), 8.25 (s, 1H),
7.92 (s, 1H), 7.6 (d, J=8.4 Hz, 2H), 7.43 (d, J=8.7 Hz, 2H), 7.35
(d, J=8.4 Hz, 2H), 7.10 (d, J=8.1 Hz, 2H), 6.52 (br s, 2H), 2.25
(s, 3H); Anal. Calcd. for C.sub.2H.sub.17N.sub.5O.s- ub.2: C,
66.84; H, 4.77; N, 19.49. Found: C, 66.58; H, 4.65; N, 19.42.
EXAMPLE 14
[0518]
N-[4-(4-aminofuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methylphenyl)u-
rea
[0519] The desired product was prepared by substituting
m-tolylisocyanate for p-tolylisocyanate in Example 13F. MS (ESI(+))
m/e 360 (M+H).sup.+; .sup.1H NMR (DMSO-d6) .delta.8.84 (s, 1H),
8.65 (s, 1H), 8.25 (s, 1H), 7.93 (s, 1H), 7.62-7.59 (m, 2H),
7.45-7.42 (m, 2H), 7.31 (br s, 1H), 7.25 (d, J=8.1 Hz, 1H), 7.25
(d, J=8.1 Hz, 1H), 7.17 (t, J=7.2 Hz, 1H), 6.80 (d, J=7.2 Hz, 1H),
6.54 (br s, 2H), 2.28 (s, 3H); Anal. Calcd. for
C20H.sub.17N.sub.5O.sub.2 0.25H.sub.2O: C, 66.00; H, 4.85; N,
19.25. Found: C, 66.15; H, 4.68; N, 19.31.
EXAMPLE 15
[0520]
N-[4-(4-Aminofuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2-methylphenyl)u-
rea
[0521] The desired product was prepared by substituting
o-tolylisocyanate for p-tolylisocyanate in Example 13F. MS (ESI(+))
mi/e 360 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6) .delta.9.19 (s,
1H), 8.25 (s, 1H), 7.98 (s, 1H), 7.92 (s, 1H), 7.84 (d, J=7.8 Hz,
1H), 7.62 (d, J=8.7 Hz, 2H), 7.44 (d, J=9.0 Hz, 2H), 7.20-7.13 (m,
2H), 6.96 (dt, J=7.4, 0.9 Hz, 1H), 6.52 (br s, 2H), 2.26 (s, 3H);
Anal. Calcd. for C.sub.20H.sub.17N.sub.5O.sub.2 0.25H.sub.2O: C,
66.01; H, 4.85; N, 19.25. Found: C, 65.907; H, 4.74; N, 18.98.
EXAMPLE 16
[0522]
N-[4-(4-Aminofuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-chlorophenyl)u-
rea
[0523] The desired product was prepared by substituting
3-chlorophenylisocyanate for p-tolylisocyanate in Example 13F. MS
(ESI(+)) mi/e 378, 380 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6)
.delta.8.94 (s, 2H), 8.25 (s, 1H), 7.93 (s, 1H), 7.73-7.72 (m 1H),
7.61 (d, J=8.4 Hz, 2H), 7.44 (d, J=8.4 Hz, 2H), 7.44 (d, J=8.4 HZ,
2H), 7.32-7.29 (m, 2H), 7.03 (dt, J=6.5, 2.2 Hz, 1H); Anal. Calcd.
for C.sub.19H.sub.14ClN.sub.5O.sub.2. 025H.sub.2O: C, 59.38, H,
3.80; N, 18.22. Found: C, 59.42; H, 3.80; N, 18.12. 38
EXAMPLE 17
[0524]
5-[4-(1,3-Benzoxazol-2-ylamino)phenyl]furo[2,3-d]pyrimidin-4-amine
[0525] A solution of Example 13E (80 mg, 0.35 mmol) in pyridine (3
mL) was added dropwise via cannula to a 0.degree. C. solution of
1,1-thiocarbonyldiimidazole (63 mg, 0.35 mmol) in pyridine (3 mL).
The reaction was stirred at 0.degree. C. for 1.5 hours, treated
with 2-aminophenol (393 mg, 0.359 mmol), warmed to room
temperature, stirred overnight, treated with
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (81 mg,
0.42 mmol), and heated to 55.degree. C. for 8 hours. The mixture
was concentrated and the residue was partitioned between ethyl
acetate and water. The aqueous phase was extracted three times with
ethyl acetate and the combined extracts were washed with brine,
dried (Na.sub.2SO.sub.4), filtered, and concentrated. The
concentrate was purified by flash column chromatography on silica
gel with ethyl acetate to provide 31 mg (25%) of the desired
product. MS (ESI(+)) m/e 344 (M+H).sup.+; .sup.1H NMR
(DMSO-d.sub.6) .delta.10.82 (s, 1H), 2.56 (s, 1H), 7.94 (s, 1H),
7.93-7.89 (m, 2H), 7.56-7.48 (m, 4H), 7.24 (dt, J=7.2, 1.2 Hz, 1H),
7.15 (dt, J=7.8, 1.2 Hz. 1H), 6.54 (br s, 2H). Anal. Calcd. for
C.sub.18H.sub.13N.sub.5O.sub.2. 025H.sub.2O: C, 65.61; H, 3.91; N,
20.13. Found: C, 65.75; H, 3.96; N, 19.78.
EXAMPLE 18
[0526] N-[4-(4-Aminofuro[2,3-d]pyrimidin-5-yl)phenyl]benzamide
[0527] A 0.degree. C. suspension of Example 13E (74 mg, 0.33 mmol)
in dichloromethane (3 mL) was treated with pyridine (0.032 mL, 0.4
mmol) and benzoyl chloride (0.040 mL, 0.34 mmol), stirred at 0
.degree. C. for 1 hour, warmed to room temperature, and stirred
overnight. The mixture was triturated with hexanes and the
precipitate was collected by vacuum filtration, washed with
dichloromethane and water, and purified by flash column
chromatography on silica gel with ethyl acetate to provide 46 mg
(42%) of the desired product. MS (ESI(+)) m/e 331 (M+H).sup.+;
.sup.1H NMR (DMSO-d.sub.6) .delta.10.41 (s, 1H), 8.26 (s, 1H),
7.99-7.94 (m, 5H), 7.62-7.50 (m, 5H), 6.50 (br s, 2H); Anal. Calcd.
for C.sub.19H.sub.14N.sub.4O.sub.20.25H.sub.2O: C, 68.15; H, 4.36;
N, 16.73. Found: C, 68.20; H, 4.21; N, 19.78.
EXAMPLE 19
[0528]
N-[4-(4-Aminofuro[2,3-d]pyrimidin-5-yl)phenyl]benzenesulfonamide
[0529] A 0.degree. C. suspension of Example 13E (0.05 g, 0.22 mmol)
in dichloromethane (4 mL) was treated with pyridine (0.022 mL, 0.26
mmol) and benzenesulfonyl chloride (0.03 mL, 0.23 mmol), stirred at
0.degree. C. for 1 hour, warmed to room temperature, and stirred
overnight. The reaction mixture was diluted with water and
extracted twice with dichloromethane. The combined extracts were
washed with brine, dried (Na.sub.2SO.sub.4), filtered, and
concentrated. The concentrate was triturated with
dichloromethane/hexanes to provide 52 mg (64%) of the desired
product. MS (ESI(+)) m/e 367 (M+H).sup.+; .sup.1H NMR (DMSO-.sub.6)
.delta.10.51 (s, 1H), 8.23 (s, 1H), 7.88 (s, 1H), 7.84-7.81 (m,
2H), 7.64-7.54 (m, 3H), 7.38 (d, J=8.5 Hz, 2H), 7.22 (d, J=8.5 Hz,
2H), 6.45 (br s, 2H) Anal. Calcd. for
C.sub.18H.sub.14N.sub.4O.sub.3S: C, 59.01; H, 3.85; N, 15.29.
Found: C, 58.77; H, 3.88; N, 15.18.
EXAMPLE 20
[0530]
N-[4-(4-Amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(2-methy-
lphenyl)urea
EXAMPLE 20A
[0531] 1-(4-Nitrophenyl)propan-1-one
[0532] A solution of 0.5M ZnCl.sub.2 in THF (60 mL, 30 mmol) in THF
(20 mL) at room temperature was treated with 2M ethyl magnesium
chloride in THF (15 ml, 30 mmol) dropwise via syringe, cooled with
an ice bath for about 10 minutes, stirred at room temperature for
20 minutes, cooled to 0.degree. C., and treated sequentially with
Pd(PPh.sub.3).sub.4 (1.73 g, 1.5 mmol) and a solution of
4-nitrobenzoyl chloride (6.12 g, 33 mmol) in THF (20 mL). The
mixture was stirred at 0.degree. C. for 40 minutes, diluted with
water and extracted three times with ethyl acetate. The combined
extracts were washed with saturated Na.sub.2CO.sub.3, water, and
brine, dried (MgSO.sub.4), filtered, and concentrated. The
concentrate was purified by flash column chromatography on silica
gel with 6:1 hexanes/ethyl acetate to provide 2.17 g (40%) of the
desired product. R.sub.f=0.6 (3:1 hexanes/ethyl acetate).
EXAMPLE 20B
[0533] 2-Bromo-1-(4-nitrophenyl)propan-1-one
[0534] A solution of bromine (0.805 mL, 15.6 mmol) in CCl.sub.4 (10
mL) was added dropwise to a solution of Example 20A (2.8 g, 15.6
mmol) in CCl.sub.4 (20 mL) at room temperature, stirred for 1 hour,
quenched with 1:1 saturated NaHCO.sub.3/10% NaHSO.sub.3, and
extracted with dichloromethane. The combined extracts were washed
with water, dried (Na.sub.2SO.sub.4), filtered, and concentrated to
provide 3.95 g (98%) of the desired product. R.sub.f=0.62 (2:1
hexanes/ethyl acetate).
EXAMPLE 20C
[0535] 2-Hydroxy-1 -(4-nitrophenyl)propan-1-one
[0536] A solution of LiOH H.sub.2O (642 mg, 15.3 mmol) in water (15
mL) was added drowise to a 0.degree. C. solution of Example 20B
(3.95g, 15.3 mmol) in DMF (54 mL), stirred at 0.degree. C. for 1
hour, diluted with water, and extracted three times with ethyl
acetate. The combined extracts were washed with brine, dried
(Na.sub.2SO.sub.4), filtered, and concentrated to provide 2.65
(89%) of the desired product. R.sub.f=0.27 (2:1 hexanes/ethyl
acetate).
EXAMPLE 20D
[0537] 5-(4-Aminophenyl)-6-methylfuro[2,3-d]pyrimidin4-amine
[0538] The desired product was prepared by substituting Example 20C
for Example 13A in Examples 13B-13E. .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta.2.33 (s, 3H), 5.33 (s, 2H), 6.13 (br s, 2H),
6.70 (m, 2H), 7.08 (m, 2H), 8.16 (s, 1H); Anal. Calcd. for
C.sub.13H.sub.12N.sub.4O: C, 64.99; H, 5.03; N, 23.32. Found: C,
64.67; H, 5.02; N, 23.05.
EXAMPLE 20E
[0539]
N-[4-(4-Amino-6-methylfuro[2.3-d]pyrimidin-5-yl)phenyl]-N'-(2-methy-
lphenyl)urea
[0540] The desired product was by substituting Example 20D and
o-tolylisocyanate for Example 13E and p-tolylisocyanate,
respectively, in Example 13F. .sup.1H NMR (500 MHz, DMSO-d.sub.6)
.delta.2.26 (s, 3H), 2.37 (s, 3H), 6.18 (br s, 2H), 6.97 (t, J=7.5
Hz, 1H), 7.16 (t, J=7.8 Hz, 1H), 7.98 (s,1H), Hz, 1H), 7.36 (d,
J=8.4 Hz, 2H), 7.63 (d, J=8.4 Hz, 2H), 7.83 (d, J=7.8 Hz, 1H), 7.98
(s, 1H), 8.19 (s, 1H), 9.17 (s, 1H); Anal. Calcd. for
C.sub.21H.sub.19N.sub.5O.sub.2. 025H.sub.2O: C, 66.74; H, 5.20; N,
18.53. Found: C, 66.63; H, 4.90; N, 18.55.
EXAMPLE 21
[0541]
N-[4-(4-Amino-6-methylfuro[2,3-pyrimidin-5-yl)phenyl-N'-(4-methylph-
enyl)urea
[0542] The desired product was prepared by substituting Example 20D
for Example 13E in Example 13F. .sup.1H NMR (500 MHz, DMSO-d.sub.6)
.delta.2.25 (s, 3H), 2.37 (s, 3H), 6.18 (br, s2H), 7.10 (d, J=8.4
Hz, 2H), 7.35 (m, 4H), 7.61 (d, J=8.4 Hz, 2H), 8.19 (s, 1H), 8.59
(s, 1H), 8.78 (s, 1H); Anal. Calcd. for
C.sub.21H.sub.19N.sub.5O.sub.2 0.4H.sub.2O: C, 66.27; H, 5.24; N,
18.40. Found: C, 65.84; H, 4.80; N, 18.07.
EXAMPLE 22
[0543]
N-[4-(4-Amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]benzamide
[0544] The desired product was prepared by substituting Example 20D
for Example 13E in EXAMPLE 18. MS (DCI) m/e 345 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.2.39 (s, 3H), 6.23 (br
s, 2H), 7.43 (m, 2H), 7.59 (m, 3H), 7.96 (m, 2H), 7.98 (m, 2H),
8.20 (s, 1H), 10.42 (s, 1H); Anal. Calcd. for
C.sub.20H16N.sub.4O.sub.22 0.5H.sub.2O: C, 67.98; H, 4.85; N,
15.85. Found: C, 67.83; H, 4.73; N, 15.61.
EXAMPLE 23
[0545]
N-[4-(4-Amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]benzenesulfo-
namide
[0546] The desired product was prepared by substituting Example 20D
for Example 13E in Example 19. MS (DCI) m/e 381 (M+H).sup.+;
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.2.30 (s, 3H), 6.16 (br
s, 2H), 7.24 (d, J=8.4 Hz, 2H), 7.30 (d, J=8.4 Hz, 2H), 7.57 (t,
J=7.6 Hz, 2H), 7.64 (t, J=7.3 Hz, 1H), 7.80 (d, J=7.2 Hz, 2H), 8.19
(s, 1H), 10.49 (s, 1H); Anal. Calcd. for
C.sub.19H.sub.16N.sub.4O.sub.3S. 1.0H.sub.2O: C, 57.28; H, 4.55; N,
14.06. Found: C, 57.67, H, 4.13; N, 14.04.
EXAMPLE 24
[0547]
N-[4-(4-Amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methy-
lphenyl)urea
[0548] The desired product was prepared by substituting Example 20D
and m-tolylisocyanate for Example 13E and p-tolylisocyanate,
respectively, in Example 13F. MS (DCI) m/e 374 (M+H).sup.+; .sup.1H
NMR (300 MHz, DMSO-d.sub.6) .delta.2.29 (s, 3H), 2.37 (s, 3H), 6.22
(br s, 2H), 6.80 (d, J=7.1 Hz, 1H), 7.17 (t, J=7.6 Hz, 1H), 7.31
(m, 1H), 7.35 (d, J=8.5 Hz, 2H), 7.62 (d, J=8.8 Hz, 2H), 8.19 (s,
1H), 8.65 (s, 1H), 8.83 (s, 1H); Anal. Calcd. for
C.sub.21H.sub.19N.sub.5O.sub.2: C, 67.55; H, 5.13; N, 18.75. Found:
C, 67.32; H, 5.11; N, 18.70.
EXAMPLE 25
[0549]
N-[4-(4-Amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-chlor-
ophenyl)urea
[0550] The desired product was prepared by substituting Example 20D
and 3-chlorophenylisocyanate for Example 13E and p-tolylisocyanate,
respectively, in Example 13F. MS (DCI) m/e 394 (M+H).sup.+; .sup.1H
NMR (300 MHz, DMSO-d.sub.6) .delta.2.37 (s, 3H), 6.21 (br s, 2H),
7.03 (dt, J=6.4, 2.0 Hz, 1H), 7.31 (m, 2H), 7.36 (d, J=8.5 Hz, 2H),
7.62 (d, J=8.8 Hz, 2H), 7.73 (m 1H), 8.19 (s, 1H), 8.93 (s, 111),
8.94 (s, 1H); Anal. Calcd. for C.sub.20H.sub.16ClN.sub.5O.sub.2
035H2O: C, 60.03; H, 4.21; N, 17.50. Found: C, 60.51; H, 3.88; N,
17.02.
EXAMPLE 26
[0551]
N-[4-(4-Amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-metho-
xyphenyl)urea
[0552] The desired product was prepared by substituting Example 20D
and 3-methoxyphenylisocyanate for Example 13E and
p-tolylisocyanate, respectively, in Example 13F. MS (DCI) m/e 390
(M+H).sup.+; .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.2.37 (s,
3H), 3.74 (s, 3H), 6.21 (br s, 2H), 6.56 (m, 1H), 6.95 (m, 1H),
7.18 (s, 1H), 7.20 (m, 1H), 7.35 (d, J=8.5 Hz, 2H), 7.62 (d, J=8.5
Hz, 2H), 8.19 (s, 1H), 8.73 (s, 1H), 8.83 (s, 1H); Anal. Calcd. for
C.sub.21H.sub.19N.sub.5O.sub.3; C, 64.77; H, 4.92; N, 17.98. Found:
C, 64.41; H, 4.83; N, 17.71.
EXAMPLE 27
[0553]
N-[4-(4-Amino-6-bromofuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methyl-
phenyl)urea
EXAMPLE 27A
[0554] tert-Butyl
5-(4-nitrophenyl)furo[2,3-d]pyrimidin-4-ylcarbamate
[0555] A 0.degree. C. suspension of Example 13D (0.44 g, 1.7 mmol)
in THF (20 mL) was treated with 60% NaH oil dispersion (172 mg,
4.25 mmol), stirred at 0.degree. C. for 15 minutes, treated with
di-t-butyl dicarbonate (450 mg, 2.04 mmol), stirred at 0.degree. C.
for 1 hour, and quenched with saturated NH.sub.4Cl. The mixture was
extracted three times with ethyl acetate and the combined extracts
were washed with water and brine, dried (Na.sub.2SO.sub.4),
filtered, and concentrated. The concentrate was purified by flash
column chromatography on silica gel with 2:1 hexanes/ethyl acetate
to provide 550 mg (89%) of the desired product. MS (ESI(+)) m/e 357
(M+H).sup.+.
EXAMPLE 27B
[0556] tert-Butyl
6-bromo-5-(4-nitrophenyl)furo[2,3-d]pyrimidin4-ylcarbama- te
[0557] A 0.degree. C. solution of Example 27A (350 mg, 0.98 mmol)
in DMF (10 mL) was treated with Br.sub.2 (0.102 mL, 1.98 mmol),
warmed to room temperature, and stirred for 1 hour. The reaction
was cooled to 0.degree. C., quenched with 1:1 10%
NaHSO.sub.3/saturated NaHCO.sub.3, and extracted three times with
ethyl acetate. The combined extracts were washed with water and
brine, dried (Na.sub.2SO.sub.4), filtered, and concentrated to
provide 400 mg (93%) of the desired product. MS (ESI(-)) m/e
433,435 (M-H).sup.-.
EXAMPLE 27C
[0558] tert-Butyl
6-bromo-5-[4-({[(3-methylphenyl)amino]carbonyl}amino)phe-
nyl]furo[2,3-d]pyrimidin4-ylcarbamate
[0559] The desired product was prepared by substituting Example 27B
and m-tolylisocyanate for EXAMPLE 13D and p-tolylisocyanate,
respectively, in Examples 13E and 13F. MS (ESI(-)) m/e 536, 538
(M-H).sup.-.
EXAMPLE 27D
[0560]
N-[4-(4-Amino-6-bromofuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-methyl-
phenyl)urea
[0561] A 0.degree. C. suspension of Example 27C (94 mg, 0.17 mmol)
in dichloromethane (4 mL) was treated with TFA (1 mL), warmed to
room temperature, stirred for 1 hour, and concentrated. The
concentrate was purified by flash column chromatography with 5%
methanol/dichloromethane to provide 64 mg (88%) of the desired
product. MS (ESI(+)) mle 438,440 (M+H).sup.+; .sup.1H NMR
(DMSO-d.sub.6) .delta.8.88 (s, 1H), 8.66 (s, 1H), 8.24 (s, 1H),
7.64 (d, J=8.4 Hz, 2H), 7.41 (d, J=8.7 Hz, 2H), 7.32 (br s, 1H),
7.25 (d, J=8.7 Hz, 1H), 7.17 (t, J=7.6 Hz, 1H), 6.81 (d, J=7.8 Hz,
1H), 6.48 (br s, 2H), 2.29 (s, 3H); Anal. Calcd. for
C.sub.20H.sub.16N.sub.5O.sub.2Br. H.sub.2O C, 52.65; H, 3.98; N,
15.35. Found: C, 52.50 ; H, 3.77; N, 15.10.
EXAMPLE 28
[0562]
N-[4-(4-Amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-bromo-
phenyl)urea
EXAMPLE 28A
[0563] 6-Methyl-5-(4-nitrophenyl)furo[23-d]pyrimidin-4-amine
[0564] The desired product was prepared by substituting Example 20C
for Example 13A in Examples 13B-13D.
EXAMPLE 28B
[0565] tert-Butyl
6-methyl-5-(4-nitrophenyl)furo[2,3-d]pyrimidin-4-ylcarba- mate
[0566] The desired product was prepared by substituting Example 28A
for Example 13D in Example 27A.
EXAMPLE 28C
[0567] tert-Butyl
5-[4-({[(3-bromophenyl)amino]carbonyl}amino)phenyl]-6-me-
thylfuro[2,3-d]pyrimidin-4-ylcarbamate
[0568] The desired product was prepared by substituting Example 28B
and 3-bromophenylisocyanate for Example 13D and p-tolylisocyanate,
respectively, in Examples 13E and 13F.
EXAMPLE 28D
[0569]
N-[4-(4-Amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-bromo-
phenyl)urea
[0570] The desired product was prepared by substituting Example 28C
for Example 27C in Example 27D. .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta.2.40 (s, 3H), 5.93 (br s, 2H), 7.16 (m, 1H), 7.25 (t, J=7.98
Hz, 1H), 7.36 (m, 3H), 7.65 (m, 2H), 7.89 (t, J=1.84 Hz, 1H), 8.34
(s, 1H), 9.11 (s, 1H), 9.12 (s, 1H); Anal. Calcd. for
C.sub.20H.sub.16BrN.sub.5O.s- ub.2. 14CF.sub.3CO.sub.2H: C, 44.23;
H, 3.02; N, 12.05. Found: C, 44.42; H, 3.03; N, 11.79.
EXAMPLE 29
[0571] 3-(4-Nitrophenyl)isoxazolo[5,4-d]pyrimidin4-amine
EXAMPLE 29A
[0572] 5-Amino-3-(4-nitrophenyl)isoxazole4-carbonitrile
[0573] A mixture of 0.5M sodium methoxide in methanol (62.8 mL,
31.4 mmol) and malononitrile (2.07 g, 31.4 mmol) was stirred at
0.degree. C. for 10 minutes then treated dropwise with solution of
N-[(Z)-2-chloro-2-(4-nitro- phenyl)vinyl]hydroxylamine (prepared
according to the procedure described in U.S. Pat. No. 5,567,843,
6.3 g, 31.4 mmol) in THF (30 mL), warmed to room temperature, and
stirred for two hours. The mixture was diluted with water (500 mL)
and filtered. The filter cake was washed with water and hexanes and
dried to provide 5.4 g (75% yield) of the desired product. MS
(ESI(-)) m/e 229 (M-H).sup.-.
EXAMPLE 29B
[0574] 3-(4-Nitrophenyl)isoxazolo[5,4-d]pyrimidin4-amine
[0575] A mixture of Example 29A (3.0 g, 13 mmol),
(NH.sub.4).sub.2SO.sub.4 (172 mg, 1.3 mmol), and
HC(OCH.sub.2CH.sub.3).sub.3 (105 mL) was heated to reflux for 6
hours, then filtered while hot. The filtrate was treated with
saturated NH.sub.3 in ethanol (150 mL), stirred overnight at room
temperature, and filtered. The filter cake was washed with ethanol
and dried to provide 1.84 g (55% yield) of the desired product.
EXAMPLE 30
[0576] 3-(4-Aminophenyl)isoxazolo[5,4-d]pyrimidin-4-amine
[0577] A 0.degree. C. suspension of Example 29B (124 mg, 0.5 mmol)
in concentrated HCl (2 mL) was treated with a solution of
SnCl.sub.2 (450 mg) in concentrated HCl (1 mL), warmed to room
temperature, stirred for 3 hours, and filtered. The filtrate was
partitioned between ethyl acetate and saturated NaHCO.sub.3 and the
organic phase was washed with brine, dried (MgSO.sub.4), filtered,
and concentrated to provide 37mg (32%) of the desired product. MS
(ESI(-)) m/e 226 (M-H).sup.-.
EXAMPLE 31
[0578]
N-[4-(4-Aminoisoxazolo[5,4-d]pyrimidin-3-yl)phenyl]-N'-(3-methylphe-
nyl)urea
[0579] A 0.degree. C. solution of Example 30 (126 mg, 0.3 mmol) in
DMF (2 mL) at room temperature was treated with pyridine (0.121 mL,
1.5 mmol) and 3-methylphenylisocyanate (0.038 mL, 0.3 mmol) and
stirred overnight. The reaction mixture was poured into ice water
and filtered. The filter cake was recrystallized from ethyl
acetate/hexanes to provide 87 mg (80% yield) of the desired
product. MS (ESI(+)) m/e 361 (M+H).sup.+; .sup.1H NMR
(DMSO-d.sub.6) .delta.9.00 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H),
7.68 (q, J=15, 8.7 Hz, 4H), 7.10-7.40 (m, 3H), 6.82 (d, J=7.2 Hz,
1H), 2.28 (s, 3H).
EXAMPLE 32
[0580] N-[4-(4-Aminoisoxazolo[5,
4-d]pyrimidin-3-yl)phenyl]-N'-(3-ethylphe- nyl)urea
[0581] The desired product was prepared by substituting
3-ethylphenylisocyanate for m-tolyisocyanate in Example 31. .sup.1H
NMR (DMSO-d.sub.6) .delta.9.00 (s, 1H), 8.87 (s, 1H), 8.42 (s, 1H)
7.66 (q, J=15, 8.7 Hz, 4H), 7.10-7.40 (m, 3H), 6.83 (d, J=7.2 Hz,
1H), 2.59 (q, J=7.5 Hz, 2H), 1.20 (t, J=7.5 Hz, 3H).
EXAMPLE 33
[0582]
N-[4-(4-aminoisoxazolo[5,4-d]pyrimidin-3-yl)phenyl]-N'-(3-chlorophe-
nyl)urea
[0583] The desired product was prepared by substituting
3-chlorophenylisocyanate for m-tolyisocyanate in Example 31. MS
(ESI(+)) m/e 380(M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6) .delta.9.07
(s, 1H), 9.00 (s, 1H), 8.42 (s, 1H), 7.60-7.80 (m, 5H), 7.20-7.40
(m, 2H), 6.90-7.10 (m, 1).
EXAMPLE 34
[0584]
N-[4-(4-Aminoisoxazolo[5,4-d]pyrimidin-3-yl)phenyl]benzamide
[0585] The desired product was prepared by substituting Example 20
for Example 13E in Example 18. MS (ESI(+)) m/e 332 (M+H).sup.+;
.sup.1H NMR (DMSO-d.sub.6) .delta.10.48 (s, 1H), 8.42 (s, 1H),
7.90-8.10 (m, 4H), 7.50-7.80 (m, 5H).
EXAMPLE 35
[0586]
N-[4-(4-Amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3-ethyl-
phenyl)urea
[0587] The desired product was prepared by substituting Example 20D
and 3-ethylphenylisocyanate for Example 13E and p-tolylisocyanate,
respectively, in Example 13F.
[0588] .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta.1.19 (t, J=7.7
Hz, 3H), 2.37 (s, 3H), 2.59 (q, J=7.6 Hz, 2H), 6.19 (br s, 2H),
6.84 (d, J=7.5 Hz, 1H), 7.19 (t, J=7.8 Hz, 1H), 7.27 (d, J=8.1 Hz,
1H), 7.34 (m, 1H), 7.35 (m, 2H), 7.62 (m, 2H), 8.19 (s, 1H), 8.64
(s, 1H), 8.80 (s, 1H); Anal. Cald. for
C.sub.22H.sub.21N.sub.5O.sub.2 0.25H.sub.2O: C, 67.42; H, 5.53; N,
17.87. Found: C, 67.48; H, 5.24; N, 18.17.
EXAMPLE 36
[0589]
N-[4-(4-Amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3,5-dim-
ethylphenyl)urea
[0590] The desired product was prepared by substituting Example 20D
and 3,5-dimethylphenylisocyanate for Example 13E and
p-tolylisocyanate, respectively, in Example 13F. MS (DCI) m/e 388
(M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta.2.27 (s,
6H), 2.37 (s, 3H), 6.18 (br, s 2H), 6.63 (s, 1H), 7.09 (s, 2H),
7.35 (d, J=8.4 Hz, 2H), 7.61 (d, J=8.4 Hz, 2H), 8.19 (s, 1H), 8.54
(s, 1H), 8.79 (s, 1H); Anal. Calcd. for
C.sub.22H.sub.21N.sub.5O.sub.2. 025 H.sub.2O: C, 67.42; H, 5.53; N,
17.87. Found C, 67.13; H, 5.20; N, 17.96. 39
EXAMPLE 37
[0591]
N-[4-(4-Amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-(3,5-dic-
hlorophenyl)urea
[0592] The desired product was prepared by substituting Example 20D
and 3,5-dichlorophenylisocyanate for Example 13E and
p-tolylisocyanate, respectively, in Example 13F. .sup.1H NMR (500
MHz, DMSO-d.sub.6) .delta.2.37 (s, 3H), 6.19 (br s, 2H), 7.17 (s,
1H), 7.38 (d, J=8.4 Hz, 2H), 7.56 (s, 2H), 7.63 (d, J=8.4 Hz, 2H),
8.19 (s, 1H), 9.04 (s, 1H), 9.10 (s, 1H); Anal. Calcd. for
C.sub.20H.sub.15Cl.sub.2N.sub.5O.sub.2 0.25 H.sub.2O: C, 55.51; H,
3.61; N, 16.18. Found: C, 55.14; H, 3.32; N, 15.99.
EXAMPLE 38
[0593]
N-[4-(4-Amino-6-methylfuro[2,3-d]pyrimidin-5-yl)phenyl]-N'-[2-fluor-
o-5-(trifluoromethyl)phenyl]urea
[0594] The desired product was prepared by substituting Example 20D
and 2-fluoro-5-trifluoromethylphenylisocyanate for Example 13E and
p-tolylisocyanate, respectively, in Example 13F. MS (DCI) m/e 446
(M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta.2.38 (s,
3H), 6.20 (br s, 2H), 7.38-7.42 (m, 3H), 7.51 (m, 1H), 7.64 (d,
J=8.4 Hz, 2H), 8.19 (s, 1H), 8.64 (dd, J=2.2, 7.2 Hz, 1H), 8.95 (d,
J=2.5 Hz, 1H), 9.34 (s, 1H1); Anal. Calcd. for
C.sub.21H15F.sub.4N.sub.5O.sub.2. 025H.sub.2O: C, 56.07; H, 3.47;
N, 15.57. Found: C, 55.89; H, 3.20; N, 15.80.
EXAMPLE 39
[0595]
1-4-(4-Amino-6-methyl-furo[2,3-d]pyrimidin-5-yl)-phenyl]-3-(4-cyano-
-phenyl)-urea
[0596] The desired product was prepared by substituting Example 20D
and 4-cyanophenylisocyanate for Example 13E and p-tolylisocyanate,
respectively, in Example 13F. MS (DCI) m/e 385 (M+H).sup.+; .sup.1H
NMR (500 MHz, DMSO-d.sub.6) .delta.2.37 (s, 3H), 6.19 (br s, 2H),
7.38 (d, J=8.73 Hz, 2H), 7.63 (d, J=8.73 Hz, 2 H), 7.66 (d, J=8.73
Hz, 2H), 7.74 (d, J=8.73 Hz, 2H), 8.19 (s, 1H), 9.03 (s, 1H), 9.25
(s, 1H); Anal. Calcd. for C.sub.21H.sub.16N.sub.6O.sub.2.
05CH.sub.2Cl.sub.2: C, 60.50; H, 4.01; N, 19.69. Found: C, 60.15;
H, 4.28; N, 19.75. 40
EXAMPLE 40
[0597]
1-[4-(4-Amino-6-methyl-furo[2,3-d]pyrimidin-5-yl)-phenyl]-3-(3-trif-
luoromethylphenyl)-urea
[0598] The desired product was prepared by substituting Example 20D
and 3-trifluoromethylphenylisocyanate for Example 13E and
p-tolylisocyanate, respectively, in Example 13F. MS (ESI) m/e 428
(M+H).sup.+; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta.2.38 (s,
3H), 6.20 (br s, 2H), 7.33 (d, J=7.49 Hz, 1H), 7.37 (d, J=8.11 Hz,
2H), 7.53 (t, J=7.80 Hz, 1H), 7.61 (d, J=8.11 Hz, 1H), 7.64 (d,
J=8.11 Hz, 2H), 8.04 (s, 1H), 8.20 (s, 1H), 8.96 (s, 1H), 9.09 (s,
1H), Anal. Calcd. for C.sub.21H.sub.16F.sub.3N.sub- .5O.sub.2: C,
59.02; H, 3.77; N, 16.39. Found: C, 58.79; H, 3.64; N, 16.23.
EXAMPLE 41
[0599]
N-[4-(4-Aminoisoxazolo[54-d]pyrimidin-3-yl)phenyl]-N'-[3-(trifluoro-
methyl)phenyl]urea
[0600] The desired product was prepared by substituting
3-trifluoromethylphenylisocyanate for m-tolylisocyanate in Example
31. MS (ESI(+)) m/e 415.1 (M+H).sup.+; .sup.1H NMR (DMSO-d.sub.6)
.delta.9.17 (s, 1H), 8.41 (s, 1H), 8.02 (s, 1H), 7.45-7.80 (m, 7H),
7.35 (d, J=8.4 Hz, 1H).
EXAMPLE 42
[0601]
N-[4-(4-Aminoisoxazolo[5,4-d]pyrimidin-3-yl)phenyl]-N'-[2-fluoro-5--
(trifluoromethyl)phenyl]urea
[0602] The desired product was prepared by substituting
2-fluoro-5-trifluoromethylphenyliso-cyanate for m-tolylisocyanate
in Example 31. MS (ESI(+)) m/e 433.0 (M+H).sup.+; .sup.1H NMR
(DMSO-d.sub.6) .delta.9.50 (s, 1H), 9.00 (d, J=2 Hz, 1H), 8.24 (dd,
J=7.2, 2 Hz, 1H), 8.41 (s, 1), 7.40-7,80 (m, 6H.)
* * * * *